In vitro fertilisation
View on Wikipedia
| In vitro fertilisation | |
|---|---|
This image shows intracytoplasmic sperm injection, the most commonly used IVF technique. | |
| Specialty | Endocrinology, gynecology |
| ICD-10-PCS | 8E0ZXY1 |
In vitro fertilisation (IVF) is a process of fertilisation in which an egg is combined with sperm in vitro ("in glass"). The process involves monitoring and stimulating the ovulatory process, then removing an ovum or ova (egg or eggs) from the ovaries and enabling sperm to fertilise them in a culture medium in a laboratory. After a fertilised egg (zygote) undergoes embryo culture for 2–6 days, it is transferred by catheter into the uterus, with the intention of establishing a successful pregnancy.
IVF is a type of assisted reproductive technology (ART) used to treat infertility, enable gestational surrogacy, and, in combination with pre-implantation genetic testing, avoid the transmission of abnormal genetic conditions. When a fertilised egg from egg and sperm donors implants in the uterus of a genetically unrelated surrogate, the resulting child is also genetically unrelated to the surrogate. Some countries have banned or otherwise regulated the availability of IVF treatment, giving rise to fertility tourism. Financial cost and age may also restrict the availability of IVF as a means of carrying a healthy pregnancy to term.
In July 1978, Louise Brown was the first child successfully born after her mother received IVF treatment.[1] Brown was born as a result of natural-cycle IVF, where no stimulation was made. The procedure took place at Dr Kershaw's Cottage Hospital in Royton, Oldham, England. Robert Edwards, surviving member of the development team, was awarded the Nobel Prize in Physiology or Medicine in 2010.[2][3]
When assisted by egg donation and IVF, many women who have reached menopause, have infertile partners, or have idiopathic female-fertility issues, can still become pregnant. After the IVF treatment, some couples get pregnant without any fertility treatments.[4] In 2023, it was estimated that twelve million children had been born worldwide using IVF and other assisted reproduction techniques.[5] A 2019 study that evaluated the use of 10 adjuncts with IVF (screening hysteroscopy, DHEA, testosterone, GH, aspirin, heparin, antioxidants, seminal plasma and PRP) suggested that (with the exception of hysteroscopy) these adjuncts should be avoided until there is more evidence to show that they are safe and effective.[6]
Some men suffer from mental health issues both during and after treatment.[7]
Terminology
[edit]The Latin term in vitro, meaning "in glass", is used because early biological experiments involving cultivation of tissues outside the living organism were carried out in glass containers, such as beakers, test tubes, or Petri dishes. The modern scientific term "in vitro" refers to any biological procedure that is performed outside the organism in which it would normally have occurred, to distinguish it from an in vivo procedure (such as in vivo fertilisation), where the tissue remains inside the living organism in which it is normally found.
A colloquial term for babies conceived as the result of IVF, "test tube babies", refers to the tube-shaped containers of glass or plastic resin, called test tubes, that are commonly used in chemistry and biology labs. However, IVF is usually performed in Petri dishes, which are both wider and shallower and often used to cultivate cultures.
IVF is a form of assisted reproductive technology.
History
[edit]The first successful birth of a child after IVF treatment, Louise Brown, occurred in 1978. Louise Brown was born as a result of natural cycle IVF where no stimulation was made. The procedure took place at Dr Kershaw's Cottage Hospital (now Dr Kershaw's Hospice) in Royton, Oldham, England. Robert G. Edwards, the physiologist who co-developed the treatment, was awarded the Nobel Prize in Physiology or Medicine in 2010. His co-workers, Patrick Steptoe and Jean Purdy, were not eligible for consideration as the Nobel Prize is not awarded posthumously.[2][3]
The second successful birth of a 'test tube baby' occurred in India on October 3, 1978, just 67 days after Louise Brown was born. The girl, named Durga, was conceived in vitro using a method developed independently by Subhash Mukhopadhyay, a physician and researcher from Hazaribag. Mukhopadhyay had been performing experiments on his own with primitive instruments and a household refrigerator.[8] However, state authorities prevented him from presenting his work at scientific conferences,[9] and it was many years before Mukhopadhyay's contribution was acknowledged in works dealing with the subject.[10][better source needed]
Adriana Iliescu held the record as the oldest woman to give birth using IVF and a donor egg, when she gave birth in 2004 at the age of 66, a record passed in 2006. After the IVF treatment some couples are able to get pregnant without any fertility treatments.[4] In 2018 it was estimated that eight million children had been born worldwide using IVF and other assisted reproduction techniques.[11]
Medical uses
[edit]Indications
[edit]IVF may be used to overcome female infertility when it is due to problems with the fallopian tubes, making in vivo fertilisation difficult. It can also assist in male infertility, in those cases where there is a defect in sperm quality; in such situations intracytoplasmic sperm injection (ICSI) may be used, where a sperm cell is injected directly into the egg cell. This is used when sperm has difficulty penetrating the egg. ICSI is also used when sperm numbers are very low. When indicated, the use of ICSI has been found to increase the success rates of IVF.
According to UK's National Institute for Health and Care Excellence (NICE) guidelines, IVF treatment is appropriate in cases of unexplained infertility for people who have not conceived after 2 years of regular unprotected sexual intercourse.[12]
In people with anovulation, it may be an alternative after 7–12 attempted cycles of ovulation induction, since the latter is expensive and more easy to control.[13]
Success rates
[edit]IVF success rates are the percentage of all IVF procedures that result in favourable outcomes. Depending on the type of calculation used, this outcome may represent the number of confirmed pregnancies, called the pregnancy rate, or the number of live births, called the live birth rate. Due to advances in reproductive technology, live birth rates by cycle five of IVF have increased from 76% in 2005 to 80% in 2010, despite a reduction in the number of embryos being transferred (which decreased the multiple birth rate from 25% to 8%).[14]
The success rate depends on variable factors such as age of the woman, cause of infertility, embryo status, reproductive history, and lifestyle factors. Younger candidates of IVF are more likely to get pregnant. People older than 41 are more likely to get pregnant with a donor egg.[15] People who have been previously pregnant are in many cases more successful with IVF treatments than those who have never been pregnant.[15]
Live birth rate
[edit]The live birth rate is the percentage of all IVF cycles that lead to a live birth. This rate does not include miscarriage or stillbirth; multiple-order births, such as twins and triplets, are counted as one pregnancy.
A 2021 summary compiled by the Society for Assisted Reproductive Technology (SART) which reports the average IVF success rates in the United States per age group using non-donor eggs compiled the following data:[16]
| < 35 | 35–37 | 38–40 | 41–42 | > 42 | |
|---|---|---|---|---|---|
| Live birth rate (%) | 54 | 40.5 | 26 | 13.3 | 4 |
In 2006, Canadian clinics reported a live birth rate of 27%.[17] Birth rates in younger patients were slightly higher, with a success rate of 35.3% for those 21 and younger, the youngest group evaluated. Success rates for older patients were also lower and decrease with age, with 37-year-olds at 27.4% and no live births for those older than 48, the oldest group evaluated.[18] Some clinics exceeded these rates, but it is impossible to determine if that is due to superior technique or patient selection, since it is possible to artificially increase success rates by refusing to accept the most difficult patients or by steering them into oocyte donation cycles (which are compiled separately). Further, pregnancy rates can be increased by the placement of several embryos at the risk of increasing the chance for multiples.
Because not each IVF cycle that is started will lead to oocyte retrieval or embryo transfer, reports of live birth rates need to specify the denominator, namely IVF cycles started, IVF retrievals, or embryo transfers. The SART summarised 2008–9 success rates for US clinics for fresh embryo cycles that did not involve donor eggs and gave live birth rates by the age of the prospective mother, with a peak at 41.3% per cycle started and 47.3% per embryo transfer for patients under 35 years of age.
IVF attempts in multiple cycles result in increased cumulative live birth rates. Depending on the demographic group, one study reported 45% to 53% for three attempts, and 51% to 71% to 80% for six attempts.[19]
According to the 2021 National Summary Report compiled by the Society for Assisted Reproductive Technology (SART), the mean number of embryos transfers for patients achieving live birth go as follows:[20]
| < 35 | 35–37 | 38–40 | 41–42 | > 42 | |
|---|---|---|---|---|---|
| Mean # of transfers | 1.33 | 1.28 | 1.19 | 1.11 | 1.10 |
Effective from 15 February 2021 the majority of Australian IVF clinics publish their individual success rate online via YourIVFSuccess.com.au. This site also contains a predictor tool.[21]
Pregnancy rate
[edit]Pregnancy rate may be defined in various ways. In the United States, SART and the Centers for Disease Control (and appearing in the table in the Success Rates section above) include statistics on positive pregnancy test and clinical pregnancy rate.
The 2019 summary compiled by the SART the following data for non-donor eggs (first embryo transfer) in the United States:[22]
| <35 | 35-37 | 38-40 | 41–42 | >42 | |
|---|---|---|---|---|---|
| Positive pregnancy test rate (%) | 55.1 | 44.8 | 32.9 | 19.1 | 8.5 |
| Clinical pregnancy rate (%) | 47.5 | 38.3 | 27.5 | 15.5 | 6.3 |
In 2006, Canadian clinics reported an average pregnancy rate of 35%.[17] A French study estimated that 66% of patients starting IVF treatment finally succeed in having a child (40% during the IVF treatment at the centre and 26% after IVF discontinuation). Achievement of having a child after IVF discontinuation was mainly due to adoption (46%) or spontaneous pregnancy (42%).[23]
Miscarriage rate
[edit]According to a study done by the Mayo Clinic, miscarriage rates for IVF are somewhere between 15 and 25% for those under the age of 35.[24] In naturally conceived pregnancies, the rate of miscarriage is between 10 and 20% for those under the age of 35.[25] Risk of miscarriage, regardless of the method of conception, does increase with age.[24]
Predictors of success
[edit]The main potential factors that influence pregnancy (and live birth) rates in IVF have been suggested to be maternal age, duration of infertility or subfertility, bFSH and number of oocytes, all reflecting ovarian function.[26] Optimal age is 23–39 years at time of treatment.[27]

Biomarkers that affect the pregnancy chances of IVF include:
- Antral follicle count, with higher count giving higher success rates.[29]
- Anti-Müllerian hormone levels, with higher levels indicating higher chances of pregnancy,[29] as well as of live birth after IVF, even after adjusting for age.[30]
- Level of DNA fragmentation[31] as measured, e.g. by Comet assay, advanced maternal age and semen quality.
- People with ovary-specific FMR1 genotypes including het-norm/low have significantly decreased pregnancy chances in IVF.[32]
- Progesterone elevation on the day of induction of final maturation is associated with lower pregnancy rates in IVF cycles in women undergoing ovarian stimulation using GnRH analogues and gonadotrophins.[33] At this time, compared to a progesterone level below 0.8 ng/ml, a level between 0.8 and 1.1 ng/ml confers an odds ratio of pregnancy of approximately 0.8, and a level between 1.2 and 3.0 ng/ml confers an odds ratio of pregnancy of between 0.6 and 0.7.[33] On the other hand, progesterone elevation does not seem to confer a decreased chance of pregnancy in frozen–thawed cycles and cycles with egg donation.[33]
- Characteristics of cells from the cumulus oophorus and the membrana granulosa, which are easily aspirated during oocyte retrieval. These cells are closely associated with the oocyte and share the same microenvironment, and the rate of expression of certain genes in such cells are associated with higher or lower pregnancy rate.[34]
- An endometrial thickness (EMT) of less than 7 mm decreases the pregnancy rate by an odds ratio of approximately 0.4 compared to an EMT of over 7 mm. However, such low thickness rarely occurs, and any routine use of this parameter is regarded as not justified.[35]
Other determinants of outcome of IVF include:
- As maternal age increases, the likelihood of conception decreases[36] and the chance of miscarriage increases.[37]
- With increasing paternal age, especially 50 years and older, the rate of blastocyst formation decreases.[38]
- Tobacco smoking reduces the chances of IVF producing a live birth by 34% and increases the risk of an IVF pregnancy miscarrying by 30%.[39]
- A body mass index (BMI) over 27 causes a 33% decrease in likelihood to have a live birth after the first cycle of IVF, compared to those with a BMI between 20 and 27.[39] Also, pregnant people who are obese have higher rates of miscarriage, gestational diabetes, hypertension, thromboembolism and problems during delivery, as well as leading to an increased risk of fetal congenital abnormality.[39] Ideal body mass index is 19–30,[27] and many clinics restrict this BMI range as a criterion for initiation of the IVF process.[40]
- Salpingectomy or laparoscopic tubal occlusion before IVF treatment increases chances for people with hydrosalpinges.[27][41]
- Success with previous pregnancy and/or live birth increases chances[27]
- Low alcohol/caffeine intake increases success rate[27]
- The number of embryos transferred in the treatment cycle[42]
- Embryo quality
- Some studies also suggest that autoimmune disease may also play a role in decreasing IVF success rates by interfering with the proper implantation of the embryo after transfer.[32]
Aspirin is sometimes prescribed to people for the purpose of increasing the chances of conception by IVF, but as of 2016[update] there was no evidence to show that it is safe and effective.[43][44]
A 2013 review and meta analysis of randomised controlled trials of acupuncture as an adjuvant therapy in IVF found no overall benefit, and concluded that an apparent benefit detected in a subset of published trials where the control group (those not using acupuncture) experienced a lower than average rate of pregnancy requires further study, due to the possibility of publication bias and other factors.[45]
A Cochrane review came to the result that endometrial injury performed in the month prior to ovarian induction appeared to increase both the live birth rate and clinical pregnancy rate in IVF compared with no endometrial injury. There was no evidence of a difference between the groups in miscarriage, multiple pregnancy or bleeding rates. Evidence suggested that endometrial injury on the day of oocyte retrieval was associated with a lower live birth or ongoing pregnancy rate.[41]
Intake of antioxidants (such as N-acetyl-cysteine, melatonin, vitamin A, vitamin C, vitamin E, folic acid, myo-inositol, zinc or selenium) has not been associated with a significantly increased live birth rate or clinical pregnancy rate in IVF according to Cochrane reviews.[41] The review found that oral antioxidants given to the sperm donor with male factor or unexplained subfertility may improve live birth rates, but more evidence is needed.[41]
A Cochrane review in 2015 came to the result that there is no evidence identified regarding the effect of preconception lifestyle advice on the chance of a live birth outcome.[41]
Method
[edit]This section needs additional citations for verification. (July 2020) |

Theoretically, IVF could be performed by collecting the contents from the fallopian tubes or uterus after natural ovulation, mixing it with sperm, and reinserting the fertilised ova into the uterus. However, without additional techniques, the chances of pregnancy would be extremely small. The additional techniques that are routinely used in IVF include ovarian hyperstimulation to generate multiple eggs, ultrasound-guided transvaginal oocyte retrieval directly from the ovaries, co-incubation of eggs and sperm, as well as culture and selection of resultant embryos before embryo transfer into a uterus.
Ovarian hyperstimulation
[edit]Ovarian hyperstimulation is the stimulation to induce development of multiple follicles of the ovaries. It should start with response prediction based on factors such as age, antral follicle count and level of anti-Müllerian hormone.[46] The resulting prediction (e.g. poor or hyper-response to ovarian hyperstimulation) determines the protocol and dosage for ovarian hyperstimulation.[46]
Ovarian hyperstimulation also includes suppression of spontaneous ovulation, for which two main methods are available: Using a (usually longer) GnRH agonist protocol or a (usually shorter) GnRH antagonist protocol.[46] In a standard long GnRH agonist protocol the day when hyperstimulation treatment is started and the expected day of later oocyte retrieval can be chosen to conform to personal choice, while in a GnRH antagonist protocol it must be adapted to the spontaneous onset of the previous menstruation. On the other hand, the GnRH antagonist protocol has a lower risk of ovarian hyperstimulation syndrome (OHSS), which is a life-threatening complication.[46]
For the ovarian hyperstimulation in itself, injectable gonadotropins (usually FSH analogues) are generally used under close monitoring. Such monitoring frequently checks the estradiol level and, by means of gynecologic ultrasonography, follicular growth. Typically approximately 10 days of injections will be necessary.
When stimulating ovulation after suppressing endogenous secretion, it is necessary to supply exogenous gonadotropines. The most common one is the human menopausal gonadotropin (hMG), which is obtained by donation of menopausal women. Other pharmacological preparations are FSH+LH or coripholitropine alpha.
Natural IVF
[edit]There are several methods termed natural cycle IVF:[47]
- IVF using no drugs for ovarian hyperstimulation, while drugs for ovulation suppression may still be used.
- IVF using ovarian hyperstimulation, including gonadotropins, but with a GnRH antagonist protocol so that the cycle initiates from natural mechanisms.
- Frozen embryo transfer; IVF using ovarian hyperstimulation, followed by embryo cryopreservation, followed by embryo transfer in a later, natural, cycle.[48]
IVF using no drugs for ovarian hyperstimulation was the method for the conception of Louise Brown. This method can be successfully used when people want to avoid taking ovarian stimulating drugs with its associated side-effects. HFEA has estimated the live birth rate to be approximately 1.3% per IVF cycle using no hyperstimulation drugs for women aged between 40 and 42.[49]
Mild IVF[50] is a method where a small dose of ovarian stimulating drugs are used for a short duration during a natural menstrual cycle aimed at producing 2–7 eggs and creating healthy embryos. This method appears to be an advance in the field to reduce complications and side-effects for women, and it is aimed at quality, and not quantity of eggs and embryos. One study comparing a mild treatment (mild ovarian stimulation with GnRH antagonist co-treatment combined with single embryo transfer) to a standard treatment (stimulation with a GnRH agonist long-protocol and transfer of two embryos) came to the result that the proportions of cumulative pregnancies that resulted in term live birth after 1 year were 43.4% with mild treatment and 44.7% with standard treatment.[51] Mild IVF can be cheaper than conventional IVF and with a significantly reduced risk of multiple gestation and OHSS.[52]
Final maturation induction
[edit]When the ovarian follicles have reached a certain degree of development, induction of final oocyte maturation is performed, generally by an injection of human chorionic gonadotropin (hCG). Commonly, this is known as the "trigger shot."[53] hCG acts as an analogue of luteinising hormone, and ovulation would occur between 38 and 40 hours after a single HCG injection,[54] but the egg retrieval is performed at a time usually between 34 and 36 hours after hCG injection, that is, just prior to when the follicles would rupture. This avails for scheduling the egg retrieval procedure at a time when the eggs are fully mature. HCG injection confers a risk of ovarian hyperstimulation syndrome. Using a GnRH agonist instead of hCG eliminates most of the risk of ovarian hyperstimulation syndrome, but with a reduced delivery rate if the embryos are transferred fresh.[55] For this reason, many centers will freeze all oocytes or embryos following agonist trigger.
Egg retrieval
[edit]The eggs are retrieved from the patient using a transvaginal technique called transvaginal ultrasound aspiration involving an ultrasound-guided needle being injected through follicles upon collection. Through this needle, the oocyte and follicular fluid are aspirated and the follicular fluid is then passed to an embryologist to identify ova. It is common to remove between ten and thirty eggs. The retrieval process, which lasts approximately 20 to 40 minutes, is performed under conscious sedation or general anesthesia to ensure patient comfort. Following optimal follicular development, the eggs are meticulously retrieved using transvaginal ultrasound guidance with the aid of a specialised ultrasound probe and a fine needle aspiration technique. The follicular fluid, containing the retrieved eggs, is expeditiously transferred to the embryology laboratory for subsequent processing.[56]
Egg and sperm preparation
[edit]In the laboratory, for ICSI treatments, the identified eggs are stripped of surrounding cells (also known as cumulus cells) and prepared for fertilisation. An oocyte selection may be performed prior to fertilisation to select eggs that can be fertilised, as it is required they are in metaphase II. There are cases in which if oocytes are in the metaphase I stage, they can be kept being cultured so as to undergo a posterior sperm injection. In the meantime, semen is prepared for fertilisation by removing inactive cells and seminal fluid in a process called sperm washing. If semen is being provided by a sperm donor, it will usually have been prepared for treatment before being frozen and quarantined, and it will be thawed ready for use.[citation needed]
Co-incubation
[edit]
The sperm and the egg are incubated together at a ratio of about 75,000:1 in a culture media in order for the actual fertilisation to take place. A review in 2013 came to the result that a duration of this co-incubation of about 1 to 4 hours results in significantly higher pregnancy rates than 16 to 24 hours.[57] In most cases, the egg will be fertilised during co-incubation and will show two pronuclei. In certain situations, such as low sperm count or motility, a single sperm may be injected directly into the egg using intracytoplasmic sperm injection (ICSI). The fertilised egg is passed to a special growth medium and left for about 48 hours until the embryo consists of six to eight cells.
In gamete intrafallopian transfer, eggs are removed from the woman and placed in one of the fallopian tubes, along with the man's sperm. This allows fertilisation to take place inside the woman's body. Therefore, this variation is actually an in vivo fertilisation, not in vitro.[58][59]
Embryo culture
[edit]The main durations of embryo culture are until cleavage stage (day two to four after co-incubation) or the blastocyst stage (day five or six after co-incubation).[60] Embryo culture until the blastocyst stage confers a significant increase in live birth rate per embryo transfer, but also confers a decreased number of embryos available for transfer and embryo cryopreservation, so the cumulative clinical pregnancy rates are increased with cleavage stage transfer.[41] Transfer day two instead of day three after fertilisation has no differences in live birth rate.[41] There are significantly higher odds of preterm birth (odds ratio 1.3) and congenital anomalies (odds ratio 1.3) among births having from embryos cultured until the blastocyst stage compared with cleavage stage.[60]
Embryo selection
[edit]Laboratories have developed grading methods to judge ovocyte and embryo quality. In order to optimise pregnancy rates, there is significant evidence that a morphological scoring system is the best strategy for the selection of embryos.[61] Since 2009 where the first time-lapse microscopy system for IVF was approved for clinical use, morphokinetic scoring systems has shown to improve to pregnancy rates further.[62] However, when all different types of time-lapse embryo imaging devices, with or without morphokinetic scoring systems, are compared against conventional embryo assessment for IVF, there is insufficient evidence of a difference in live-birth, pregnancy, stillbirth or miscarriage to choose between them.[63] Active efforts to develop a more accurate embryo selection analysis based on Artificial Intelligence and Deep Learning are underway. Embryo Ranking Intelligent Classification Assistant (ERICA),[64] is a clear example. This Deep Learning software substitutes manual classifications with a ranking system based on an individual embryo's predicted genetic status in a non-invasive fashion.[65] Studies on this area are still pending and current feasibility studies support its potential.[66]
Embryo transfer
[edit]The number to be transferred depends on the number available, the age of the patient and other health and diagnostic factors. In countries such as Canada, the UK, Australia and New Zealand, a maximum of two embryos are transferred except in unusual circumstances. In the UK and according to HFEA regulations, a woman over 40 may have up to three embryos transferred, whereas in the US, there is no legal limit on the number of embryos which may be transferred, although medical associations have provided practice guidelines. Most clinics and country regulatory bodies seek to minimise the risk of multiple pregnancy, as it is not uncommon for multiple embryos to implant if multiple embryos are transferred. Embryos are transferred to the patient's uterus through a thin, plastic catheter, which goes through their vagina and cervix. Several embryos may be passed into the uterus to improve chances of implantation and pregnancy.[67][68]
Luteal support
[edit]Luteal support is the administration of medication, generally progesterone, progestins, hCG, or GnRH agonists, and often accompanied by estradiol, to increase the success rate of implantation and early embryogenesis, thereby complementing and/or supporting the function of the corpus luteum. A Cochrane review found that hCG or progesterone given during the luteal phase may be associated with higher rates of live birth or ongoing pregnancy, but that the evidence is not conclusive.[69] Co-treatment with GnRH agonists appears to improve outcomes,[69] by a live birth rate RD of +16% (95% confidence interval +10 to +22%).[70] On the other hand, growth hormone or aspirin as adjunctive medication in IVF have no evidence of overall benefit.[41]
Expansions
[edit]There are various expansions or additional techniques that can be applied in IVF, which are usually not necessary for the IVF procedure itself, but would be virtually impossible or technically difficult to perform without concomitantly performing methods of IVF.
Preimplantation genetic screening or diagnosis
[edit]Preimplantation genetic screening (PGS) or preimplantation genetic diagnosis (PGD) has been suggested to be able to be used in IVF to select an embryo that appears to have the greatest chances for successful pregnancy. However, a systematic review and meta-analysis of existing randomised controlled trials came to the result that there is no evidence of a beneficial effect of PGS with cleavage-stage biopsy as measured by live birth rate.[71] On the contrary, for those of advanced maternal age, PGS with cleavage-stage biopsy significantly lowers the live birth rate.[71] Technical drawbacks, such as the invasiveness of the biopsy, and non-representative samples because of mosaicism are the major underlying factors for inefficacy of PGS.[71]
Still, as an expansion of IVF, patients who can benefit from PGS/PGD include:
- Those who have a family history of inherited disease
- Those who want prenatal sex discernment. This can be used to diagnose monogenic disorders with sex linkage. It can potentially be used for sex selection, wherein a fetus is aborted if having an undesired sex.
- Those who already have a child with an incurable disease and need compatible cells from a second healthy child to cure the first, resulting in a "saviour sibling" that matches the sick child in HLA type.[72]
PGS screens for numeral chromosomal abnormalities while PGD diagnosis the specific molecular defect of the inherited disease. In both PGS and PGD, individual cells from a pre-embryo, or preferably trophectoderm cells biopsied from a blastocyst, are analysed during the IVF process. Before the transfer of a pre-embryo back to a person's uterus, one or two cells are removed from the pre-embryos (8-cell stage), or preferably from a blastocyst. These cells are then evaluated for normality. Typically within one to two days, following completion of the evaluation, only the normal pre-embryos are transferred back to the uterus. Alternatively, a blastocyst can be cryopreserved via vitrification and transferred at a later date to the uterus. In addition, PGS can significantly reduce the risk of multiple pregnancies because fewer embryos, ideally just one, are needed for implantation.
Cryopreservation
[edit]Cryopreservation can be performed as oocyte cryopreservation before fertilisation, or as embryo cryopreservation after fertilisation.
The Rand Consulting Group has estimated there to be 400,000 frozen embryos in the United States in 2006.[73] The advantage is that patients who fail to conceive may become pregnant using such embryos without having to go through a full IVF cycle. Or, if pregnancy occurred, they could return later for another pregnancy. Spare oocytes or embryos resulting from fertility treatments may be used for oocyte donation or embryo donation to another aspiring parent, and embryos may be created, frozen and stored specifically for transfer and donation by using donor eggs and sperm. Also, oocyte cryopreservation can be used for those who are likely to lose their ovarian reserve due to undergoing chemotherapy.[74]
By 2017, many centres have adopted embryo cryopreservation as their primary IVF therapy, and perform few or no fresh embryo transfers. The two main reasons for this have been better endometrial receptivity when embryos are transferred in cycles without exposure to ovarian stimulation and also the ability to store the embryos while awaiting the results of preimplantation genetic testing.
The outcome from using cryopreserved embryos has uniformly been positive with no increase in birth defects or development abnormalities.[75]
Sperm selection
[edit]Intracytoplasmic sperm injection (ICSI) is where a single sperm is injected directly into an egg. Its main usage as an expansion of IVF is to overcome male infertility problems, although it may also be used where eggs cannot easily be penetrated by sperm, and occasionally in conjunction with sperm donation. It can be used in teratozoospermia, since once the egg is fertilised abnormal sperm morphology does not appear to influence blastocyst development or blastocyst morphology.[76]
Physiological intracytoplasmic sperm injection (PICSI) is a variation of ICSI that uses hyaluronic acid binding to select mature sperm with better DNA integrity. Since only mature sperm bind to hyaluronic acid, PICSI may help reduce the risk of chromosomal abnormalities and improve fertilisation and pregnancy outcomes.[77]
Magnetic-activated cell sorting (MACS) is a sperm selection technique used in assisted reproductive technologies to remove apoptotic sperm with compromised DNA integrity. The method involves using magnetic microbeads coated with annexin V, a protein that binds to phosphatidylserine — an early marker of apoptosis. When passed through a magnetic field, sperm bound to the beads are retained, allowing only viable, non-apoptotic sperm to be collected for fertilisation. MACS is often combined with conventional sperm preparation methods and is used in cases of recurrent miscarriage, male factor infertility, or high DNA fragmentation levels.[78]
Microfluidic sperm sorting devices are designed to isolate highly motile, morphologically normal, and DNA-intact sperm. They are intended to improve ICSI and IVF outcomes by reducing the risk of injecting sperm with high DNA fragmentation into the oocyte.[79]
These technologies aim to improve fertilisation rates, embryo quality, and overall IVF success by enhancing gamete selection at the cellular level.
Other expansions
[edit]- Additional methods of embryo profiling. For example, methods are emerging in making comprehensive analyses of up to entire genomes, transcriptomes, proteomes and metabolomes which may be used to score embryos by comparing the patterns with ones that have previously been found among embryos in successful versus unsuccessful pregnancies.[80]
- Assisted zona hatching (AZH) can be performed shortly before the embryo is transferred to the uterus. A small opening is made in the outer layer surrounding the egg in order to help the embryo hatch out and aid in the implantation process of the growing embryo.
- In egg donation and embryo donation, the resultant embryo after fertilisation is inserted in another person than the one providing the eggs. These are resources for those with no eggs due to surgery, chemotherapy, or genetic causes; or with poor egg quality, previously unsuccessful IVF cycles or advanced maternal age. In the egg donor process, eggs are retrieved from a donor's ovaries, fertilised in the laboratory with sperm, and the resulting healthy embryos are returned to the recipient's uterus.
- In oocyte selection, the oocytes with optimal chances of live birth can be chosen. It can also be used as a means of preimplantation genetic screening.
- Embryo splitting can be used for twinning to increase the number of available embryos.[81]
- Cytoplasmic transfer is where the cytoplasm from a donor egg is injected into an egg with compromised mitochondria. The resulting egg is then fertilised with sperm and introduced into a uterus, usually that of the person who provided the recipient egg and nuclear DNA. Cytoplasmic transfer was created to aid those who experience infertility due to deficient or damaged mitochondria, contained within an egg's cytoplasm.
Complications and health effects
[edit]Multiple births
[edit]The major complication of IVF is the risk of multiple births. This is directly related to the practice of transferring multiple embryos at embryo transfer. Multiple births are related to increased risk of pregnancy loss, obstetrical complications, prematurity, and neonatal morbidity with the potential for long term damage. Strict limits on the number of embryos that may be transferred have been enacted in some countries (e.g. Britain, Belgium) to reduce the risk of high-order multiples (triplets or more), but are not universally followed or accepted. Spontaneous splitting of embryos in the uterus after transfer can occur, but this is rare and would lead to identical twins. A double blind, randomised study followed IVF pregnancies that resulted in 73 infants, and reported that 8.7% of singleton infants and 54.2% of twins had a birth weight of less than 2,500 grams (5.5 lb).[82] There is some evidence that making a double embryo transfer during one cycle achieves a higher live birth rate than a single embryo transfer; but making two single embryo transfers in two cycles has the same live birth rate and would avoid multiple pregnancies.[83]
Sex ratio distortions
[edit]Certain kinds of IVF have been shown to lead to distortions in the sex ratio at birth. Intracytoplasmic sperm injection (ICSI), which was first applied in 1991, leads to slightly more female births (51.3% female). Blastocyst transfer, which was first applied in 1984, leads to significantly more male births (56.1% male). Standard IVF done at the second or third day leads to a normal sex ratio.[citation needed]
Epigenetic modifications caused by extended culture leading to the death of more female embryos has been theorised as the reason why blastocyst transfer leads to a higher male sex ratio; however, adding retinoic acid to the culture can bring this ratio back to normal.[84] A second theory is that the male-biased sex ratio may due to a higher rate of selection of male embryos. Male embryos develop faster in vitro, and thus may appear more viable for transfer.[85]
Spread of infectious disease
[edit]By sperm washing, the risk that a chronic disease in the individual providing the sperm would infect the birthing parent or offspring can be brought to negligible levels.
If the sperm donor has hepatitis B, The Practice Committee of the American Society for Reproductive Medicine advises that sperm washing is not necessary in IVF to prevent transmission, unless the birthing partner has not been effectively vaccinated.[86][87] In women with hepatitis B, the risk of vertical transmission during IVF is no different from the risk in spontaneous conception.[87] However, there is not enough evidence to say that ICSI procedures are safe in women with hepatitis B in regard to vertical transmission to the offspring.[87]
Regarding potential spread of HIV/AIDS, Japan's government prohibited the use of IVF procedures in which both partners are infected with HIV. Despite the fact that the ethics committees previously allowed the Ogikubo, Tokyo Hospital, located in Tokyo, to use IVF for couples with HIV, the Ministry of Health, Labour and Welfare of Japan decided to block the practice. Hideji Hanabusa, the vice president of the Ogikubo Hospital, states that together with his colleagues, he managed to develop a method through which scientists are able to remove HIV from sperm.[88]
In the United States, people seeking to be an embryo recipient undergo infectious disease screening required by the Food and Drug Administration (FDA), and reproductive tests to determine the best placement location and cycle timing before the actual embryo transfer occurs. The amount of screening the embryo has already undergone is largely dependent on the genetic parents' own IVF clinic and process. The embryo recipient may elect to have their own embryologist conduct further testing.
Other risks to the egg provider/retriever
[edit]A risk of ovarian stimulation is the development of ovarian hyperstimulation syndrome, particularly if hCG is used for inducing final oocyte maturation. This results in swollen, painful ovaries. It occurs in 30% of patients. Mild cases can be treated with over the counter medications and cases can be resolved in the absence of pregnancy. In moderate cases, ovaries swell and fluid accumulated in the abdominal cavities and may have symptoms of heartburn, gas, nausea or loss of appetite. In severe cases, patients have sudden excess abdominal pain, nausea, vomiting and will result in hospitalisation.
During egg retrieval, there exists a small chance of bleeding, infection, and damage to surrounding structures such as bowel and bladder (transvaginal ultrasound aspiration) as well as difficulty in breathing, chest infection, allergic reactions to medication, or nerve damage (laparoscopy).
Ectopic pregnancy may also occur if a fertilised egg develops outside the uterus, usually in the fallopian tubes and requires immediate destruction of the foetus.
IVF does not seem to be associated with an elevated risk of cervical cancer, nor with ovarian cancer or endometrial cancer when neutralising the confounder of infertility itself.[89] Nor does it seem to impart any increased risk for breast cancer.[90]
Regardless of pregnancy result, IVF treatment is usually stressful for patients.[91] Neuroticism and the use of escapist coping strategies are associated with a higher degree of distress, while the presence of social support has a relieving effect.[91] A negative pregnancy test after IVF is associated with an increased risk for depression, but not with any increased risk of developing anxiety disorders.[92] Pregnancy test results do not seem to be a risk factor for depression or anxiety among men in the case of relationships between two cisgender, heterosexual people.[92] Hormonal agents such as gonadotropin-releasing hormone agonist (GnRH agonist) are associated with depression.[93]
Studies show that there is an increased risk of venous thrombosis or pulmonary embolism during the first trimester of IVF.[94] When looking at long-term studies comparing patients who received or did not receive IVF, there seems to be no correlation with increased risk of cardiac events. There are more ongoing studies to solidify this.[95]
Spontaneous pregnancy has occurred after successful and unsuccessful IVF treatments.[96] Within 2 years of delivering an infant conceived through IVF, subfertile patients had a conception rate of 18%.[97]
Birth defects
[edit]A review in 2013 came to the result that infants resulting from IVF (with or without ICSI) have a relative risk of birth defects of 1.32 (95% confidence interval 1.24–1.42) compared to naturally conceived infants.[98] In 2008, an analysis of the data of the National Birth Defects Study in the US found that certain birth defects were significantly more common in infants conceived through IVF, notably septal heart defects, cleft lip with or without cleft palate, esophageal atresia, and anorectal atresia; the mechanism of causality is unclear.[99] However, in a population-wide cohort study of 308,974 births (with 6,163 using assisted reproductive technology and following children from birth to age five) researchers found: "The increased risk of birth defects associated with IVF was no longer significant after adjustment for parental factors."[100] Parental factors included known independent risks for birth defects such as maternal age, smoking status, etc. Multivariate correction did not remove the significance of the association of birth defects and ICSI (corrected odds ratio 1.57), although the authors speculate that underlying male infertility factors (which would be associated with the use of ICSI) may contribute to this observation and were not able to correct for these confounders. The authors also found that a history of infertility elevated risk itself in the absence of any treatment (odds ratio 1.29), consistent with a Danish national registry study[101] and "implicates patient factors in this increased risk."[100] The authors of the Danish national registry study speculate: "our results suggest that the reported increased prevalence of congenital malformations seen in singletons born after assisted reproductive technology is partly due to the underlying infertility or its determinants."[101]
| Condition | Relative risk |
95% confidence interval |
|---|---|---|
| Beckwith–Wiedemann syndrome | 3-4 | |
| congenital anomalies | 1.67 | 1.33–2.09 |
| ante-partum haemorrhage | 2.49 | 2.30–2.69 |
| hypertensive disorders of pregnancy | 1.49 | 1.39–1.59 |
| preterm rupture of membranes | 1.16 | 1.07–1.26 |
| Caesarean section | 1.56 | 1.51–1.60 |
| gestational diabetes | 1.48 | 1.33–1.66 |
| induction of labour | 1.18 | 1.10–1.28 |
| small for gestational age | 1.39 | 1.27–1.53 |
| preterm birth | 1.54 | 1.47–1.62 |
| low birthweight | 1.65 | 1.56–1.75 |
| perinatal mortality | 1.87 | 1.48–2.37 |
Other risks to the offspring
[edit]If the underlying infertility is related to abnormalities in spermatogenesis, male offspring will have a higher risk for sperm abnormalities. In some cases genetic testing may be recommended to help assess the risk of transmission of defects to progeny and to consider whether treatment is desirable.[103]
IVF does not seem to confer any risks regarding cognitive development, school performance, social functioning, and behaviour.[104] Also, IVF infants are known to be as securely attached to their parents as those who were naturally conceived, and IVF adolescents are as well-adjusted as those who have been naturally conceived.[105]
Limited long-term follow-up data suggest that IVF may be associated with an increased incidence of hypertension, impaired fasting glucose, increase in total body fat composition, advancement of bone age, subclinical thyroid disorder, early adulthood clinical depression and binge drinking in the offspring.[104][106] It is not known, however, whether these potential associations are caused by the IVF procedure in itself, by adverse obstetric outcomes associated with IVF, by the genetic origin of the children or by yet unknown IVF-associated causes.[104][106] Increases in embryo manipulation during IVF result in more deviant fetal growth curves, but birth weight does not seem to be a reliable marker of fetal stress.[107]
IVF, including ICSI, is associated with an increased risk of imprinting disorders (including Prader–Willi syndrome and Angelman syndrome), with an odds ratio of 3.7 (95% confidence interval 1.4 to 9.7).[108]
An IVF-associated incidence of cerebral palsy and neurodevelopmental delay are believed to be related to the confounders of prematurity and low birthweight.[104] Similarly, an IVF-associated incidence of autism and attention-deficit disorder are believed to be related to confounders of maternal and obstetric factors.[104]
Overall, IVF does not cause an increased risk of childhood cancer.[109] Studies have shown a decrease in the risk of certain cancers and an increased risks of certain others including retinoblastoma,[110] hepatoblastoma[109] and rhabdomyosarcoma.[109]
Controversial cases
[edit]Mix-ups
[edit]In some cases, laboratory mix-ups (misidentified gametes, transfer of wrong embryos) have occurred, leading to legal action against the IVF provider and complex paternity suits. An example is the case of a woman in California who received the embryo of another couple and was notified of this mistake after the birth of her son.[111] This has led to many authorities and individual clinics implementing procedures to minimise the risk of such mix-ups. The HFEA, for example, requires clinics to use a double witnessing system, the identity of specimens is checked by two people at each point at which specimens are transferred. Alternatively, technological solutions are gaining favour, to reduce the manpower cost of manual double witnessing, and to further reduce risks with uniquely numbered RFID tags which can be identified by readers connected to a computer. The computer tracks specimens throughout the process and alerts the embryologist if non-matching specimens are identified. Although the use of RFID tracking has expanded in the US,[112] it is still not widely adopted.[113]
Preimplantation genetic diagnosis or screening
[edit]Pre-implantation genetic diagnosis (PGD) is criticised for giving select demographic groups disproportionate access to a means of creating a child possessing characteristics that they consider "ideal". Many fertile couples[114][115] now demand equal access to embryonic screening so that their child can be just as healthy as one created through IVF. Mass use of PGD, especially as a means of population control or in the presence of legal measures related to population or demographic control, can lead to intentional or unintentional demographic effects such as the skewed live-birth sex ratios seen in China following implementation of its one-child policy.
While PGD was originally designed to screen for embryos carrying hereditary genetic diseases, the method has been applied to select features that are unrelated to diseases, thus raising ethical questions. Examples of such cases include the selection of embryos based on histocompatibility (HLA) for the donation of tissues to a sick family member, the diagnosis of genetic susceptibility to disease, and sex selection.[116]
These examples raise ethical issues because of the morality of eugenics. It becomes frowned upon because of the advantage of being able to eliminate unwanted traits and selecting desired traits. By using PGD, individuals are given the opportunity to create a human life unethically and rely on science and not by natural selection.[117]
For example, a deaf British couple, Tom and Paula Lichy, have petitioned to create a deaf baby using IVF.[118] Some medical ethicists have been very critical of this approach. Jacob M. Appel wrote that "intentionally culling out blind or deaf embryos might prevent considerable future suffering, while a policy that allowed deaf or blind parents to select for such traits intentionally would be far more troublesome."[119]
Industry corruption
[edit]Robert Winston, professor of fertility studies at Imperial College London, had called the industry "corrupt" and "greedy" stating that "one of the major problems facing us in healthcare is that IVF has become a massive commercial industry," and that "what has happened, of course, is that money is corrupting this whole technology", and accused authorities of failing to protect couples from exploitation: "The regulatory authority has done a consistently bad job. It's not prevented the exploitation of people, it's not put out very good information to couples, it's not limited the number of unscientific treatments people have access to".[120] The IVF industry has been described as a market-driven construction of health, medicine and the human body.[121]
The industry has been accused of making unscientific claims, and distorting facts relating to infertility, in particular through widely exaggerated claims about how common infertility is in society, in an attempt to get as many couples as possible and as soon as possible to try treatments (rather than trying to conceive naturally for a longer time).[citation needed] This risks removing infertility from its social context and reducing the experience to a simple biological malfunction, which not only can be treated through bio-medical procedures, but should be treated by them.[122][123]
Older patients
[edit]All pregnancies can be risky, but there are greater risk for mothers who are older and are over the age of 40. As people get older, they are more likely to develop conditions such as gestational diabetes and pre-eclampsia. If the mother does conceive over the age of 40, their offspring may be of lower birth weight, and more likely to requires intensive care. Because of this, the increased risk is a sufficient cause for concern. The high incidence of caesarean in older patients is commonly regarded as a risk.[124]
Those conceiving at 40 have a greater risk of gestational hypertension and premature birth. The offspring is at risk when being born from older mothers, and the risks associated with being conceived through IVF.[125]

Adriana Iliescu held the record for a while as the oldest woman to give birth using IVF and a donor egg, when she gave birth in 2004 at the age of 66.[citation needed] In September 2019, a 74-year-old woman became the oldest-ever to give birth after she delivered twins at a hospital in Guntur, Andhra Pradesh.[126]
Pregnancy after menopause
[edit]Although menopause is a natural barrier to further conception, IVF has allowed people to be pregnant in their fifties and sixties. People whose uteruses have been appropriately prepared receive embryos that originated from an egg donor. Therefore, although they do not have a genetic link with the child, they have a physical link through pregnancy and childbirth. Even after menopause, the uterus is fully capable of carrying out a pregnancy.[127]
Same-sex couples, single and unmarried parents
[edit]A 2009 statement from the ASRM found no persuasive evidence that children are harmed or disadvantaged solely by being raised by single parents, unmarried parents, or homosexual parents. It did not support restricting access to assisted reproductive technologies on the basis of a prospective parent's marital status or sexual orientation.[128] A 2018 study found that children's psychological well-being did not differ when raised by either same-sex parents or heterosexual parents, even finding that psychological well-being was better amongst children raised by same-sex parents.[129]
Ethical concerns include reproductive rights, the welfare of offspring, nondiscrimination against unmarried individuals, homosexual, and professional autonomy.[128]
A controversy in California focused on the question of whether physicians opposed to same-sex relationships should be required to perform IVF for a lesbian couple. Guadalupe T. Benitez, a lesbian medical assistant from San Diego, sued doctors Christine Brody and Douglas Fenton of the North Coast Woman's Care Medical Group after Brody told her that she had "religious-based objections to treating her and homosexuals in general to help them conceive children by artificial insemination," and Fenton refused to authorise a refill of her prescription for the fertility drug Clomid on the same grounds.[130][131] The California Medical Association had initially sided with Brody and Fenton, but the case, North Coast Women's Care Medical Group v. Superior Court, was decided unanimously by the California State Supreme Court in favour of Benitez on 19 August 2008.[132][133]
Nadya Suleman came to international attention after having twelve embryos implanted, eight of which survived, resulting in eight newborns being added to her existing six-child family. The Medical Board of California sought to have fertility doctor Michael Kamrava, who treated Suleman, stripped of his licence. State officials allege that performing Suleman's procedure is evidence of unreasonable judgment, substandard care, and a lack of concern for the eight children she would conceive and the six she was already struggling to raise. On 1 June 2011 the Medical Board issued a ruling that Kamrava's medical licence be revoked effective 1 July 2011.[134][135][136]
Transgender parents
[edit]The research on transgender reproduction and family planning is limited.[137] A 2020 comparative study of children born to a transgender father and cisgender mother via donor sperm insemination in France showed no significant differences to IVF and naturally conceived children of cisgender parents.[138]
Transgender men can experience challenges in pregnancy and birthing from the cis-normative structure within the medical system,[137] as well as psychological challenges such as renewed gender dysphoria.[139] The effect of continued testosterone therapy during pregnancy and breastfeeding is undetermined.[140] Ethical concerns include reproductive rights, reproductive justice, physician autonomy, and transphobia within the health care setting.[137]
Anonymous donors
[edit]Alana Stewart, who was conceived using donor sperm, began an online forum for donor children called AnonymousUS in 2010. The forum welcomes the viewpoints of anyone involved in the IVF process.[141] In May 2012, a court ruled making anonymous sperm and egg donation in British Columbia illegal.[142]
In the UK, Sweden, Norway, Germany, Italy, New Zealand, and some Australian states, donors are not paid and cannot be anonymous.[citation needed]
In 2000, a website called Donor Sibling Registry was created to help biological children with a common donor connect with each other.[143][144]
Leftover embryos or eggs, unwanted embryos
[edit]There may be leftover embryos or eggs from IVF procedures if the person for whom they were originally created has successfully carried one or more pregnancies to term, and no longer wishes to use them. With the patient's permission, these may be donated to help others conceive by means of third party reproduction.
In embryo donation, these extra embryos are given to others for transfer, with the goal of producing a successful pregnancy. Embryo recipients have genetic issues or poor-quality embryos or eggs of their own. The resulting child is considered the child of whoever birthed them, and not the child of the donor, the same as occurs with egg donation or sperm donation. As per The National Infertility Association, typically, genetic parents donate the eggs or embryos to a fertility clinic where they are preserved by oocyte cryopreservation or embryo cryopreservation until a carrier is found for them. The process of matching the donation with the prospective parents is conducted by the agency itself, at which time the clinic transfers ownership of the embryos to the prospective parent(s).[145]
Alternatives to donating unused embryos are destroying them (or having them transferred at a time when pregnancy is very unlikely),[146] keeping them frozen indefinitely, or donating them for use in research (rendering them non-viable).[147] Individual moral views on disposing of leftover embryos may depend on personal views on the beginning of human personhood and the definition and/or value of potential future persons, and on the value that is given to fundamental research questions. Some people believe donation of leftover embryos for research is a good alternative to discarding the embryos when patients receive proper, honest and clear information about the research project, the procedures and the scientific values.[148]
During the embryo selection and transfer phases, many embryos may be discarded in favour of others. This selection may be based on criteria such as genetic disorders or the sex. One of the earliest cases of special gene selection through IVF was the case of the Collins family in the 1990s, who selected the sex of their child.[149]
The ethic issues remain unresolved as no worldwide consensus exists in science, religion, and philosophy on when a human embryo should be recognised as a person. For those who believe that this is at the moment of conception, IVF becomes a moral question when multiple eggs are fertilised, begin development, and only a few are chosen for uterus transfer.[citation needed] If IVF were to involve the fertilisation of only a single egg, or at least only the number that will be transferred, then this would not be an issue. However, this has the chance of increasing costs dramatically as only a few eggs can be attempted at a time. As a result, the couple must decide what to do with these extra embryos. Depending on their view of the embryo's humanity or the chance the couple will want to try to have another child, the couple has multiple options for dealing with these extra embryos. Couples can choose to keep them frozen, donate them to other infertile couples, thaw them, or donate them to medical research.[146] Keeping them frozen costs money, donating them does not ensure they will survive, thawing them renders them immediately unviable, and medical research results in their termination. In the realm of medical research, the couple is not necessarily told what the embryos will be used for, and as a result, some can be used in stem cell research.
In February 2024, the Alabama Supreme Court ruled in LePage v. Center for Reproductive Medicine that cryopreserved embryos were "persons" or "extrauterine children". After Dobbs v. Jackson Women's Health Organization (2022), some antiabortionists had hoped to get a judgement that fetuses and embryos were "person[s]".[150]
Religious response
[edit]Christianity
[edit]The Catholic Church opposes all kinds of assisted reproductive technology and artificial contraception, on the grounds that they separate the procreative goal of marital sex from the goal of uniting married couples. The Catholic Church permits the use of a small number of reproductive technologies and contraceptive methods such as natural family planning, which involves charting ovulation times, and allows other forms of reproductive technologies that allow conception to take place from normative sexual intercourse, such as a fertility lubricant. Pope Benedict XVI had publicly re-emphasised the Catholic Church's opposition to in vitro fertilisation, saying that it replaces love between a husband and wife.[151] The Catechism of the Catholic Church, in accordance with the Catholic understanding of natural law, teaches that reproduction has an "inseparable connection" to the sexual union of married couples.[152] In addition, the church opposes IVF because it might result in the disposal of embryos; in Catholicism, an embryo is viewed as an individual with a soul that must be treated as a person.[153] The Catholic Church maintains that it is not objectively evil to be infertile, and advocates adoption as an option for such couples who still wish to have children.[154]
The Lutheran Council in the United States of America, organised by the Lutheran Church–Missouri Synod and parent bodies of the Evangelical Lutheran Church in America, produced an authoritative document on the issue of in-vitro fertilisation, which "unanimously concluded that IVF does not in and of itself violate the will of God as reflected in the Bible, when the wife's egg and husband's sperm are used" (LCUSA n.d.:31).[155] The Lutheran Churches approve of artificial insemination by a husband (AIH), though representatives from the Lutheran Church-Missouri Synod hold that such IVF is only unobjectionable if the sperm and egg come from husband and wife and all of the fertilised eggs are implanted in the womb of the wife.[155] With regard to artificial insemination by a donor (AID), the Evangelical Lutheran Church in America teaches that it is a "cause for moral concern", while the Lutheran Church–Missouri Synod rejects it.[155]
Islam
[edit]Regarding the response to IVF by Islam, a general consensus from the contemporary Sunni scholars concludes that IVF methods are immoral and prohibited. However, Gad El-Hak Ali Gad El-Hak's ART fatwa includes that:[156]
- IVF of an egg from the wife with the sperm of her husband and the transfer of the fertilised egg back to the uterus of the wife is allowed, provided that the procedure is indicated for a medical reason and is carried out by an expert physician.
- Since marriage is a contract between the wife and husband during the span of their marriage, no third party should intrude into the marital functions of sex and procreation. This means that a third party donor is not acceptable, whether he or she is providing sperm, eggs, embryos, or a uterus. The use of a third party is tantamount to zina, or adultery.
Judaism
[edit]Within the Orthodox Jewish community the concept is debated as there is little precedent in traditional Jewish legal textual sources. Regarding laws of sexuality, religious challenges include masturbation (which may be regarded as "seed wasting"[153]), laws related to sexual activity and menstruation (niddah) and the specific laws regarding intercourse. An additional major issue is that of establishing paternity and lineage. For a baby conceived naturally, the father's identity is determined by a legal presumption (chazakah) of legitimacy: rov bi'ot achar ha'baal – a woman's sexual relations are assumed to be with her husband. Regarding an IVF child, this assumption does not exist and as such Rabbi Eliezer Waldenberg (among others) requires an outside supervisor to positively identify the father.[157] Reform Judaism has generally approved IVF.[153]
Society and culture
[edit]Many women of sub-Saharan Africa choose to foster their children to infertile women. IVF enables these infertile women to have their own children, which imposes new ideals to a culture in which fostering children is seen as both natural and culturally important. Many infertile women are able to earn more respect in their society by taking care of the children of other mothers, and this may be lost if they choose to use IVF instead. As IVF is seen as unnatural, it may even hinder their societal position as opposed to making them equal with fertile women. It is also economically advantageous for infertile women to raise foster children as it gives these children greater ability to access resources that are important for their development and also aids the development of their society at large. If IVF becomes more popular without the birth rate decreasing, there could be more large family homes with fewer options to send their newborn children. This could result in an increase of orphaned children and/or a decrease in resources for the children of large families. This would ultimately stifle the children's and the community's growth.[158]
In the US, the pineapple has emerged as a symbol of IVF users, possibly because some people thought, without scientific evidence, that eating pineapple might slightly increase the success rate for the procedure.[159]
Emotional involvement with children
[edit]Studies have indicated that IVF mothers show greater emotional involvement with their child, and they enjoy motherhood more than mothers by natural conception. Similarly, studies have indicated that IVF fathers express more warmth and emotional involvement than fathers by adoption and natural conception and enjoy fatherhood more. Some IVF parents become overly involved with their children.[160]
Men and IVF
[edit]Research has shown that men largely view themselves as "passive contributors",[161] since they have "less physical involvement" in IVF treatment.[162] Despite this, many men feel distressed after seeing the toll of hormonal injections and ongoing physical intervention on their female partner.[161] Fertility was found to be a significant factor in a man's perception of his masculinity, driving many to keep the treatment a secret.[161] In cases where a man did share that he and his partner were undergoing IVF, they reported to have been teased, mainly by other men, although some viewed this as an affirmation of support and friendship. For others, this led to feeling socially isolated.[161] In comparison with females, males showed less deterioration in mental health in the years following a failed treatment.[163] However, many men did feel guilt, disappointment and inadequacy, stating that they were simply trying to provide an "emotional rock" for their partners.[161]
The onset of mental health problems that some men experience during and after IVF treatment has various causes and negative influences. These include religious and cultural pressures which can cause stress and mental health strains.[7] Interviews with Polish men who were undergoing or had undergone IVF treatment found that many men held strong feelings about previous public discourse.[164] Maria Reimann argues that these showcases of strong emotions could be one of the limited outlets for long-held suppressed emotions. Engagement in public discourse may also act as a 'battle ground', with acts that showcase anger and hate being a means for men to fight for their partner, which could act as a reassurance of common notions of masculinity. The tendency to react with hate or anger is heavily influenced by common notions of masculinity.[165] Many men hold the perception that their role is for emotional stability, often leading to the concealment of emotional suffering and stress. When men experience instability in IVF treatment from continued failures or setbacks, the reaction is commonly further isolation,[166] with men often pursuing distractions in work or other activities, often ones that grant feelings of control. As seen in Polish men's experience with IVF, the lack of proper social support and a significant social stigma around IVF treatment contribute to a growing mental health issue.
Ability to withdraw consent
[edit]In certain countries, including Austria, Italy, Estonia, Hungary, Spain and Israel, the male does not have full rights to withdraw consent to storage or use of embryos once they are fertilised. In the United States, the matter has been left to the courts on a more or less ad hoc basis. If embryos are implanted and a child is born contrary to the wishes of the male, he still has the legal and financial responsibilities of a father.[167]
Availability and utilisation
[edit]Cost
[edit]Costs of IVF can be divided into direct and indirect costs. Direct costs include the medical treatments themselves, including doctor consultations, medications, ultrasound scanning, laboratory tests, the actual IVF procedure, and associated hospital charges and administrative costs. Indirect costs include the cost of addressing any complications, compensation for the gestational surrogate, patient travel costs, and lost hours of productivity.[168] These costs can be exaggerated by higher age in the woman undergoing IVF treatment (particularly those over the age of 40), and the increased costs associated with multiple births. For instance, a pregnancy with twins can cost up to three times that of a singleton pregnancy.[169] While some insurances cover one cycle of IVF, it takes multiple cycles of IVF to have a successful outcome.[170] A study completed in Northern California reveals that the IVF procedure alone that results in a successful outcome costs $61,377, and this can be more costly with the use of a donor egg.[170]
The cost of IVF reflects the costliness of the underlying healthcare system rather than the regulatory or funding environment,[171] and ranges, on average for a standard IVF cycle and in 2006 United States dollars, between $12,500 in the United States to $4,000 in Japan.[171] In Ireland, IVF costs around €4,000, with fertility drugs, if required, costing up to €3,000.[172] The cost per live birth is highest in the United States ($41,000[171]) and United Kingdom ($40,000[171]) and lowest in Scandinavia and Japan (both around $24,500[171]).
The high cost of IVF is also a barrier to access for disabled individuals, who typically have lower incomes, face higher health care costs, and seek health care services more often than non-disabled individuals.[173]
Navigating insurance coverage for transgender expectant parents presents a unique challenge. Insurance plans are designed to cater towards a specific population, meaning that some plans can provide adequate coverage for gender-affirming care but fail to provide fertility services for transgender patients.[174] Additionally, insurance coverage is constructed around a person's legally recognised sex and not their anatomy; thus, transgender people may not get coverage for the services they need, including transgender men for fertility services.[174]
Use by LGBT individuals
[edit]Same-sex couples
[edit]In larger urban centres, studies have found that lesbian, gay, bisexual, transgender and queer (LGBTQ+) populations are among the fastest-growing users of fertility care.[175] IVF is increasingly being used to allow lesbian and other LGBT couples to share in the reproductive process through a technique called reciprocal IVF.[176] The eggs of one partner are used to create embryos which the other partner carries through pregnancy. For gay male couples, many elect to use IVF through gestational surrogacy, where one partner's sperm is used to fertilise a donor ovum, and the resulting embryo is transplanted into a surrogate carrier's womb.[177] There are IVF options available for same-sex couples including, but not limited to, IVF with donor sperm, IVF with a partner's oocytes, reciprocal IVF, IVF with donor eggs, and IVF with gestational surrogate. IVF with donor sperm can be considered traditional IVF for lesbian couples, but reciprocal IVF or using a partner's oocytes are other options for lesbian couples trying to conceive to include both partners in the biological process. Using a partner's oocytes is an option for partners who are unsuccessful in conceiving with their own, and reciprocal IVF involves undergoing reproduction with a donor egg and sperm that is then transferred to a partner who will gestate. Donor IVF involves conceiving with a third party's eggs. Typically, for gay male couples hoping to use IVF, the common techniques are using IVF with donor eggs and gestational surrogates.[178]
Transgender parents
[edit]Many LGBT communities centre their support around cisgender gay, lesbian and bisexual people and neglect to include proper support for transgender people.[179] The same 2020 literature review analyses the social, emotional and physical experiences of pregnant transgender men.[137] A common obstacle faced by pregnant transgender men is the possibility of gender dysphoria. Literature shows that transgender men report uncomfortable procedures and interactions during their pregnancies as well as feeling misgendered due to gendered terminology used by healthcare providers. Outside of the healthcare system, pregnant transgender men may experience gender dysphoria due to cultural assumptions that all pregnant people are cisgender women.[137] These people use three common approaches to navigating their pregnancy: passing as a cisgender woman, hiding their pregnancy, or being out and visibly pregnant as a transgender man.[137] Some transgender and gender diverse patients describe their experience in seeking gynaecological and reproductive health care as isolating and discriminatory, as the strictly binary healthcare system often leads to denial of healthcare coverage or unnecessary revelation of their transgender status to their employer.[180]
Many transgender people retain their original sex organs and choose to have children through biological reproduction. Advances in assisted reproductive technology and fertility preservation have broadened the options transgender people have to conceive a child using their own gametes or a donor's. Transgender men and women may opt for fertility preservation before any gender affirming surgery, but it is not required for future biological reproduction.[137][181] It is also recommended that fertility preservation is conducted before any hormone therapy.[178] Additionally, while fertility specialists often suggest that transgender men discontinue their testosterone hormones prior to pregnancy, research on this topic is still inconclusive.[182][137] However, a 2019 study found that transgender male patients seeking oocyte retrieval via assisted reproductive technology (including IVF) were able to undergo treatment four months after stopping testosterone treatment, on average.[183] All patients experienced menses and normal AMH, FSH and E2 levels and antral follicle counts after coming off testosterone, which allowed for successful oocyte retrieval.[183] Despite assumptions that the long-term androgen treatment negatively impacts fertility, oocyte retrieval, an integral part of the IVF process, does not appear to be affected.
Biological reproductive options available to transgender women include, but are not limited to, IVF and IUI with the trans woman's sperm and a donor or a partner's eggs and uterus. Fertility treatment options for transgender men include, but are not limited to, IUI or IVF using his own eggs with a donor's sperm and/or donor's eggs, his uterus, or a different uterus, whether that is a partner's or a surrogate's.[184]
Use by disabled individuals
[edit]People with disabilities who wish to have children are equally or more likely than the non-disabled population to experience infertility,[173] yet disabled individuals are much less likely to have access to fertility treatment such as IVF. There are many extraneous factors that hinder disabled individuals access to IVF, such as assumptions about decision-making capacity, sexual interests and abilities, heritability of a disability, and beliefs about parenting ability.[185][186] These same misconceptions about people with disabilities that once led health care providers to sterilise thousands of women with disabilities now lead them to provide or deny reproductive care on the basis of stereotypes concerning people with disabilities and their sexuality.[173]
Not only do misconceptions about disabled individuals parenting ability, sexuality, and health restrict and hinder access to fertility treatment such as IVF, structural barriers such as providers uneducated in disability healthcare and inaccessible clinics severely hinder disabled individuals access to receiving IVF.[173]
By country
[edit]Australia
[edit]In Australia, the average age of women undergoing ART treatment is 35.5 years among those using their own eggs (one in four being 40 or older) and 40.5 years among those using donated eggs.[187] While IVF is available in Australia, Australians using IVF are unable to choose their baby's gender.[188]
Cameroon
[edit]Ernestine Gwet Bell supervised the first Cameroonian child born by IVF in 1998.[189]
Canada
[edit]In Canada, one cycle of IVF treatment can cost between $7,750 and $12,250 CAD, and medications alone can cost from $2,500 to over $7,000 CAD.[190] The funding mechanisms that influence accessibility in Canada vary by province and territory, with some provinces providing full, partial or no coverage.
New Brunswick provides partial funding through their Infertility Special Assistance Fund – a one-time grant of up to $5,000. Patients may only claim up to 50% of treatment costs or $5,000 (whichever is less) incurred after April 2014. Eligible patients must be full-time New Brunswick residents with a valid Medicare card[191] and have an official medical infertility diagnosis by a physician.[192]
In December 2015, the Ontario provincial government enacted the Ontario Fertility Program for patients with medical and non-medical infertility, regardless of sexual orientation, gender or family composition. Eligible patients for IVF treatment must be Ontario residents under the age of 43 and have a valid Ontario Health Insurance Plan card and have not already undergone any IVF cycles. Coverage is extensive, but not universal. Coverage extends to certain blood and urine tests, physician/nurse counselling and consultations, certain ultrasounds, up to two cycle monitorings, embryo thawing, freezing and culture, fertilisation and embryology services, single transfers of all embryos, and one surgical sperm retrieval using certain techniques only if necessary. Drugs and medications are not covered under this program, along with psychologist or social worker counselling, storage and shipping of eggs, sperm or embryos, and the purchase of donor sperm or eggs.[193]
In October 2025 the Ontario provincial government expanded the OFP to include an additional $250 million investment as well as a fertility tax credit.[194] The tax credit is effective as of January 2025 and covers 25% of eligible fertility-related expenses up to $20,000, providing a maximum annual credit of $5,000. The scheme is available to Ontario residents with a valid OHIP card and eligible fertility expenses paid on or after 1 January 2025, who are not being reimbursed by private insurance.[195]
China
[edit]IVF is expensive in China and not generally accessible to unmarried women.[196] In August 2022, China's National Health Authority announced that it will take steps to make assisted reproductive technology more accessible, including by guiding local governments to include such technology in its national medical system.[196]
Croatia
No egg or sperm donations take place in Croatia, however using donated sperm or egg in ART and IUI is allowed. With donated eggs, sperm or embryo, a heterosexual couple and single women have legal access to IVF. Male or female couples do not have access to ART as a form of reproduction. The minimum age for males and females to access ART in Croatia is 18 there is no maximum age. Donor anonymity applies, but the born child can be given access to the donor's identity at a certain age[197]
India
[edit]The penetration of the IVF market in India is quite low, with only 2,800 cycles per million infertile people in the reproductive age group (20–44 years), as compared to China, which has 6,500 cycles. The key challenges are lack of awareness, affordability and accessibility.[198] Since 2018, however, India has become a destination for fertility tourism, because of lower costs than in the Western world. In December 2021, the Lok Sabha passed the Assisted Reproductive Technology (Regulation) Bill 2020, to regulate ART services including IVF centres, sperm and egg banks.[199]
Israel
[edit]Israel has the highest rate of IVF in the world, with 1,657 procedures performed per million people per year.[200] Couples without children can receive funding for IVF for up to two children. The same funding is available for people without children who will raise up to two children in a single parent home. IVF is available for people aged 18 to 45.[201] The Israeli Health Ministry says it spends roughly $3450 per procedure.[citation needed]
Sweden
[edit]One, two or three IVF treatments are government subsidised for people who are younger than 40 and have no children. The rules for how many treatments are subsidised, and the upper age limit for the people, vary between different county councils.[202] Single people are treated, and embryo transfers (so-called "embryo adoptions") are allowed. There are also private clinics that offer the treatment for a fee.[203]
United Kingdom
[edit]Availability of IVF in England is determined by Clinical Commissioning Groups (CCGs). The National Institute for Health and Care Excellence (NICE) recommends up to 3 cycles of treatment for people under 40 years old with minimal success conceiving after 2 years of unprotected sex. Cycles will not be continued for people who are older than 40 years.[204] CCGs in Essex, Bedfordshire and Somerset have reduced funding to one cycle, or none, and it is expected that reductions will become more widespread. Funding may be available in "exceptional circumstances" – for example if a male partner has a transmittable infection or one partner is affected by cancer treatment. According to the campaign group Fertility Fairness "at the end of 2014 every CCG in England was funding at least one cycle of IVF".[205] Prices paid by the NHS in England varied between under £3,000 to more than £6,000 in 2014/5.[206] In February 2013, the cost of implementing the NICE guidelines for IVF along with other treatments for infertility was projected to be £236,000 per year per 100,000 members of the population.[207]
IVF increasingly appears on NHS treatments blacklists.[208] In August 2017 five of the 208 CCGs had stopped funding IVF completely and others were considering doing so.[209] By October 2017 only 25 CCGs were delivering the three recommended NHS IVF cycles to eligible people under 40.[210] Policies could fall foul of discrimination laws if they treat same sex couples differently from heterosexual ones.[211] In July 2019 Jackie Doyle-Price said that women were registering with surgeries further away from their own home in order to get around CCG rationing policies.[citation needed]
The Human Fertilisation and Embryology Authority said in September 2018 that parents who are limited to one cycle of IVF, or have to fund it themselves, are more likely choose to implant multiple embryos in the hope it increases the chances of pregnancy. This significantly increases the chance of multiple births and the associated poor outcomes, which would increase NHS costs. The president of the Royal College of Obstetricians and Gynaecologists said that funding 3 cycles was "the most important factor in maintaining low rates of multiple pregnancies and reduce(s) associated complications".[212]
United States
[edit]In the United States, overall availability of IVF in 2005 was 2.5 IVF physicians per 100,000 population, and utilisation was 236 IVF cycles per 100,000.[213] 126 procedures are performed per million people per year. Utilisation highly increases with availability and IVF insurance coverage, and to a significant extent also with percentage of single persons and median income.[213] In the US, an average cycle, from egg retrieval to embryo implantation, costs $12,400, and insurance companies that do cover treatment, even partially, usually cap the number of cycles they pay for.[214] As of 2015, more than 1 million babies had been born utilising IVF technologies.[37]
In the US, as of September 2023, 21 states and the District of Columbia had passed laws for fertility insurance coverage. In 15 of those jurisdictions, some level of IVF coverage is included, and in 17, some fertility preservation services are included. Eleven states require coverage for both fertility preservation and IVF: Colorado, Connecticut, Delaware, Maryland, Maine, New Hampshire, New Jersey, New York, Rhode Island, Utah, and Washington D.C.[215] The states that have infertility coverage laws are Arkansas, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Louisiana, Maryland, Massachusetts, Montana, New Hampshire, New Jersey, New York, Ohio, Rhode Island, Texas, Utah, and West Virginia.[216] As of July 2023, New York was reportedly the only state Medicaid program to cover IVF.[217] These laws differ by state but many require an egg be fertilised with sperm from a spouse and that in order to be covered you must show you cannot become pregnant through penile-vaginal sex.[216] These requirements are not possible for a same-sex couple to meet.[217]
Many fertility clinics in the United States limit the upper age at which people are eligible for IVF to 50 or 55 years.[218] These cut-offs make it difficult for people older than fifty-five to utilise the procedure.[218]
Legal status
[edit]Government agencies in China passed bans on the use of IVF in 2003 by unmarried people or by couples with certain infectious diseases.[219]
In India, the use of IVF as a means of sex selection (preimplantation genetic diagnosis) is banned under the Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994.[220][221][222]
Sunni Muslim nations generally allow IVF between married couples when conducted with their own respective sperm and eggs, but not with donor eggs from other couples. But Iran, which is Shi'a Muslim, has a more complex scheme. Iran bans sperm donation but allows donation of both fertilised and unfertilised eggs. Fertilised eggs are donated from married couples to other married couples, while unfertilised eggs are donated in the context of mut'ah or temporary marriage to the father.[223]
By 2012 Costa Rica was the only country in the world with a complete ban on IVF technology, it having been ruled unconstitutional by the nation's Supreme Court because it "violated life."[224] Costa Rica had been the only country in the western hemisphere that forbade IVF. A law project sent reluctantly by the government of President Laura Chinchilla was rejected by parliament. President Chinchilla has not publicly stated her position on the question of IVF. However, given the massive influence of the Catholic Church in her government any change in the status quo seems very unlikely.[225][226] In spite of Costa Rican government and strong religious opposition, the IVF ban has been struck down by the Inter-American Court of Human Rights in a decision of 20 December 2012.[227] The court said that a long-standing Costa Rican guarantee of protection for every human embryo violated the reproductive freedom of infertile couples because it prohibited them from using IVF, which often involves the disposal of embryos not implanted in a woman's uterus.[228] On 10 September 2015, President Luis Guillermo Solís signed a decree legalising in-vitro fertilisation. The decree was added to the country's official gazette on 11 September. Opponents of the practice have since filed a lawsuit before the country's Constitutional Court.[229]
All major restrictions on single but infertile people using IVF were lifted in Australia in 2002 after a final appeal to the Australian High Court was rejected on procedural grounds in the Leesa Meldrum case. A Victorian federal court had ruled in 2000 that the existing ban on all single women and lesbians using IVF constituted sex discrimination.[230] Victoria's government announced changes to its IVF law in 2007 eliminating remaining restrictions on fertile single women and lesbians, leaving South Australia as the only state maintaining them.[231]
United States
[edit]Despite strong popular support (7 out of 10 adults consider IVF access a good thing[232] and 67% believe that health insurance plans should cover IVF[233]), IVF can involve complicated legal issues and has become a contentious issue in US politics.[234][235] Federal regulations include screening requirements and restrictions on donations,[236] but these generally do not affect heterosexually intimate partners.[237] Doctors may be required to provide treatments to unmarried or LGBTQ couples under non-discrimination laws, as for example in California.[133] The state of Tennessee proposed a bill in 2009 that would have defined donor IVF as adoption.[238] During the same session, another bill proposed barring adoption from any unmarried and cohabitating couple, and activist groups stated that passing the first bill would effectively stop unmarried women from using IVF.[239][240] Neither of these bills passed.[241]
In 2023, the Practice Committee of the American Society for Reproductive Medicine (ASRM) updated its guidelines for the definition of "infertility" to include those who need medical interventions "in order to achieve a successful pregnancy either as an individual or with a partner."[242] In many states, legal and financial decisions about provision of infertility treatments reference this "official" definition.[243] On September 29, 2024, California Governor Gavin Newsom signed SB 729, legislation which aligns with the ASRM definition of "infertility".[244][245]
In the United States, much of the opposition to the use of IVF is associated with the anti-abortion movement, evangelicals, and denominations such as the Southern Baptists.[246] Current legal opposition to IVF and other fertility treatment access has stemmed from recent court rulings regarding women's reproductive healthcare. In the 2022 Dobbs v. Jackson Women's Health Organization decision,[247] the U.S. Supreme Court overturned the 1973 Roe v. Wade[248] decision which had federally protected the right to abortion. The 2024 Alabama Supreme Court decision regarding IVF has since threatened IVF access and legality in the U.S. Frozen embryos at an IVF clinic were accidentally destroyed, resulting in a lawsuit during which the attorneys for the plaintiff sought damages under the Wrongful Death of a Minor Act. The court ruled in favor of the plaintiffs, setting a state-level precedent that embryos and fetuses are given the same rights as minors/children, regardless of whether they are in utero or not.[249] This has created confusion over the status of unused embryos and questions surrounding when life begins. After the court's decision, numerous IVF clinics in Alabama halted IVF treatment services[250] for fears of civil and criminal liability associated with the new rights granted to embryos. Since, laws proposing embryonic personhood have been proposed in 13 other states,[251] creating fear of further state restrictions. This ruling raised concerns from The National Infertility Association and the American Society for Reproductive Medicine that the decision would mean Alabama's bans on abortion prohibit IVF as well,[252] while the University of Alabama at Birmingham health system paused IVF treatments.[253] Eight days later the Alabama legislature voted to protect IVF providers and patients from criminal or civil liability.[254][255]
The Right to IVF Act, federal legislation that would have codified a right to fertility treatments and provided insurance coverage for in vitro fertilisation treatments, was twice brought to a vote in the Senate in 2024. Both times it was blocked by Senate Republicans, of whom only Lisa Murkowski and Susan Collins voted to move the bill forward.[256][246][257][258]
Few American courts have addressed the issue of the "property" status of a frozen embryo. This issue might arise in the context of a divorce case, in which a court would need to determine which spouse would be able to decide the disposition of the embryos. It could also arise in the context of a dispute between a sperm donor and egg donor, even if they were unmarried. In 2015, an Illinois court held that such disputes could be decided by reference to any contract between the parents-to-be. In the absence of a contract, the court would weigh the relative interests of the parties.[259]
On February 18, 2025, President Donald Trump signed an executive order which, according to the White House website, "directs policy recommendations to protect IVF access and aggressively reduce out-of-pocket and health plan costs for such treatments".[260] Trump has expressed support for IVF programs in the past, aiming to reduce the cost of such procedures.[261]
Anthropological perspectives
[edit]Overview
[edit]Human reproduction from an anthropological perspective is not considered as a wholly biological mechanism, as it is influenced by the surrounding culture and society. These societal beliefs control what are classified as suitable methods of human reproduction.[262] Since its development in the 1970s, IVF has become a socially approved method of reproduction in many cultures. The acceptance of IVF technology in different societies has changed its perception from a 'stigmatised' medical tool to a new way to bring human life into the world.[262][263] Its acceptance can be based on sociological and anthropological models of reproduction as these societies have changed their classification of reproduction to include this technology as a valid form of procreation, just like traditional methods of conception.
Whilst IVF allows for women facing hardship with 'natural' methods to conceive, its use extends beyond that. People may seek the technology to satisfy societal and familial pressures of repopulation, ensuring that they use everything available to them to increase the chance of conception, or even as a means to strengthen affinal or kinship relations by procreating.[262] These external pressures are the inception of differing attitudes in cultures towards IVF technology being used on a regular basis as an aid in human reproduction.
Japan
[edit]In Japan, IVF has become a widely used form of assisted reproduction, shaped by culture, ethics and policy as the nation's birth rates decline and marriages and pregnancy occur later in life.[264] Cultural values deeply influence the practice; embryos are not viewed simply as biological matter but rather are ingrained with social and moral meaning.[265] Based on the interviews of 58 women in Japan who underwent IVF treatment, anthropologists suggest that the embryos' status is underexplored in Japanese public discourse due to the widespread belief that their social and emotional significance is unimportant. These interviews, however, revealed that women attribute emotional, familial and spiritual values to embryos, which largely influence the decisions around their use, storage and disposal.[266]
The commodification of IVF is reflected in the private and unregulated nature of the fertility industry in Japan. Access to IVF is often limited by societal norms and financial means, with most treatments not being covered by health insurance, hindering access for women who are unmarried, in same-sex relationships, or with limited finances.[264][266] Such practices reveal how broader social expectations, such as maintaining traditional family values and genetic lineage, can influence who can and cannot access assisted reproduction.
Alternatives
[edit]Some alternatives to IVF are:
- Artificial insemination, including intracervical insemination and intrauterine insemination of semen. It requires that a woman ovulates, but is a relatively simple procedure, and can be used in the home for self-insemination without medical practitioner assistance.[267] The beneficiaries of artificial insemination are people who desire to give birth to their own child who may be single, in a lesbian relationship, or in a heterosexual relationship where the male partner is infertile or has a physical impairment which prevents full intercourse from taking place.
- Ovulation induction (in the sense of medical treatment aiming for the development of one or two ovulatory follicles) is an alternative for people with anovulation or oligoovulation, since it is less expensive and more easy to control.[13] It generally involves antiestrogens such as clomifene citrate or letrozole, and is followed by natural or artificial insemination.
- Surrogacy, the process in which a surrogate agrees to bear a child for another person or persons, who will become the child's parent(s) after birth. People may seek a surrogacy arrangement when pregnancy is medically impossible, when pregnancy risks are too dangerous for the intended gestational carrier, or when a single man or a male couple wish to have a child.
- Adoption whereby a person assumes the parenting of another, usually a child, from that person's biological or legal parent or parents.
See also
[edit]References
[edit]- ^ "Louise Brown: World's first IVF baby's family archive unveiled". BBC News. 24 July 2018. Retrieved 29 July 2021.
- ^ a b Moreton C (14 January 2007). "World's first test-tube baby Louise Brown has a child of her own". Independent. London. Retrieved 21 May 2010.
The 28-year-old, whose pioneering conception by in-vitro fertilisation made her famous around the world. The fertility specialists Patrick Steptoe and Bob Edwards became the first to successfully carry out IVF by extracting an egg, impregnating it with sperm and planting the resulting embryo back into the mother
- ^ a b Gosden R (June 2018). "Jean Marian Purdy remembered – the hidden life of an IVF pioneer". Human Fertility. 21 (2): 86–89. doi:10.1080/14647273.2017.1351042. PMID 28881151. S2CID 5045457.
- ^ a b "After IVF, some couples get pregnant without help". Reuters. 3 May 2012. Retrieved 5 November 2015.
- ^ eClinicalMedicine (November 2023). "The current status of IVF: are we putting the needs of the individual first?". eClinicalMedicine. 65 102343. doi:10.1016/j.eclinm.2023.102343. PMC 10725012. PMID 38106562.
- ^ Kamath MS, Mascarenhas M, Franik S, Liu E, Sunkara SK (December 2019). "Clinical adjuncts in in vitro fertilization: a growing list". Fertility and Sterility. 112 (6): 978–986. doi:10.1016/j.fertnstert.2019.09.019. PMID 31703943.
- ^ a b Japji G. Madan and Madhavi Menon, "Exploring the Psychological Impact of In Vitro Fertilization," IAHRW International Journal of Social Sciences Review, Indian Association of Health, Research and Welfare, ISSN-2347-3797, https://iahrw.org/our-services/journals/iahrw-international-journal-of-social-sciences-review/
- ^ Jayaraman KS (19 October 1978). "India reveals deep-frozen test-tube baby". New Scientist. p. 159. Retrieved 4 September 2021.[permanent dead link]
- ^ "Test tube triumph & tragedy – Nobel for UK scientist stirs memory of a Bengal doctor". The Telegraph. 5 October 2010. Retrieved 22 May 2012.
- ^ Test Tube Baby. YouTube. Educational Multimedia Research Centre, Kolkata. 23 August 2013. Retrieved 4 September 2021.
- ^ European Society of Human Reproduction and Embryology (3 July 2018). "More than 8 million babies born from IVF since the world's first in 1978". ScienceDaily. Retrieved 8 December 2018.
- ^ "Fertility: assessment and treatment for people with fertility problems". NICE clinical guideline. February 2013.
- ^ a b Weiss NS, Braam S, König TE, Hendriks ML, Hamilton CJ, Smeenk JM, et al. (November 2014). "How long should we continue clomiphene citrate in anovulatory women?". Human Reproduction. 29 (11): 2482–2486. doi:10.1093/humrep/deu215. PMID 25164024.
- ^ Wade JJ, MacLachlan V, Kovacs G (October 2015). "The success rate of IVF has significantly improved over the last decade". The Australian & New Zealand Journal of Obstetrics & Gynaecology. 55 (5): 473–476. doi:10.1111/ajo.12356. PMID 26174052. S2CID 22535393.
- ^ a b "In vitro fertilization (IVF) Results – Mayo Clinic". www.mayoclinic.org. Retrieved 5 November 2015.
- ^ "Final National Summary Report for 2021". National Summary Report. Retrieved 28 April 2024.
- ^ a b Branswell H (15 December 2008). "Success rate climbs for in vitro fertilisation". The Canadian Press. Archived from the original on 18 March 2009.
- ^ "2006 Assisted Reproductive Technology (ART) Report: Section 2". Centers for Disease Control and Prevention. Archived from the original on 31 March 2009. Retrieved 25 March 2009.
- ^ Neighmond P (21 January 2009). "Study: Sixth Time May Be Charm For In Vitro". Day to Day. National Public Radio.
- ^ "Final National Summary Report for 2021". National Summary Report. Retrieved 28 April 2024.
- ^ "YourIVFSuccess". YourIVFSuccess. Retrieved 1 March 2021.
- ^ "2019 Clinic Summary Report". Society for Assisted Reproductive Technology. Archived from the original on 4 February 2020. Retrieved 21 April 2022.
- ^ de La Rochebrochard E, Quelen C, Peikrishvili R, Guibert J, Bouyer J (July 2009). "Long-term outcome of parenthood project during in vitro fertilization and after discontinuation of unsuccessful in vitro fertilization". Fertility and Sterility. 92 (1): 149–156. doi:10.1016/j.fertnstert.2008.05.067. PMID 18706550. S2CID 207633738.
- ^ a b "In vitro fertilization (IVF) – Mayo Clinic". www.mayoclinic.org. Retrieved 29 October 2022.
- ^ "Miscarriage". www.marchofdimes.org. Retrieved 18 March 2024.
- ^ van Loendersloot LL, van Wely M, Limpens J, Bossuyt PM, Repping S, van der Veen F (2010). "Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis". Human Reproduction Update. 16 (6): 577–589. doi:10.1093/humupd/dmq015. PMID 20581128.
- ^ a b c d e Fertility: Assessment and Treatment for People with Fertility Problems (PDF). London: RCOG Press. 2004. ISBN 978-1-900364-97-3. Archived from the original (PDF) on 15 November 2010.
- ^ Zhao J, Zhang Q, Li Y (November 2012). "The effect of endometrial thickness and pattern measured by ultrasonography on pregnancy outcomes during IVF-ET cycles". Reproductive Biology and Endocrinology. 10 (1) 100. doi:10.1186/1477-7827-10-100. PMC 3551825. PMID 23190428.
- ^ a b Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. (2012). "Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach". Human Reproduction Update. 19 (1): 26–36. doi:10.1093/humupd/dms041. hdl:11380/1158593. PMID 23188168.
- ^ Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM (2014). "The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature". Human Reproduction Update. 20 (4): 560–570. doi:10.1093/humupd/dmu003. PMID 24532220.
- ^ Simon L, Brunborg G, Stevenson M, Lutton D, McManus J, Lewis SE (July 2010). "Clinical significance of sperm DNA damage in assisted reproduction outcome". Human Reproduction. 25 (7): 1594–1608. doi:10.1093/humrep/deq103. PMID 20447937.
- ^ a b Gleicher N, Weghofer A, Lee IH, Barad DH (December 2010). "FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance". PLOS ONE. 5 (12) e15303. Bibcode:2010PLoSO...515303G. doi:10.1371/journal.pone.0015303. PMC 3002956. PMID 21179569.
- ^ a b c Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC (2013). "Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles". Human Reproduction Update. 19 (5): 433–457. doi:10.1093/humupd/dmt014. PMID 23827986.
- ^ Fragouli E, Lalioti MD, Wells D (2013). "The transcriptome of follicular cells: biological insights and clinical implications for the treatment of infertility". Human Reproduction Update. 20 (1): 1–11. doi:10.1093/humupd/dmt044. PMC 3845680. PMID 24082041.
- ^ Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, Opmeer BC, Broekmans FJ (2014). "Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis". Human Reproduction Update. 20 (4): 530–541. doi:10.1093/humupd/dmu011. PMID 24664156.
- ^ Baker VL, Luke B, Brown MB, Alvero R, Frattarelli JL, Usadi R, et al. (September 2010). "Multivariate analysis of factors affecting probability of pregnancy and live birth with in vitro fertilization: an analysis of the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System". Fertility and Sterility. 94 (4): 1410–1416. doi:10.1016/j.fertnstert.2009.07.986. PMID 19740463.
- ^ a b Centers for Disease Control and Prevention; American Society for Reproductive Medicine; Society for Assisted Reproductive Technology (2017). 2015 Assisted Reproductive Technology National Summary Report (PDF) (Report). US Dept of Health and Human Services.
- ^ Frattarelli JL, Miller KA, Miller BT, Elkind-Hirsch K, Scott RT (July 2008). "Male age negatively impacts embryo development and reproductive outcome in donor oocyte assisted reproductive technology cycles". Fertility and Sterility. 90 (1): 97–103. doi:10.1016/j.fertnstert.2007.06.009. PMID 17765235.
- ^ a b c "Regulated fertility services: a commissioning aid". Department of Health UK. 18 June 2009. Archived from the original on 3 January 2011.
- ^ Kelley AS, Badon SE, Lanham MS, Fisseha S, Moravek MB (June 2019). "Body mass index restrictions in fertility treatment: a national survey of OB/GYN subspecialists". J Assist Reprod Genet. 36 (6): 1117–1125. doi:10.1007/s10815-019-01448-3. PMC 6603101. PMID 30963351.
- ^ a b c d e f g h Farquhar C, Marjoribanks J (August 2018). "Assisted reproductive technology: an overview of Cochrane Reviews". The Cochrane Database of Systematic Reviews. 2018 (8) CD010537. doi:10.1002/14651858.CD010537.pub5. PMC 6953328. PMID 30117155.
- ^ "Factors affecting IVF success". IVF-infertility.com. February 2011.
- ^ Siristatidis CS, Basios G, Pergialiotis V, Vogiatzi P (November 2016). "Aspirin for in vitro fertilisation". The Cochrane Database of Systematic Reviews. 11 (11) CD004832. doi:10.1002/14651858.CD004832.pub4. PMC 6463901. PMID 27807847.
- ^ Groeneveld E, Broeze KA, Lambers MJ, Haapsamo M, Dirckx K, Schoot BC, et al. (2011). "Is aspirin effective in women undergoing in vitro fertilization (IVF)? Results from an individual patient data meta-analysis (IPD MA)". Human Reproduction Update. 17 (4): 501–509. doi:10.1093/humupd/dmr007. PMID 21422062.
- ^ Manheimer E, van der Windt D, Cheng K, Stafford K, Liu J, Tierney J, et al. (2013). "The effects of acupuncture on rates of clinical pregnancy among women undergoing in vitro fertilization: a systematic review and meta-analysis". Human Reproduction Update. 19 (6): 696–713. doi:10.1093/humupd/dmt026. PMC 3796945. PMID 23814102.
- ^ a b c d La Marca A, Sunkara SK (2014). "Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice". Human Reproduction Update. 20 (1): 124–140. doi:10.1093/humupd/dmt037. hdl:11380/1061844. PMID 24077980.
- ^ Allersma T, Farquhar C, Cantineau AE (August 2013). "Natural cycle in vitro fertilisation (IVF) for subfertile couples". The Cochrane Database of Systematic Reviews. 2013 (8) CD010550. doi:10.1002/14651858.CD010550.pub2. PMC 7390465. PMID 23990351.
- ^ Evans J, Hannan NJ, Edgell TA, Vollenhoven BJ, Lutjen PJ, Osianlis T, et al. (2014). "Fresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence". Human Reproduction Update. 20 (6): 808–821. doi:10.1093/humupd/dmu027. PMID 24916455.
- ^ "Natural cycle IVF". Human Fertilisation and Embryology Authority. Archived from the original on 12 May 2012.
- ^ Nargund G (July 2009). "Natural/mild assisted reproductive technologies: reducing cost and increasing safety". Women's Health. 5 (4): 359–360. doi:10.2217/whe.09.32. PMID 19586428.
- ^ Heijnen EM, Eijkemans MJ, De Klerk C, Polinder S, Beckers NG, Klinkert ER, et al. (March 2007). "A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial". Lancet. 369 (9563): 743–749. doi:10.1016/S0140-6736(07)60360-2. PMID 17336650. S2CID 25591825.
- ^ Fauser BC, Nargund G, Andersen AN, Norman R, Tarlatzis B, Boivin J, Ledger W (November 2010). "Mild ovarian stimulation for IVF: 10 years later". Human Reproduction. 25 (11): 2678–2684. doi:10.1093/humrep/deq247. PMID 20858698.
- ^ "IVF Treatment Step Four: Final Oocyte". Infertility.about.com. Archived from the original on 18 November 2012. Retrieved 22 May 2012.
- ^ Kovacs P (23 April 2004). "HCG Injection After Ovulation Induction With Clomiphene Citrate]". Medscape.
- ^ Humaidan P, Kol S, Papanikolaou EG, et al. (Copenhagen GnRH Agonist Triggering Workshop Group) (2011). "GnRH agonist for triggering of final oocyte maturation: time for a change of practice?". Human Reproduction Update. 17 (4): 510–524. doi:10.1093/humupd/dmr008. PMID 21450755.
- ^ IVF Process, Methods and Solutions https://techxplore.online/ivf-process-methods-and-solutions/ Archived 9 June 2023 at the Wayback Machine
- ^ Zhang XD, Liu JX, Liu WW, Gao Y, Han W, Xiong S, et al. (2013). "Time of insemination culture and outcomes of in vitro fertilization: a systematic review and meta-analysis". Human Reproduction Update. 19 (6): 685–695. doi:10.1093/humupd/dmt036. PMID 23912477.
- ^ Abyholm T, Tanbo T, Dale PO, Magnus O (February 1992). "In vivo fertilization procedures in infertile women with patent fallopian tubes: a comparison of gamete intrafallopian transfer, combined intrauterine and intraperitoneal insemination, and controlled ovarian hyperstimulation alone". Journal of Assisted Reproduction and Genetics. 9 (1): 19–23. doi:10.1007/BF01204109. PMID 1617244. S2CID 25057205.
- ^ Wetscher F, Havlicek V, Huber T, Gilles M, Tesfaye D, Griese J, et al. (July 2005). "Intrafallopian transfer of gametes and early stage embryos for in vivo culture in cattle". Theriogenology. 64 (1): 30–40. doi:10.1016/j.theriogenology.2004.11.018. PMID 15935840.
- ^ a b Dar S, Lazer T, Shah PS, Librach CL (2014). "Neonatal outcomes among singleton births after blastocyst versus cleavage stage embryo transfer: a systematic review and meta-analysis". Human Reproduction Update. 20 (3): 439–448. doi:10.1093/humupd/dmu001. PMID 24480786.
- ^ Rebmann V, Switala M, Eue I, Grosse-Wilde H (July 2010). "Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study". Human Reproduction. 25 (7): 1691–1698. doi:10.1093/humrep/deq120. PMID 20488801.
- ^ Meseguer M, Rubio I, Cruz M, Basile N, Marcos J, Requena A (December 2012). "Embryo incubation and selection in a time-lapse monitoring system improves pregnancy outcome compared with a standard incubator: a retrospective cohort study". Fertility and Sterility. 98 (6): 1481–9.e10. doi:10.1016/j.fertnstert.2012.08.016. PMID 22975113.
- ^ Armstrong S, Bhide P, Jordan V, Pacey A, Marjoribanks J, Farquhar C (May 2019). "Time-lapse systems for embryo incubation and assessment in assisted reproduction". The Cochrane Database of Systematic Reviews. 5 (5) CD011320. doi:10.1002/14651858.CD011320.pub4. PMC 6539473. PMID 31140578.
- ^ "ERICA Embryo Ranking | Artificial Intelligence for Assisted Reproduction".
- ^ Chavez-Badiola A, Farias AF, Mendizabal-Ruiz G, Drakeley AJ, Garcia-Sánchez R, Zhang JJ (2019). "Artificial vision and machine learning designed to predict PGT-A results". Fertility and Sterility. 112 (3): e231. doi:10.1016/j.fertnstert.2019.07.715.
- ^ Chavez-Badiola A, Flores-Saiffe Farias A, Mendizabal-Ruiz G, Garcia-Sanchez R, Drakeley AJ, Garcia-Sandoval JP (March 2020). "Predicting pregnancy test results after embryo transfer by image feature extraction and analysis using machine learning". Scientific Reports. 10 (1) 4394. Bibcode:2020NatSR..10.4394C. doi:10.1038/s41598-020-61357-9. PMC 7064494. PMID 32157183.
- ^ Timeva T, Shterev A, Kyurkchiev S (October 2014). "Recurrent implantation failure: the role of the endometrium". Journal of Reproduction & Infertility. 15 (4): 173–183. PMC 4227974. PMID 25473625.
- ^ "In vitro fertilization (IVF) – Mayo Clinic". www.mayoclinic.org. Retrieved 31 August 2020.
- ^ a b van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M (July 2015). "Luteal phase support for assisted reproduction cycles". The Cochrane Database of Systematic Reviews. 2015 (7) CD009154. doi:10.1002/14651858.CD009154.pub3. hdl:2066/98072. PMC 6461197. PMID 26148507.
- ^ Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC (2011). "Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis". Human Reproduction Update. 17 (6): 734–740. doi:10.1093/humupd/dmr029. PMID 21733980.
- ^ a b c Mastenbroek S, Twisk M, van der Veen F, Repping S (2011). "Preimplantation genetic screening: a systematic review and meta-analysis of RCTs". Human Reproduction Update. 17 (4): 454–466. doi:10.1093/humupd/dmr003. PMID 21531751.
- ^ Britten N (7 May 2011). "Saviour Sibling Cures Sick Older Brother". The Daily Telegraph, Health News. Archived from the original on 10 May 2011. Retrieved 8 May 2011.
- ^ Mundy L (July–August 2006). "Souls On Ice: America's Embryo Glut and the Wasted Promise of Stem Cell Research". Motherjones.com.
- ^ Porcu E, Fabbri R, Damiano G, Fratto R, Giunchi S, Venturoli S (April 2004). "Oocyte cryopreservation in oncological patients". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 113 (Suppl 1): S14 – S16. doi:10.1016/j.ejogrb.2003.11.004. PMID 15041124.
- ^ "Genetics & IVF Institute". Givf.com. Archived from the original on 21 May 2009. Retrieved 2 November 2016.
- ^ French DB, Sabanegh ES, Goldfarb J, Desai N (March 2010). "Does severe teratozoospermia affect blastocyst formation, live birth rate, and other clinical outcome parameters in ICSI cycles?". Fertility and Sterility. 93 (4): 1097–1103. doi:10.1016/j.fertnstert.2008.10.051. PMID 19200957.
- ^ Worrilow, K. C.; Eid, S.; Matthews, J. M.; Pelts, E. J.; Khoury, C.; Liebermann, J. (1 September 2009). "A multi-site clinical trial evaluating PICSI® versus intracytoplasmic sperm injection (ICSI): positive clinical outcomes observed in a prospective, randomized and double-blinded study". Fertility and Sterility. 92 (3): S36 – S37. doi:10.1016/j.fertnstert.2009.07.141. ISSN 0015-0282.
- ^ Hasanen, Eman; Elqusi, Khaled; ElTanbouly, Salma; Hussin, Abd ElGhafar; AlKhadr, Hanaa; Zaki, Hosam; Henkel, Ralf; Agarwal, Ashok (October 2020). "PICSI vs. MACS for abnormal sperm DNA fragmentation ICSI cases: a prospective randomized trial". Journal of Assisted Reproduction and Genetics. 37 (10): 2605–2613. doi:10.1007/s10815-020-01913-4. ISSN 1573-7330. PMC 7550434. PMID 32772268.
- ^ Banti, Maria; Van Zyl, Estee; Kafetzis, Dimitrios (June 2024). "Sperm Preparation with Microfluidic Sperm Sorting Chip May Improve Intracytoplasmic Sperm Injection Outcomes Compared to Density Gradient Centrifugation". Reproductive Sciences (Thousand Oaks, Calif.). 31 (6): 1695–1704. doi:10.1007/s43032-024-01483-1. ISSN 1933-7205. PMC 11111481. PMID 38393626.
- ^ Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, et al. (2011). "Contemporary genetic technologies and female reproduction". Human Reproduction Update. 17 (6): 829–847. doi:10.1093/humupd/dmr033. PMC 3191938. PMID 21896560.
- ^ Illmensee K, Levanduski M, Vidali A, Husami N, Goudas VT (February 2010). "Human embryo twinning with applications in reproductive medicine". Fertility and Sterility. 93 (2): 423–427. doi:10.1016/j.fertnstert.2008.12.098. PMID 19217091.
- ^ Olivennes F, Mannaerts B, Struijs M, Bonduelle M, Devroey P (August 2001). "Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report". Human Reproduction. 16 (8): 1588–1591. doi:10.1093/humrep/16.8.1588. PMID 11473947.
- ^ Kamath MS, Mascarenhas M, Kirubakaran R, Bhattacharya S (August 2020). "Number of embryos for transfer following in vitro fertilisation or intra-cytoplasmic sperm injection". The Cochrane Database of Systematic Reviews. 2020 (8) CD003416. Cochrane Database Syst Rev. (published 21 August 2020). doi:10.1002/14651858.CD003416.pub5. PMC 8094586. PMID 32827168.
- ^ Tan K, An L, Miao K, Ren L, Hou Z, Tao L, et al. (March 2016). "Impaired imprinted X chromosome inactivation is responsible for the skewed sex ratio following in vitro fertilization". Proceedings of the National Academy of Sciences of the United States of America. 113 (12): 3197–3202. Bibcode:2016PNAS..113.3197T. doi:10.1073/pnas.1523538113. PMC 4812732. PMID 26951653.
- ^ Lou H, Li N, Zhang X, Sun L, Wang X, Hao D, Cui S (July 2020). "Does the sex ratio of singleton births after frozen single blastocyst transfer differ in relation to blastocyst development?". Reproductive Biology and Endocrinology. 18 (1) 72. doi:10.1186/s12958-020-00623-x. PMC 7362517. PMID 32669110.
- ^ Practice Committee of American Society for Reproductive Medicine (November 2008). "Hepatitis and reproduction". Fertility and Sterility. 90 (5 Suppl): S226 – S235. doi:10.1016/j.fertnstert.2008.08.040. PMID 19007636.
- ^ a b c Lutgens SP, Nelissen EC, van Loo IH, Koek GH, Derhaag JG, Dunselman GA (November 2009). "To do or not to do: IVF and ICSI in chronic hepatitis B virus carriers". Human Reproduction. 24 (11): 2676–2678. doi:10.1093/humrep/dep258. PMID 19625309.
- ^ "Japan Bans in Vitro Fertilisation for HIV Couples". Infoniac.com. 21 July 2008. Archived from the original on 19 September 2013. Retrieved 3 August 2013.
- ^ Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. (2012). "Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta-analysis". Human Reproduction Update. 19 (2): 105–123. doi:10.1093/humupd/dms051. PMID 23255514. S2CID 10086076.
- ^ Sergentanis TN, Diamantaras AA, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET (2013). "IVF and breast cancer: a systematic review and meta-analysis". Human Reproduction Update. 20 (1): 106–123. doi:10.1093/humupd/dmt034. PMID 23884897.
- ^ a b Rockliff HE, Lightman SL, Rhidian E, Buchanan H, Gordon U, Vedhara K (2014). "A systematic review of psychosocial factors associated with emotional adjustment in in vitro fertilization patients". Human Reproduction Update. 20 (4): 594–613. doi:10.1093/humupd/dmu010. PMID 24676468.
- ^ a b Volgsten H, Skoog Svanberg A, Ekselius L, Lundkvist O, Sundström Poromaa I (March 2010). "Risk factors for psychiatric disorders in infertile women and men undergoing in vitro fertilization treatment". Fertility and Sterility. 93 (4): 1088–1096. doi:10.1016/j.fertnstert.2008.11.008. PMID 19118826.
- ^ Botts S, Ryan M. Drug-Induced Diseases Section IV: Drug-Induced Psychiatric Diseases Chapter 18: Depression. pp. 1–23. Archived from the original on 23 December 2010.
- ^ Henriksson P, Westerlund E, Wallén H, Brandt L, Hovatta O, Ekbom A (January 2013). "Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study". BMJ. 346 (3) e8632. doi:10.1136/bmj.e8632. PMC 3546085. PMID 23321489.
- ^ Dayan N, Filion KB, Okano M, Kilmartin C, Reinblatt S, Landry T, et al. (September 2017). "Cardiovascular Risk Following Fertility Therapy: Systematic Review and Meta-Analysis". Journal of the American College of Cardiology. 70 (10): 1203–1213. doi:10.1016/j.jacc.2017.07.753. PMID 28859782.
- ^ Hunault CC, Habbema JD, Eijkemans MJ, Collins JA, Evers JL, te Velde ER (September 2004). "Two new prediction rules for spontaneous pregnancy leading to live birth among subfertile couples, based on the synthesis of three previous models". Human Reproduction. 19 (9): 2019–2026. doi:10.1093/humrep/deh365. hdl:1765/13422. PMID 15192070.
- ^ Shimizu Y, Kodama H, Fukuda J, Murata M, Kumagai J, Tanaka T (January 1999). "Spontaneous conception after the birth of infants conceived through in vitro fertilization treatment". Fertility and Sterility. 71 (1): 35–39. doi:10.1016/S0015-0282(98)00417-8. PMID 9935113.
- ^ Hansen M, Kurinczuk JJ, Milne E, de Klerk N, Bower C (2013). "Assisted reproductive technology and birth defects: a systematic review and meta-analysis". Human Reproduction Update. 19 (4): 330–353. doi:10.1093/humupd/dmt006. PMID 23449641.
- ^ Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA (February 2009). "Assisted reproductive technology and major structural birth defects in the United States". Human Reproduction. 24 (2): 360–366. doi:10.1093/humrep/den387. PMID 19010807.
- ^ a b Davies MJ, Moore VM, Willson KJ, Van Essen P, Priest K, Scott H, et al. (May 2012). "Reproductive technologies and the risk of birth defects". The New England Journal of Medicine. 366 (19): 1803–1813. doi:10.1056/NEJMoa1008095. PMID 22559061. S2CID 12552533.
- ^ a b Zhu JL, Basso O, Obel C, Bille C, Olsen J (September 2006). "Infertility, infertility treatment, and congenital malformations: Danish national birth cohort". BMJ. 333 (7570): 679. doi:10.1136/bmj.38919.495718.AE. PMC 1584372. PMID 16893903.
- ^ Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari A (2012). "Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis". Human Reproduction Update. 18 (5): 485–503. doi:10.1093/humupd/dms018. PMID 22611174.
- ^ Leslie, Stephen W.; Soon-Sutton, Taylor L.; Khan, Moien AB (25 February 2024). Male Infertility. Treasure Island (FL): StatPearls Publishing. PMID 32965929.
- ^ a b c d e Hart R, Norman RJ (2013). "The longer-term health outcomes for children born as a result of IVF treatment. Part II—Mental health and development outcomes". Human Reproduction Update. 19 (3): 244–250. doi:10.1093/humupd/dmt002. PMID 23449643.
- ^ Berk LE (December 2010). Infants, Children, and Adolescents (7th ed.). Pearson Learning Solutions. p. 67. ISBN 978-0-205-77541-5 – via VitalBook.
- ^ a b Hart R, Norman RJ (2013). "The longer-term health outcomes for children born as a result of IVF treatment: Part I—General health outcomes". Human Reproduction Update. 19 (3): 232–243. doi:10.1093/humupd/dms062. PMID 23449642.
- ^ Bloise E, Feuer SK, Rinaudo PF (2014). "Comparative intrauterine development and placental function of ART concepti: implications for human reproductive medicine and animal breeding". Human Reproduction Update. 20 (6): 822–839. doi:10.1093/humupd/dmu032. PMC 4196686. PMID 24947475.
- ^ Lazaraviciute G, Kauser M, Bhattacharya S, Haggarty P, Bhattacharya S (2014). "A systematic review and meta-analysis of DNA methylation levels and imprinting disorders in children conceived by IVF/ICSI compared with children conceived spontaneously". Human Reproduction Update. 20 (6): 840–852. doi:10.1093/humupd/dmu033. PMID 24961233.
- ^ a b c Williams CL, Bunch KJ, Stiller CA, Murphy MF, Botting BJ, Wallace WH, et al. (November 2013). "Cancer risk among children born after assisted conception". The New England Journal of Medicine. 369 (19): 1819–1827. doi:10.1056/NEJMoa1301675. PMID 24195549.
- ^ Marees T, Dommering CJ, Imhof SM, Kors WA, Ringens PJ, van Leeuwen FE, Moll AC (December 2009). "Incidence of retinoblastoma in Dutch children conceived by IVF: an expanded study". Human Reproduction. 24 (12): 3220–3224. doi:10.1093/humrep/dep335. PMID 19783550.
- ^ Ayers C (2004). "Mother wins $1m for IVF mix-up but may lose son". The Times. Archived from the original on 8 February 2007.
- ^ Swedberg C (15 October 2007). "Reproductive Clinic Uses RFID to Guarantee Parental Identity". RFID Journal. Archived from the original on 16 June 2013.
- ^ Jäschke ML (2020). "Vertauschte Keimzellen und Embryonen". Vertauschte Keimzellen und Embryonen – Analyse reproduktionsmedizinischer Zwischenfälle: Normkontext, Rechtsfolgen, Regelungsbedarf. Studien zum Medizin- und Gesundheitsrecht. Vol. 2. Mohr Siebeck. pp. 1–376. ISBN 978-3-16-159182-2.
{{cite book}}:|work=ignored (help) - ^ Stern HJ (March 2014). "Preimplantation Genetic Diagnosis: Prenatal Testing for Embryos Finally Achieving Its Potential". Journal of Clinical Medicine. 3 (1): 280–309. doi:10.3390/jcm3010280. PMC 4449675. PMID 26237262.
- ^ "Fertility is an Equal-Opportunity Issue for Couples – Penn Medicine". www.pennmedicine.org. Retrieved 31 August 2020.
- ^ Damian BB, Bonetti TC, Horovitz DD (January 2015). "Practices and ethical concerns regarding preimplantation diagnosis. Who regulates preimplantation genetic diagnosis in Brazil?". Brazilian Journal of Medical and Biological Research = Revista Brasileira de Pesquisas Medicas e Biologicas. 48 (1): 25–33. doi:10.1590/1414-431X20144083. PMC 4288489. PMID 25493379.
- ^ Edwards RG (March 2005). "Ethics and moral philosophy in the initiation of IVF, preimplantation diagnosis and stem cells". Reproductive Biomedicine Online. 10 (Suppl 1): 1–8. doi:10.1016/S1472-6483(10)62195-5. PMID 15819997.
- ^ Lawson D (11 March 2008). "Of course a deaf couple want a deaf child". The Independent. London. Retrieved 12 November 2009.
- ^ Appel J (12 March 2009). More 'designer' options. The Winnipeg Sun (Report).
- ^ Jha A (31 May 2007). "Winston: IVF clinics corrupt and greedy". The Guardian. London.
- ^ Dumit J (2012). Drugs for life: how pharmaceutical companies define our health. Durham, NC: Duke University Press. ISBN 978-0-8223-4860-3. OCLC 782252371.
- ^ Dietrich H (May 1986). IVF: what can we do?. Liberation or Loss?. Canberra.
- ^ Warren MA (January 1988). "IVF and women's interests: an analysis of feminist concerns". Bioethics. 2 (1): 37–57. doi:10.1111/j.1467-8519.1988.tb00034.x. PMID 11649236.
- ^ Šťastná, Anna; Fait, Tomáš; Kocourková, Jiřina; Waldaufová, Eva (30 December 2022). "Does Advanced Maternal Age Comprise an Independent Risk Factor for Caesarean Section? A Population-Wide Study". International Journal of Environmental Research and Public Health. 20 (1): 668. doi:10.3390/ijerph20010668. ISSN 1661-7827. PMC 9819592. PMID 36612987.
- ^ Smajdor A (May 2011). "The ethics of IVF over 40". Maturitas. 69 (1): 37–40. doi:10.1016/j.maturitas.2011.02.012. PMID 21435805.
- ^ "At 74, Andhra Woman Becomes The Oldest-Ever To Give Birth". NDTV.com. 6 September 2019. Retrieved 5 November 2015.
- ^ Parks JA (April 1996). "A closer look at reproductive technology and postmenopausal motherhood". CMAJ. 154 (8): 1189–1191. PMC 1487687. PMID 8612255.
- ^ a b The Ethics Committee of the American Society for Reproductive Medicine (October 2009). "Access to fertility treatment by gays, lesbians, and unmarried persons". Fertility and Sterility. 92 (4): 1190–1193. doi:10.1016/j.fertnstert.2009.07.977. PMID 19732884.
- ^ Mechcatie E, Rosenberg K (November 2018). "No Detrimental Effects in Children of Same-Sex Parents". American Journal of Nursing. 118 (11): 55. doi:10.1097/01.NAJ.0000547663.85215.a6. ISSN 0002-936X. PMID 30358598. S2CID 53028172.
- ^ Appel JM (2006). "May doctors refuse infertility treatments to gay patients?". The Hastings Center Report. 36 (4): 20–21. doi:10.1353/hcr.2006.0053. PMID 16898357. S2CID 39694945.
- ^ Dolan M (29 May 2008). "State high court may give gays another victory". Los Angeles Times.
- ^ Goldstein J (19 August 2008). "California Doctors Can't Refuse Care to Gays on Religious Grounds". Wall Street Journal.
- ^ a b Egelko B (19 August 2008). "Bob Doctors can't use bias to deny gays treatment". San Francisco Chronicle.
- ^ Mohajer ST (25 October 2010). "License hearing for Octomom doctor resumes in LA". Associated Press.
- ^ Breuer H (22 October 2010). "Octomom's Doctor Tearfully Apologizes, Admits Mistake". People. Archived from the original on 4 March 2016. Retrieved 22 May 2012.
- ^ "Michael Kamrava's medical license revoked". Los Angeles Times. 1 June 2011.
- ^ a b c d e f g h Besse M, Lampe NM, Mann ES (September 2020). "Experiences with Achieving Pregnancy and Giving Birth Among Transgender Men: A Narrative Literature Review". The Yale Journal of Biology and Medicine. 93 (4): 517–528. PMC 7513446. PMID 33005116.
- ^ Condat A, Mamou G, Lagrange C, Mendes N, Wielart J, Poirier F, et al. (19 November 2020). "Transgender fathering: Children's psychological and family outcomes". PLOS ONE. 15 (11) e0241214. Bibcode:2020PLoSO..1541214C. doi:10.1371/journal.pone.0241214. PMC 7676740. PMID 33211742.
- ^ Obedin-Maliver & Makadon 2016, § "Psychological considerations".
- ^ Obedin-Maliver & Makadon 2016, § "Fertility and achieving pregnancy".
- ^ Scheller CA. "The Untold Story of Donor-Conceived Children". Christianity Today. Archived from the original on 18 July 2012.
- ^ Motluk A (27 May 2011). "Canadian court bans anonymous sperm and egg donation". Nature. doi:10.1038/news.2011.329.
- ^ "'My Daddy's Name is Donor'". NPR. 16 August 2010.
- ^ "Donor-conceived children use Internet to find relatives and share information". Washington Post. 26 September 2011.
- ^ "Donor Embryo: Online Guide for Potential Donors". RESOLVE. Archived from the original on 19 February 2013. Retrieved 3 August 2013.
- ^ a b Beil L (1 September 2009). "What happens to extra embryos after IVF?". CNN.
- ^ Douglas T, Savulescu J (April 2009). "Destroying unwanted embryos in research. Talking Point on morality and human embryo research". EMBO Reports. 10 (4): 307–312. doi:10.1038/embor.2009.54. PMC 2672894. PMID 19337299.
- ^ Hug K (February 2008). "Motivation to donate or not donate surplus embryos for stem-cell research: literature review". Fertility and Sterility. 89 (2): 263–277. doi:10.1016/j.fertnstert.2007.09.017. PMID 18166188.
- ^ Lemonick MD (1999). "Designer Babies". Time Magazine. 153 (1): 64–67. PMID 11656968. Archived from the original on 8 March 2016.
- ^ Feinberg, Rebecca S.; Sinha, Michael S.; Cohen, I. Glenn (4 March 2024). "The Alabama Embryo Decision—The Politics and Reality of Recognizing "Extrauterine Children"". JAMA. 331 (13): 1083–1084. doi:10.1001/jama.2024.3559. ISSN 0098-7484. PMID 38436995.
- ^ "Pope Benedict XVI Declares Embryos Developed For In Vitro Fertilization Have Right To Life", Medical news today, archived from the original on 29 December 2008
- ^ Pope Paul VI (25 July 1968). "Humanae Vitae: Encyclical of Pope Paul VI on the Regulation of Birth, sec 12". Rome: Vatican. Retrieved 25 November 2008.
- ^ a b c Dain A (30 July 2009). "Reconciling religion and infertility". Archived from the original on 4 November 2013.
- ^ "Catechism of the Catholic Church. Section 2377". Rome: Vatican. 1993. Retrieved 25 November 2008.
- ^ a b c Deborah Abbott; Paul Nelson (2002). "The Lutheran Tradition: Religious Beliefs and Healthcare Decisions" (PDF). Park Ridge Center for the Study of Health, Faith, and Ethics. p. 9 February 2021. Archived from the original (PDF) on 9 February 2021.
- ^ Inhorn MC (December 2006). "Making Muslim babies: IVF and gamete donation in Sunni versus Shi'a Islam". Culture, Medicine and Psychiatry. 30 (4): 427–450. doi:10.1007/s11013-006-9027-x. PMC 1705533. PMID 17051430. Archived from the original on 24 June 2009. Retrieved 3 November 2013.
- ^ Tzitz Eliezer 9 p. 247
- ^ Drah B (2012). "Orphans in Sub-Saharan Africa: The Crisis, the Interventions, and the Anthropologist". Africa Today. 59 (2 (Winter2012 2012)): 3–21. doi:10.2979/africatoday.59.2.3. S2CID 144808526.
- ^ Lorenz T (2 October 2019). "How the Pineapple Became the Icon of I.V.F." The New York Times. ISSN 0362-4331. Retrieved 4 October 2019.
- ^ Ilioi EC, Golombok S (2014). "Psychological adjustment in adolescents conceived by assisted reproduction techniques: a systematic review". Human Reproduction Update. 21 (1): 84–96. doi:10.1093/humupd/dmu051. PMC 4255607. PMID 25281685.
- ^ a b c d e Throsby K, Gill R (April 2004). ""It's different for men": masculinity and IVF" (PDF). Men and Masculinities. 6 (4): 330–348. doi:10.1177/1097184X03260958. S2CID 145574208.
- ^ Whittaker A (2009). "Global technologies and transnational reproduction in Thailand". Asian Studies Review. 33 (3): 324. doi:10.1080/10357820903154101. S2CID 143676709.
- ^ Beutel M, Kupfer J, Kirchmeyer P, Kehde S, Köhn FM, Schroeder-Printzen I, et al. (January 1999). "Treatment-related stresses and depression in couples undergoing assisted reproductive treatment by IVF or ICSI". Andrologia. 31 (1): 27–35. doi:10.1111/j.1439-0272.1999.tb02839.x. PMID 9949886. S2CID 22578866.
- ^ Maria Reimann, "Polish men's narratives of IVF treatment," Reproductive BioMedicine and Society Online, Vol. 3 (2016): 120–125
- ^ Japji G. Madan and Madhavi Menon, "Exploring the Psychological Impact of In Vitro Fertilization," IAHRW International Journal of Social Sciences Review, Indian Association of Health, Research and Welfare, ISSN-2347-3797, NAAS Rating 4.42, https://iahrw.org/our-services/journals/iahrw-international-journal-of-social-sciences-review/
- ^ Japji G. Madan and Madhavi Menon, "Exploring the Psychological Impact of In Vitro Fertilization," IAHRW International Journal of Social Sciences Review, Indian Association of Health, Research and Welfare, ISSN-2347-3797, NAAS Rating 4.42, https://iahrw.org/our-services/journals/iahrw-international-journal-of-social-sciences-review/
- ^ Thornton, Rosy (21 March 2008). "European Court of Human Rights: Consent to IVF treatment". International Journal of Constitutional Law. 6 (2): 317–330. doi:10.1093/icon/mon001. Retrieved 7 August 2023.
- ^ Keane M, Long J, O'Nolan G, Faragher L (2017). Assisted reproductive technologies: international approaches to public funding mechanisms and criteria. An evidence review (Report). Dublin: Health Research Board.
- ^ Chambers GM, Adamson GD, Eijkemans MJ (August 2013). "Acceptable cost for the patient and society". Fertility and Sterility. 100 (2): 319–27. doi:10.1016/j.fertnstert.2013.06.017. PMID 23905708.
- ^ a b Weigel G, Ranji U, Long M (15 September 2020). "Coverage and Use of Fertility Services in the U.S." KFF. Retrieved 30 November 2022.
- ^ a b c d e Chambers GM, Sullivan EA, Ishihara O, Chapman MG, Adamson GD (June 2009). "The economic impact of assisted reproductive technology: a review of selected developed countries". Fertility and Sterility. 91 (6): 2281–2294. doi:10.1016/j.fertnstert.2009.04.029. PMID 19481642.
- ^ "Call for infertility care awareness". RTÉ News. 23 September 2009.
- ^ a b c d "Chapter 11: Assisted Reproductive Technologies". ncd.gov. 3 August 2015. Archived from the original on 25 November 2021. Retrieved 7 December 2021.
- ^ a b Learmonth C, Viloria R, Lambert C, Goldhammer H, Keuroghlian AS (September 2018). "Barriers to insurance coverage for transgender patients". American Journal of Obstetrics and Gynecology. 219 (3): 272.e1–272.e4. doi:10.1016/j.ajog.2018.04.046. PMID 29733842. S2CID 205373980.
- ^ Kirubarajan A, Patel P, Leung S, Park B, Sierra S (May 2021). "Cultural competence in fertility care for lesbian, gay, bisexual, transgender, and queer people: a systematic review of patient and provider perspectives". Fertility and Sterility. 115 (5): 1294–1301. doi:10.1016/j.fertnstert.2020.12.002. PMID 33610322. S2CID 231990647.
- ^ "Shared motherhood: The amazing way lesbian couples are having babies". Cosmopolitan. 14 February 2018. Retrieved 21 March 2018.
- ^ Berkowitz D (2020), Goldberg AE, Allen KR (eds.), "Gay Men and Surrogacy", LGBTQ-Parent Families: Innovations in Research and Implications for Practice, Cham: Springer International Publishing, pp. 143–160, doi:10.1007/978-3-030-35610-1_8, ISBN 978-3-030-35610-1
- ^ a b Bayer SR (2017). Bayer SR, Alper MM, Penzias AS (eds.). A Practical Guide for Practitioners Who Care for Infertile Couples, Fourth Edition. CRC Press. doi:10.4324/9781351241496. ISBN 978-1-351-24149-6.
- ^ Hoffkling A, Obedin-Maliver J, Sevelius J (November 2017). "From erasure to opportunity: a qualitative study of the experiences of transgender men around pregnancy and recommendations for providers". BMC Pregnancy and Childbirth. 17 (Suppl 2) 332. doi:10.1186/s12884-017-1491-5. PMC 5688401. PMID 29143629.
- ^ Ghofranian A, Aharon D, Friedenthal J, Hanley WJ, Lee JA, Daneyko M, et al. (2 September 2022). "Family Building in Transgender Patients: Modern Strategies with Assisted Reproductive Technology Treatment". Transgender Health. 9 (1) trgh.2021.0210: 76–82. doi:10.1089/trgh.2021.0210. ISSN 2688-4887. PMC 10835155. PMID 38312448. S2CID 252136338.
- ^ Maxwell S, Noyes N, Keefe D, Berkeley AS, Goldman KN (June 2017). "Pregnancy Outcomes After Fertility Preservation in Transgender Men". Obstetrics and Gynecology. 129 (6): 1031–1034. doi:10.1097/AOG.0000000000002036. PMID 28486372.
- ^ Obedin-Maliver, Juno; Makadon, Harvey J (March 2016). "Transgender men and pregnancy". Obstetric Medicine. 9 (1): 4–8. doi:10.1177/1753495X15612658. PMC 4790470. PMID 27030799.
- ^ a b Leung A, Sakkas D, Pang S, Thornton K, Resetkova N (November 2019). "Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine". Fertility and Sterility. 112 (5): 858–865. doi:10.1016/j.fertnstert.2019.07.014. PMID 31594633. S2CID 203983887.
- ^ ColoCRM. "Transgender Pregnancy Options for Men and Women". CCRM Fertility. Retrieved 7 December 2021.
- ^ Silvers A, Francis L, Badesch B (April 2016). "Reproductive Rights and Access to Reproductive Services for Women with Disabilities". AMA Journal of Ethics. 18 (4): 430–437. doi:10.1001/journalofethics.2016.18.4.msoc1-1604. PMID 27099193.
- ^ Acharya K, Lantos JD (April 2016). "Considering Decision-Making and Sexuality in Menstrual Suppression of Teens and Young Adults with Intellectual Disabilities". AMA Journal of Ethics. 18 (4): 365–372. doi:10.1001/journalofethics.2016.18.4.ecas2-1604. PMID 27099185.
- ^ "More IVF babies but less multiple births". The Australian. 24 September 2009. Archived from the original on 24 September 2009.
- ^ Kippen R, Evans A, Gray E (April 2011). "Australian attitudes toward sex-selection technology". Fertility and Sterility. 95 (5): 1824–1826. doi:10.1016/j.fertnstert.2010.11.050. PMID 21163475.
- ^ Gates Jr HL, Akyeampong E, Niven SJ (2 February 2012). Dictionary of African Biography. OUP USA. pp. 25–. ISBN 978-0-19-538207-5.
- ^ "Assisted reproductive technologies: International approaches to public funding mechanisms and criteria". Health Research Board. 2017. Retrieved 30 November 2019.
- ^ "Medicare and Drug Plans". Government of New Brunswick. 19 April 2013. Archived from the original on 5 December 2019. Retrieved 30 November 2019.
- ^ "Infertility Treatment – Special Assistance Fund". Service New Brunswick. 2018. Archived from the original on 3 October 2019. Retrieved 30 November 2019.
- ^ "Ontario Fertility: Funding Explained". TRIO Fertility. 2016. Retrieved 30 November 2019.
- ^ "Ontario Health Minister Sylvia Jones Announces Ontario's $250 M Fertility-Care Investment LIVE from Pollin Fertility in Toronto". Pollin Fertility. 14 October 2025. Retrieved 18 October 2025.
- ^ "Ontario Connecting More Families to Fertility Supports". Government of Ontario. 8 October 2025. Retrieved 18 October 2025.
- ^ a b "China to discourage abortions to boost low birth rate". Reuters. 16 August 2022. Archived from the original on 16 August 2022. Retrieved 16 August 2022.
{{cite web}}: CS1 maint: bot: original URL status unknown (link) - ^ De Geyter, C; Calhaz-Jorge, C; Kupka, M S; Wyns, C; Mocanu, E; Motrenko, T; Scaravelli, G; Smeenk, J; Vidakovic, S; Goossens, V (2020). "Corrigendum. ART in Europe, 2015: results generated from European registries by ESHRE". Human Reproduction Open. 2020 (3) hoaa038. doi:10.1093/hropen/hoaa038. ISSN 2399-3529. PMC 7508022. PMID 32995563.
- ^ Chatterjee P. "IVF: Fertile Ground". BW Businessworld. Retrieved 8 July 2017.
- ^ "Assisted Reproductive Technology (Regulation) Bill, 2020". Retrieved 2 December 2021.
- ^ Mancini, Susanna (2014). Constitutional Secularism in an Age of Religious Revival. Michel Rosenfeld. Oxford: Oxford University Press, Incorporated. p. 238. ISBN 978-0-19-102516-7.
- ^ "In Vitro Fertilization". health.gov.il. Retrieved 1 August 2019.
- ^ "Three IVF attempts double chances". 14 May 2024.
- ^ "IVF, provrörsbefruktning". 1177.se (in Swedish). Retrieved 23 February 2019.
- ^ "Fertility problems: assessment and treatment". 20 February 2013.
- ^ "RIP IVF? NHS cuts to fertility treatment 'will deny thousands parenthood'". Independent. 2 November 2015. Retrieved 2 November 2015.
- ^ "IVF costs to NHS 'must be capped', says fertility expert". BBC News. 29 October 2015. Retrieved 30 October 2015.
- ^ Fertility: assessment and treatment for people with fertility problems (Report) (2016 update ed.). National Institute for Health and Clinical Excellence. February 2013. p. 7. Archived from the original on 17 February 2017. Retrieved 17 February 2017.
- ^ "NHS access to IVF being cut in England". BBC News. 7 August 2017. Retrieved 5 September 2017.
- ^ "CCGs propose range of new rationing cuts to fill deficit". Healthcare Leader. 16 August 2017. Archived from the original on 6 October 2017. Retrieved 5 October 2017.
- ^ "Number of CCGs offering recommended cycles of IVF drops 50% in 4 years". Healthcare Leader. 30 October 2017. Archived from the original on 26 December 2017. Retrieved 24 December 2017.
- ^ "CCGs warned policies could break discrimination laws". Health Service Journal. 9 November 2017. Retrieved 26 December 2017.
- ^ "Regulator says IVF cuts put mothers and babies at risk". Health Service Journal. 4 September 2018. Retrieved 8 October 2018.
- ^ a b Hammoud AO, Gibson M, Stanford J, White G, Carrell DT, Peterson M (May 2009). "In vitro fertilization availability and utilization in the United States: a study of demographic, social, and economic factors". Fertility and Sterility. 91 (5): 1630–1635. doi:10.1016/j.fertnstert.2007.10.038. PMID 18539275.
- ^ Kraft D (17 July 2011). "Where Families Are Prized, Help Is Free". The New York Times.
- ^ "In what states is IVF covered by insurance?: A comprehensive guide for HR leaders". www.mavenclinic.com. Retrieved 2 October 2024.
- ^ a b "RESOLVE: Insurance Coverage by State". RESOLVE: The National Infertility Association. 17 June 2024. Retrieved 2 October 2024.
- ^ a b Henderson, Tim (29 July 2023). "Fertility health coverage is still hard to come by in many states • Washington State Standard". Washington State Standard. Retrieved 2 October 2024.
- ^ a b Appel JS (15 July 2009). "Motherhood: Is It Ever Too Late?". New York Times.
- ^ "China Bars In-Vitro Fertilization for Pregnancy". Redorbit.com. 12 November 2003. Archived from the original on 15 July 2011. Retrieved 22 May 2012.
- ^ Sharma NC (5 January 2018). "Health ministry receives complaints against web giants for sex determination violations". liveMint. Retrieved 9 July 2020.
- ^ "To ensure prized baby boy, Indians flock to Bangkok | India News – Times of India". The Times of India. 27 December 2010.
- ^ "Chandigarh IVF expert helps police arrest Delhi resident seeking sex selection | Chandigarh News – Times of India". The Times of India. 26 June 2016.
- ^ Inhorn MC. "Islam, IVF and Everyday Life in the Middle East" (PDF). AIME: Anthropology of the Middle East. 1 (1): 37–45. Archived from the original (PDF) on 7 July 2011.
- ^ "IVF Prohibition In Costa Rica". Ivfcostworldwide.com. Archived from the original on 3 March 2017. Retrieved 22 May 2012.
- ^ Murillo Á (12 July 2011). "La Costa Rica católica se atasca con la fertilización in vitro". El Pais.
- ^ "CIDH Extends Deadline For Approval Of Law For In-Vitro Fertilization In Costa Rica". insidecostarica.com. 24 February 2011.
- ^ Catanzaro M (28 December 2012). "Human-rights court orders world's last IVF ban to be lifted". NEWS BLOG. Nature. Retrieved 5 January 2017.
- ^ "Court strikes down Costa Rican ban on in-vitro fertilization". New York Times. Associated Press. 22 December 2012.
- ^ "Costa Rica Finally Allows In Vitro Fertilisation after 15-Year Ban | Inter Press Service". ipsnews.net. 15 September 2015.
- ^ O'Connor P (18 April 2002). "Australian court OKs fertility treatment for single people, lesbians". Associated Press.
- ^ Hoare D (15 December 2007). "Lesbian community welcomes Vic IVF changes". abc.net.au. Archived from the original on 17 December 2007.
- ^ Borelli, Gabriel (13 May 2024). "Americans overwhelmingly say access to IVF is a good thing". Pew Research Center. Retrieved 2 October 2024.
- ^ "Survey shows strong support for increased access to fertility treatments". American Society for Reproductive Medicine. 23 April 2024. Archived from the original on 14 September 2024. Retrieved 2 October 2024.
- ^ Cohen, Rachel M. (26 March 2024). "Why IVF looks different in the US than in the rest of the world". Vox. Retrieved 2 October 2024.
- ^ Parry, John Preston (22 September 2023). "7 Fertility Legal Insights To Avoid Common Pitfalls". positivestepsfertility.com. Retrieved 2 October 2024.
- ^ "21 CFR 1271.90(a)(2)". US Food and Drug Administration. Archived from the original on 28 September 2006.
- ^ "Federal Register, Volume 81 Issue 120 (Wednesday, June 22, 2016)". www.govinfo.gov. Retrieved 2 October 2024.
- ^ "Fiscal Note, HB 2159 – SB 2136, from Tennessee General Assembly Fiscal Review Committee" (PDF). Retrieved 22 May 2012.
- ^ "SB 0078 by Stanley, Bunch. (HB 0605 by DeBerry J, Hensley.)". Wapp.capitol.tn.gov. Archived from the original on 23 August 2014. Retrieved 22 May 2012.
- ^ "Tennessee Seeking To Ban IVF For Unmarried Individuals". Eggdonor.com. 31 March 2009. Retrieved 22 May 2012.
- ^ "Legislative Update". Tnep.org. Archived from the original on 7 February 2008. Retrieved 22 May 2012.
- ^ Sealy, Amanda (23 October 2023). "Infertility gets a new, expanded definition to address 'the reality of all' seeking care, medical group says". CNN. Retrieved 2 October 2024.
- ^ Merelli, Annalisa (24 October 2023). "The official definition of infertility now includes LGBTQ+ and single people". STAT. Retrieved 2 October 2024.
- ^ "California Expands Access to IVF and Makes Infertility Care More LGBTQ Inclusive". Mombian. 30 September 2024. Retrieved 2 October 2024.
- ^ "Governor Signs SB 729, A Victory for Reproductive Justice in California". California State Senator Caroline Menjivar. 29 September 2024. Retrieved 2 October 2024.
- ^ a b Miller, Maya C. (17 June 2024). "Senate G.O.P. Blocks I.V.F. Access Bill as Democrats Press for Political Edge". The New York Times. Retrieved 2 October 2024.
- ^ U.S. Supreme Court (24 June 2022). "Dobbs v. Jackson Women's Health Organization, No. 19-1392" (PDF).
{{cite journal}}: Cite journal requires|journal=(help) - ^ U.S. Supreme Court (22 January 1973). "Roe v. Wade, No. 70-18" (PDF).
{{cite journal}}: Cite journal requires|journal=(help) - ^ Crockin & Nardi. "Alabama Supreme Court Rules Frozen Embryos are "Unborn Children" and admonishes IVF's "Wild West" treatment". American Society for Reproductive Medicine. Archived from the original on 11 November 2024. Retrieved 6 October 2024.
- ^ Sharfstein, Joshua (27 February 2024). "The Alabama Supreme Court's Ruling on Frozen Embryos". Johns Hopkins Bloomberg School of Public Health. Retrieved 6 October 2024.
- ^ Krebs, Natalie (4 June 2024). "The push for embryo rights in state legislatures worries IVF patients and doctors". NPR. Retrieved 11 November 2024.
- ^ "Alabama Supreme Court rules frozen embryos are 'children' under state law". NPR. 20 February 2024.
- ^ Tamsett, Isabel Rosales, Christina Maxouris, Meg Tirrell, Chris Youd, Maxime (21 February 2024). "Days after Alabama's Supreme Court ruling that frozen embryos are children, one facility pauses IVF treatment". CNN. Retrieved 22 February 2024.
{{cite web}}: CS1 maint: multiple names: authors list (link) - ^ Hennessy-Fiske, Molly (1 March 2024). "Alabama lawmakers pass legislation to protect IVF treatment". Washington Post. ISSN 0190-8286. Retrieved 1 March 2024.
- ^ Davis, Erin (1 March 2024). "Bills to protect in vitro fertilization pass in both chambers of Alabama Legislature". WFSA. Retrieved 1 March 2024.
- ^ Karni, Annie (17 September 2024). "Senate Republicans Block I.V.F. Protection Bill a Second Time, Breaking With Trump". The New York Times. Retrieved 2 October 2024.
- ^ Groves, Stephen (13 June 2024). "Senate Republicans block bill on women's right to IVF as Democrats make push on reproductive care". AP News. Retrieved 2 October 2024.
- ^ Trachman, Ellen (20 June 2024). "Keeping Up With IVF Legal Developments (Summer 2024 Edition) - Above the Law". Above The Law. Retrieved 2 October 2024.
- ^ Knight RD (30 May 2020). "Frozen Embryos and Divorce in Illinois". rdklegal.com. Retrieved 11 June 2020.
- ^ "Fact Sheet: President Donald J. Trump Expands Access to In Vitro Fertilization (IVF)". The White House. 18 February 2025. Retrieved 18 February 2025.
- ^ Yilek, Caitlin (18 February 2025). "Trump signs executive order aimed at reducing IVF costs - CBS News". www.cbsnews.com. Retrieved 18 February 2025.
- ^ a b c Franklin, Sarah (2013). "Conception through a looking glass: the paradox of IVF". Reproductive BioMedicine Online. 27 (6): 747–755. doi:10.1016/j.rbmo.2013.08.010. PMID 24139598. Retrieved 17 August 2025.
- ^ Franklin, Sarah (1 December 2006). "Origin stories revisited: ivf as an anthropological project". Culture, Medicine and Psychiatry. 30 (4): 547–555. doi:10.1007/s11013-006-9036-9. ISSN 1573-076X.
- ^ a b Castro-Vazquez, Genaro (2015). "Assisted Reproductive Technologies in Contemporary Japan: Experiences and Perceptions of Some Japanese Mothers". Gender, Technology and Development. 19 (3): 271–291. doi:10.1177/0971852415596862 – via Taylor & Francis.
- ^ Sleeboom-Faulkner, Margaret (2010). "Contested Embryonic Culture in Japan—Public Discussion, and Human Embryonic Stem Cell Research in an Aging Welfare Society". Medical Anthropology. 29 (1): 44–66. doi:10.1080/01459740903304256. PMID 20391158 – via Taylor & Francis.
- ^ a b Kato, Masae; Sleeboom-Faulkner, Margaret (2011). "Meanings of the embryo in Japan: narratives of IVF experience and embryo ownership". Sociology of Health & Illness. 33 (3): 434–447. doi:10.1111/j.1467-9566.2010.01282.x. ISSN 0141-9889. PMID 21226731.
- ^ "Demystifying IUI, ICI, IVI and IVF". Seattle Sperm Bank. 4 January 2014.
Further reading
[edit]- Henig RM (2004). Pandora's Baby: How the First Test Tube Babies Sparked the Reproductive Revolution. New York: Houghton Mifflin. ISBN 978-0-618-22415-9.
- Hope T, Lockwood G, Lockwood M, Bewley S, Jackson J, Craft I (June 1995). "Should older women be offered in vitro fertilisation?". BMJ. 310 (6992): 1455–1458. doi:10.1136/bmj.310.6992.1455. PMC 2549820. PMID 7613283.
- Seng SW, Yeong CT, Loh SF, Sadhana N, Loh SK (March 2005). "In-vitro fertilisation in women aged 40 years and above" (PDF). Singapore Medical Journal. 46 (3): 132–136. PMID 15735878.
External links
[edit]- "UK IVF clinics and statistics]". Human Fertilisation and Embryology Authority. Archived from the original on 7 August 2009.
- "US information, statistics, and lists on assisted reproductive technology". Centers for Disease Control and Prevention. Archived from the original on 23 March 2005.
In vitro fertilisation
View on GrokipediaDefinitions and Terminology
Core Concepts and Procedures
In vitro fertilization (IVF) refers to the process of fertilizing an egg with sperm outside the human body, typically in a laboratory culture dish, with "in vitro" denoting an artificial environment distinct from natural physiological conditions where oocytes mature in the ovary and embryos implant in the uterus.[10][11] This technique addresses infertility by bypassing barriers to natural conception, such as tubal blockages or low sperm motility, through controlled manipulation of gametes and early embryonic development.[12] Core to IVF is the isolation of mature oocytes (eggs), their fertilization to form zygotes that develop into embryos, and subsequent transfer to the uterus for potential implantation, fundamentally altering the site and timing of conception compared to in vivo processes.[10] The procedure begins with ovarian hyperstimulation, where exogenous gonadotropins, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH) analogs, are administered via daily injections for 8-14 days (most commonly 9-12 days, with an average around 10-11 days) to recruit and mature multiple follicles, aiming to yield 10-15 oocytes per cycle rather than the single egg typically released in a natural cycle.[13] The trigger shot (hCG or GnRH agonist) is typically administered when lead follicles reach approximately 18-22 mm in diameter, which often corresponds to stimulation days 9-12, most frequently on days 10 or 11, depending on individual response monitored via ultrasound and estradiol levels. Progress is monitored through transvaginal ultrasound and serial blood estradiol measurements to assess follicular growth and prevent ovarian hyperstimulation syndrome (OHSS), a potential complication involving fluid shifts and abdominal pain.[10] Ovulation is triggered 34-36 hours before egg retrieval, which involves ultrasound-guided aspiration of follicular fluid through a vaginal approach under light sedation, recovering oocytes for immediate lab processing.[13][14] Sperm is collected via masturbation or surgical extraction (e.g., testicular sperm aspiration for severe male factor infertility) and prepared by density gradient centrifugation to select motile spermatozoa, concentrating samples to 50,000-100,000 sperm per oocyte for insemination.[10] Fertilization occurs either conventionally, by co-incubating oocytes with sperm for 4-6 hours to allow natural penetration, achieving rates of 60-70% with normospermic samples, or via intracytoplasmic sperm injection (ICSI), where a single spermatozoon is microinjected into the oocyte cytoplasm, particularly for cases of oligoasthenoteratozoospermia.[10] Resulting zygotes are cultured in specialized media under controlled conditions (37°C, 5% CO2) for 3-5 days, reaching cleavage-stage or blastocyst-stage embryos, with morphological grading (e.g., based on cell number, fragmentation, and symmetry) guiding selection for transfer or cryopreservation.[12][14] Embryo transfer involves catheter insertion through the cervix to deposit 1-2 embryos (per guidelines to minimize multiples) directly into the uterine cavity, typically 2-6 days post-retrieval, without anesthesia.[13] Luteal phase support follows with progesterone supplementation (vaginal, intramuscular, or oral) to sustain endometrial receptivity until pregnancy confirmation via serum hCG testing 9-14 days later, as the procedure disrupts natural corpus luteum function.[10] A full cycle spans 2-3 weeks from stimulation to transfer, though preparation and monitoring extend the timeline.[13] Variations include preimplantation genetic testing (PGT) for aneuploidy screening via embryo biopsy, enhancing selection but adding procedural complexity.[12] After embryo transfer, confirmation of pregnancy is typically done via a beta-hCG blood test 9-14 days later. Considerations for cycle type (fresh vs frozen) affect potential interference from medications (e.g., residual hCG from ovulation trigger in fresh cycles) and optimal testing windows to avoid false positives or misinterpretation.Historical Development
Pioneering Research and Ethical Debates (Pre-1978)
Early experiments in mammalian reproduction laid the groundwork for in vitro fertilisation. In 1878, Samuel Leopold Schenk conducted the first documented attempts at IVF using rabbits and guinea pigs, though without achieving live births.[15] Significant progress occurred in 1959 when Min Chueh Chang at the Worcester Foundation for Experimental Biology successfully fertilized rabbit ova in vitro and achieved the first live birth following embryo transfer to a surrogate, demonstrating that mammalian eggs could develop post-fertilization outside the body.[16][17] These animal models established key principles of sperm capacitation and embryo viability, informing later human applications.[18] Human research advanced in the 1960s under Robert G. Edwards, a physiologist who shifted from animal studies to human oocyte maturation and fertilization. By 1965, Edwards reported maturing human eggs in vitro, building on insights from rabbit and hamster models.[19] In 1968, Edwards collaborated with gynecologist Patrick C. Steptoe, who had pioneered laparoscopy for minimally invasive egg retrieval since the early 1960s.[20] Their joint efforts culminated in 1969 with the first confirmed human IVF, where 18 of 56 oocytes showed evidence of fertilization in vitro, as documented in laboratory observations of pronuclei formation.[20][21] Between 1971 and 1972, the pair performed initial human embryo transfers using hormonal stimulation, though pregnancies were not sustained until later refinements.[22] These advancements sparked intense ethical controversies, primarily over the moral status of embryos and risks of human experimentation. The UK Medical Research Council rejected funding for Edwards and Steptoe's work in 1971, citing ethical reservations about proceeding without prior primate trials and concerns over the experimental use of laparoscopy on women, which limited resources and forced reliance on private support.[23] Religious organizations, including Catholic authorities, opposed IVF as interfering with natural procreation and endangering nascent life, viewing fertilized embryos as possessing full human rights from conception and decrying their potential discard as morally equivalent to infanticide.[24] Right-to-life advocates and segments of the medical establishment echoed these views, labeling the research "unnatural" and prone to eugenic misuse, exacerbated by Edwards' prior involvement in the British Eugenics Society.[25] Public correspondence in the UK during the early 1970s revealed widespread opposition, with critics fearing dehumanization and unknown long-term effects on children.[26] Despite this, Edwards argued that IVF addressed infertility—a natural human drive—and emphasized informed consent and embryo welfare, though institutional biases against non-traditional reproduction delayed progress.[27]First Human Births and Initial Expansion (1978-1990s)
The world's first successful in vitro fertilisation (IVF) birth occurred on 25 July 1978, when Louise Joy Brown was delivered at Oldham General Hospital in England, weighing 2.9 kg after 32 weeks of gestation.[28] [29] Her conception resulted from a natural-cycle IVF procedure performed by gynaecologist Patrick Steptoe and physiologist Robert Edwards, involving the laparoscopic retrieval of a single oocyte, in vitro fertilisation with her father's sperm, and transfer of the resulting embryo to her mother's uterus.[30] [4] This achievement followed over a decade of animal research and human trials, marking the culmination of efforts to overcome tubal infertility.[31] Initial success rates were low, with early IVF cycles yielding live birth rates under 10% per transfer, limited by single-embryo transfers and rudimentary culture media.[4] [32] Subsequent IVF births rapidly followed internationally, demonstrating the technique's replicability despite persistent challenges. Australia's first IVF infant arrived in 1980, followed by the United States' initial success with Elizabeth Jordan Carr on 28 December 1981 at Eastern Virginia Medical School in Norfolk, Virginia, after 67 failed attempts at that clinic.[33] [34] Sweden and France reported their first live births in 1982, expanding IVF beyond the UK.[33] By 1986, more than 1,000 children had been born worldwide via IVF, reflecting growing clinician adoption and procedural refinements such as the introduction of controlled ovarian hyperstimulation with human menopausal gonadotropin (hMG) to retrieve multiple oocytes—averaging 2.1–2.6 per cycle by the early 1980s, which boosted per-transfer pregnancy rates to around 23%.[31] [35] The 1980s and early 1990s saw IVF's initial commercial and institutional expansion, with clinics proliferating in developed nations amid rising infertility awareness and demand. In the US alone, IVF programs grew from a handful in 1981 to dozens by the mid-1980s, driven by private initiatives despite regulatory hurdles and variable state funding.[36] Globally, the technique spread to over 25 countries by 1991, though cumulative live births remained modest—totaling thousands annually by the late 1980s—due to costs exceeding $5,000–$10,000 per cycle and success rates hovering at 5–15% per initiated cycle, influenced by maternal age and embryo quality.[37] [38] Innovations like cryopreservation of embryos (first successful birth in 1984) and improved laboratory conditions began addressing implantation failures, laying groundwork for broader accessibility, though ethical concerns over multiple pregnancies and excess embryos persisted without uniform regulation.[4] [32]Technological Maturation and Global Spread (2000s-Present)
Following the initial decades of IVF, technological refinements in the 2000s and 2010s markedly enhanced embryo viability and procedural efficiency. Vitrification, a rapid cryopreservation technique using ultra-fast freezing to minimize ice crystal formation, supplanted slower traditional methods around 2005, achieving embryo survival rates exceeding 90% compared to 60-70% previously, thereby enabling higher success in frozen embryo transfers.[4] Time-lapse imaging systems, introduced commercially in the early 2010s, allowed non-invasive, continuous monitoring of embryo development without disrupting culture conditions, correlating with improved implantation rates by identifying optimal blastocyst stages more precisely.[39] Preimplantation genetic testing (PGT) advanced with next-generation sequencing integration by the mid-2010s, reducing aneuploidy-related failures and boosting live birth rates per transfer to 50-60% in women under 35 using euploid embryos.[4] These innovations, grounded in empirical lab data, shifted IVF toward single-embryo transfers, cutting multiple gestation risks from over 30% in the 1990s to under 5% by 2020 in high-volume centers.[40] Live birth rates per IVF cycle rose substantially, reflecting cumulative tech impacts: from approximately 20% in 2000 for women under 35 to nearly 50% by the 2010s in optimized protocols, though age-related declines persist, with rates dropping below 10% for women over 40 regardless of advancements.[4] Egg vitrification, validated as non-experimental by the American Society for Reproductive Medicine in 2012 after survival and pregnancy rates matched fresh cycles (around 40-50% per transfer), expanded elective oocyte cryopreservation, with over 100,000 U.S. procedures by 2020.[41] Intracytoplasmic sperm injection (ICSI) refinements, including physiological variants to mimic natural fertilization, addressed male-factor infertility in up to 50% of cycles by the 2010s, sustaining patency rates above 70%.[4] Emerging adjuncts like artificial intelligence for embryo grading, piloted in the late 2010s, show preliminary gains in predictive accuracy over morphokinetics alone, though large-scale validation remains ongoing.[42] IVF's global footprint expanded dramatically, with annual cycles surging from about 500,000 in 2000 to over 3 million by 2018, driven by clinic proliferation in Asia (e.g., India and China accounting for 20-30% of volume) and regulatory easing in Europe.[37] In the U.S., cycles grew from 99,000 in 2000 to 432,000 in 2023 across 371 reporting clinics, yielding over 95,000 babies annually and comprising 2-3% of total births.[3] Developing regions saw uptake via cost reductions (e.g., mini-IVF protocols halving expenses) and medical tourism, though disparities persist: Western Europe and North America host 60% of clinics despite lower infertility burdens, while sub-Saharan Africa lags due to infrastructure limits.[43] By 2023, the global market exceeded $25 billion, with IVF births totaling over 10 million since 1978, underscoring maturation into a standardized intervention amid varying national policies on donor gametes and surrogacy.[44][45]Clinical Process
The clinical process of in vitro fertilisation (IVF) can be described at a middle-school level as follows: Hormone medications are used to stimulate the mother's ovaries to produce multiple eggs, which are then retrieved. In a laboratory, these eggs are combined with sperm from the father. The resulting embryos, which represent the early stage of the developing baby, are cultured for a few days, during which they divide from a single cell into two, then four, eight, and eventually form a ball-shaped blastocyst after about 5-6 days. Doctors examine the embryos and select the healthiest ones for transfer into the mother's uterus, where the pregnancy can continue.Ovarian Hyperstimulation and Egg Retrieval
Ovarian hyperstimulation, also known as controlled ovarian stimulation, entails the administration of exogenous gonadotropins to induce the development of multiple ovarian follicles, thereby increasing the number of eggs available for retrieval in IVF cycles.[46] This process typically spans 8 to 14 days, beginning early in the menstrual cycle, with daily subcutaneous injections of follicle-stimulating hormone (FSH) preparations such as recombinant human FSH (r-hFSH, e.g., Gonal-F or Follistim) at doses ranging from 150 to 450 IU, adjusted based on patient age, ovarian reserve, and response.[46] Protocols vary, including the long GnRH agonist protocol using leuprolide (Lupron) for pituitary downregulation to prevent premature luteinizing hormone (LH) surges, or the shorter GnRH antagonist protocol employing ganirelix or cetrotide, which has demonstrated lower rates of ovarian hyperstimulation syndrome (OHSS) compared to agonists.[47][48] Monitoring occurs via serial transvaginal ultrasounds to assess follicle size (targeting 18-22 mm diameter) and blood assays for estradiol levels, which rise to 200-400 pg/mL per mature follicle, guiding dose adjustments to optimize yield while minimizing risks.[46] Final oocyte maturation is triggered by human chorionic gonadotropin (hCG, e.g., 5,000-10,000 IU intramuscularly) or a GnRH agonist to reduce OHSS incidence, administered 35-36 hours prior to egg retrieval, as this timing aligns with ovulation to capture metaphase II-stage eggs.[49] In high-risk patients, such as those with polycystic ovary syndrome (PCOS) or prior OHSS, milder stimulation or agonist triggers are employed, yielding 5-15 eggs on average per cycle, though outcomes depend on factors like age and baseline antral follicle count.[50][51] Common side effects during ovarian stimulation are frequent but typically mild and temporary. These include fatigue (often pronounced in the later days of stimulation, including the day before egg retrieval), bloating, abdominal discomfort, headaches, mood swings, breast tenderness, and injection site reactions. Fatigue arises primarily from elevated hormone levels—particularly progesterone, which mimics early pregnancy symptoms—as well as the physical toll of multiple growing follicles enlarging the ovaries, frequent early-morning monitoring appointments disrupting sleep, and the emotional stress of the cycle. These symptoms are considered normal and usually resolve after the trigger shot and egg retrieval once stimulation medications cease. Patients are advised to rest, stay hydrated, and contact their clinic if symptoms escalate to severe pain, rapid weight gain, or other signs of OHSS. For managing mild symptoms such as headaches, abdominal discomfort, bloating, or cramping during ovarian stimulation and beyond, patients should be aware of medication guidelines. Many fertility clinics recommend avoiding nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin), naproxen (Aleve), and high-dose aspirin throughout the IVF cycle, particularly from stimulation through embryo transfer. These medications may interfere with ovulation in natural or modified cycles, affect the uterine lining, or impact implantation and early pregnancy due to inhibition of prostaglandins involved in reproductive processes. Evidence on risks is mixed—some studies indicate short-term use has no significant harm or can even be used intentionally to delay ovulation in specific protocols, while others highlight potential concerns, leading to precautionary avoidance recommendations. Some clinics permit limited NSAID use early in stimulation but advise stopping before the trigger shot or retrieval. Acetaminophen (paracetamol, Tylenol) is widely regarded as safe for pain relief during the entire IVF cycle when used at recommended doses (typically not exceeding 4,000 mg daily, often lower for caution), including for post-retrieval discomfort. Non-medication options include heating pads, rest, and hydration. Patients should always follow their specific clinic's protocols, as guidance varies, and contact the fertility team for persistent or severe pain, which may indicate complications like ovarian hyperstimulation syndrome (OHSS). Supporting sources include guidelines from clinics such as LA IVF Clinic, CARE Fertility, UIHC, UCSF CRH, and relevant studies on NSAIDs in fertility.Patient Preparation and Lifestyle Factors During Stimulation
During the ovarian stimulation phase, which involves daily hormone injections to promote multiple follicle development, patients are generally advised to adopt certain lifestyle measures to optimize egg quality and cycle outcomes. A key recommendation from most fertility clinics is complete abstinence from alcohol consumption throughout the stimulation period and up to egg retrieval. Evidence from observational studies indicates that alcohol intake can negatively impact IVF results. For instance, a large study analyzing over 4,700 IVF cycles found that women or men consuming four or more alcoholic drinks per week at the start of the cycle had a 48% higher risk of failed fertilization and a 21% lower live birth rate. Other research has linked even moderate alcohol use (as little as one additional drink per day) to a 13% decrease in eggs aspirated at retrieval and increased miscarriage risks if consumed close to the procedure. Potential mechanisms include hormonal disruption, dehydration (exacerbated by stimulation medications), and direct effects on oocyte quality or meiotic processes. While some clinics permit very moderate intake until 2-3 days before retrieval, the consensus leans toward avoidance to maximize success chances, particularly given the high stakes and costs of IVF cycles. Patients should consult their specific clinic's protocol, as guidelines vary slightly, but abstaining is the safest and most commonly recommended approach. Egg retrieval, or oocyte aspiration, is a minimally invasive procedure performed under conscious sedation or general anesthesia in an outpatient setting, lasting 20-30 minutes.[52] A transvaginal ultrasound probe guides a thin needle (typically 17-gauge) through the posterior vaginal fornix into each ovary, aspirating follicular fluid containing eggs; the fluid is immediately examined in the embryology lab for oocyte recovery, with yields varying from 0 to over 20 per cycle.[52][53] Post-retrieval, constipation is common due to anesthesia, dehydration, medications, and subsequent progesterone supplementation; stool softeners such as docusate sodium (e.g., Colace) are generally safe, commonly recommended, and preferred over stimulant laxatives during the pre-embryo transfer period, though patients should consult their fertility specialist before use.[54] Complications are rare, including bleeding (incidence <0.5%) or infection (<0.1%), managed conservatively.[52] For patients undergoing multiple cycles, a common cautious standard waiting time between egg retrievals is 3 months to minimize physical strain on the ovaries and ensure optimal response in subsequent cycles.[55] A primary risk associated with hyperstimulation is OHSS, characterized by ovarian enlargement, vascular permeability, and third-space fluid shifts, with moderate-to-severe cases occurring in 1-5% of IVF cycles and severe cases in 0.1-2%, disproportionately affecting young women, those with low BMI, PCOS, or high estradiol peaks (>4,000 pg/mL).[50][56] Risk mitigation includes GnRH antagonist protocols, cabergoline prophylaxis, or embryo freezing to defer transfer, as pregnancy exacerbates OHSS via endogenous hCG.[48] Empirical data indicate antagonist protocols reduce OHSS by up to 50% relative to long agonist regimens, underscoring the causal role of LH receptor overstimulation in pathophysiology.[48]Fertilization, Embryo Culture, and Selection
Following oocyte retrieval, fertilization in IVF is performed by combining mature oocytes with spermatozoa in a laboratory setting. Conventional insemination involves adding 50,000 to 100,000 motile sperm per oocyte in a culture dish, permitting natural capacitation and acrosome reaction, with typical fertilization rates of 50-70%.[57] Intracytoplasmic sperm injection (ICSI), introduced in 1991, entails direct microinjection of a single spermatozoon into the oocyte cytoplasm, primarily for male factor infertility, achieving fertilization rates of 70-80%.[58] In non-male factor cases, however, randomized trials demonstrate that ICSI does not enhance cumulative live birth rates over conventional IVF and may reduce blastocyst formation, supporting conventional insemination as the first-line approach when sperm parameters are normal.[59] Fertilization success is verified 16-18 hours later by observing two pronuclei indicating syngamy. Zygotes are then cultured in incubators maintaining 37°C, stable pH, and low oxygen (5% O₂, 6% CO₂) with sequential or single-step media mimicking tubal and uterine environments to support cleavage and compaction. Embryos may be transferred at the cleavage stage (day 3, 6-8 cells) or extended to blastocyst stage (day 5-6, >100 cells with distinct inner cell mass and trophectoderm). Extended culture self-selects robust embryos, as only 30-50% of day-3 embryos reach blastocyst, but risks cycle cancellation if none develop sufficiently.[60] Cochrane reviews confirm higher live birth rates per fresh blastocyst transfer (odds ratio 1.96) versus cleavage-stage, attributed to improved implantation potential, though per started cycle rates may not differ significantly due to attrition.[61][62] Embryo selection integrates morphological grading—assessing fragmentation (<10% ideal), symmetry, and developmental uniformity—with optional adjuncts like time-lapse cinematography for kinetic parameters or oxygen consumption metrics. Preimplantation genetic testing (PGT), especially PGT-A (aneuploidy screening), biopsies trophectoderm cells at blastocyst stage for chromosomal analysis via next-generation sequencing, targeting euploid embryos to minimize aneuploidy-driven failures (prevalence 40-60% in embryos from women >35). PGT-A lowers miscarriage rates (from 20-30% to <10%) and multiples, but large trials show no consistent live birth rate gains, potentially due to mosaicism (10-30% discordance between biopsied and whole embryo cells) causing discard of viable embryos or biopsy artifacts.[63] Recent evidence highlights PGT-A's failure to detect certain structural variants or predict all implantation outcomes, emphasizing its adjunctive rather than definitive role.[64][65]Embryo Transfer and Luteal Phase Support
Embryo transfer involves the placement of one or more cultured embryos into the uterine cavity, typically performed as an outpatient procedure without anesthesia. A thin catheter loaded with embryos is passed through the cervix under transabdominal ultrasound guidance to deposit them into the uterus, allowing for visual confirmation of placement.[66][13] The process occurs 3 to 5 days post-egg retrieval, aligning with natural embryonic development timelines to optimize implantation potential.[12] Transfers are classified by embryonic stage: cleavage-stage (day 3, 6-8 cells) or blastocyst-stage (day 5-6, expanded with inner cell mass and trophectoderm). Blastocyst transfers yield higher live birth rates, such as 74.8% versus 66.3% for cleavage-stage in comparative studies, due to improved selection of viable embryos and better uterine synchrony, though they carry risks of cycle cancellation if no blastocysts develop.[67][60] Excess embryos of suitable quality are cryopreserved for future transfers, enabling sequential attempts without repeated stimulation.[68] To minimize multiple gestations, which complicate approximately 30% of IVF pregnancies with twins when multiple embryos are transferred, elective single embryo transfer (eSET) is recommended for patients under 38 with high-quality embryos, achieving comparable cumulative live birth rates to double transfers while reducing twin rates.[69][70] Guidelines limit transfers to one embryo in favorable cases, escalating to two only for older patients or poorer prognosis, as eSET lowers perinatal risks without compromising overall success when combined with cryopreservation.[71] Luteal phase support addresses the corpus luteum deficiency from gonadotropin suppression during stimulation, which impairs progesterone production essential for endometrial receptivity and early pregnancy maintenance. Progesterone supplementation, initiated the day after retrieval or oocyte trigger, is standard and continues until 8-12 weeks gestation or negative pregnancy test, with vaginal administration (e.g., 400-800 mg daily micronized progesterone) preferred for higher bioavailability and fewer side effects than intramuscular routes.[72][73] Protocols often combine vaginal progesterone with oral dydrogesterone (e.g., 30 mg daily) in frozen transfers, enhancing implantation rates, though optimal dosing varies by cycle type and lacks universal consensus on duration beyond biochemical confirmation.[74][75] Evidence from randomized trials supports its efficacy in fresh cycles, reducing miscarriage risk, but over-supplementation risks side effects like injection-site reactions or bloating.[76]Efficacy Metrics
Live Birth Rates and Influencing Factors
Live birth rates in in vitro fertilization (IVF) represent the proportion of treatment cycles resulting in the delivery of one or more live infants after at least 20 weeks of gestation, excluding elective pregnancy reductions. In the United States, national data from the Centers for Disease Control and Prevention (CDC) for 2022 indicate that 37.5% of assisted reproductive technology (ART) cycles using autologous (patient's own) eggs culminated in a live birth.[77] Similarly, Society for Assisted Reproductive Technology (SART) reports for 2023 show live birth rates per new patient ranging from approximately 48.8% for women under 35 years to lower figures in older groups, reflecting outcomes across intended retrievals.[78] These rates are typically higher when measured per embryo transfer (often 40-50% for younger patients) compared to per cycle initiation (20-30%), as not all cycles yield transferable embryos; live birth rates per embryo transfer typically range from 25–30% across treatments. However, worldwide estimates suggest only 5–10% of all created IVF embryos ultimately result in live births, reflecting high attrition rates from creation to successful implantation and gestation.[79][5] Success varies substantially by patient demographics and treatment specifics, with cumulative live birth rates over multiple cycles reaching 60-80% for women under 35 using untested embryos. In Europe, data from the Human Fertilisation and Embryology Authority (HFEA) for 2023 report a 25% live birth rate per fresh embryo transfer and 33% per frozen embryo transfer using own eggs, providing a typical overall rate around 25–30% across treatments, with improvements attributed to increased single embryo transfers and frozen cycles.[80] Maternal age exerts the dominant influence, as advancing age correlates with declining oocyte quantity and quality, elevated chromosomal abnormalities (aneuploidy), and reduced implantation potential. For instance, CDC-linked analyses show live birth rates dropping from over 50% per transfer for women under 35 to 23.1% for ages 38-40, and under 10% for those over 41 using own eggs.[81] Even euploid (chromosomally normal) embryo transfers exhibit age-related declines, with higher miscarriage rates in older recipients linked to endometrial receptivity or vascular factors rather than embryo genetics alone.[82]| Age Group (Patient's Own Eggs) | Live Birth Rate per Embryo Transfer (Approximate, US Data) | Source |
|---|---|---|
| <35 years | 50-55% | CDC/SART 2021-2023 [5] [78] |
| 35-37 years | 36-40% | CDC [81] |
| 38-40 years | 23-25% | CDC [81] |
| >40 years | <10% | CDC/SART [5] |
Comparative Success Across Demographics
Maternal age is the strongest predictor of IVF success, with live birth rates per embryo transfer declining sharply after age 35 due to reduced oocyte quantity and quality. For women under 35 using their own eggs, national U.S. data from 2020 report average live birth rates of approximately 54.5% per egg retrieval. Rates for ages 35-37 fall to around 40-45%, 38-40 to 25-30%, 41-42 to 10-15%, and over 42 to under 5-10% per cycle, reflecting chromosomal abnormalities and implantation failures increasingly prevalent with advanced age.[92][93][5] Racial and ethnic disparities in IVF outcomes persist after controlling for age and clinic factors, with non-Hispanic White women generally achieving higher live birth rates than Black or Hispanic women. In fresh non-donor cycles, Black women had a 18.7% live birth rate per cycle compared to 26.3% for White women, attributed partly to differences in baseline fertility, uterine receptivity, and embryo quality. Asian women show variable outcomes, with higher IVF utilization rates (17.2 per 1,000 live births) but success comparable to or slightly below Whites in some cohorts; Hispanic women exhibit lower access and success, potentially linked to socioeconomic barriers alongside biological factors like higher PCOS prevalence.[94][95][96] Body mass index (BMI) influences success independently of age, with obesity (BMI ≥30 kg/m²) associated with 10% lower live birth rates due to impaired follicular development, endometrial receptivity, and higher miscarriage risk. Normal BMI (18.5-24.9 kg/m²) correlates with optimal outcomes, while underweight (BMI <18.5) shows mixed effects but often reduced oocyte yield. Smoking, whether by female or male partners, reduces fertilization rates and embryo quality, with smokers requiring roughly twice as many cycles for success and facing up to 60% lower IVF rates in unadjusted analyses, though some adjusted studies find attenuated effects after confounders. Parity offers modest benefit, as women with prior live births have slightly higher per-transfer success (e.g., 5-10% uplift), but this is overshadowed by age. Socioeconomic status inversely correlates with outcomes, with low-SES neighborhoods linked to poorer live births via delayed treatment and comorbidities.[97][98][99]| Demographic Factor | Key Finding on Live Birth Rate | Source Example |
|---|---|---|
| Age <35 | ~50-55% per retrieval | SART/CDC data[88] |
| Age >42 | <10% per cycle | CDC ART reports[5] |
| Black vs. White race | 18.7% vs. 26.3% per cycle | CDC cohort analysis[94] |
| Obesity (BMI ≥30) | 10% reduction vs. normal | Meta-analyses[97] |
| Smoking (female/male) | Up to 60% lower unadjusted | Fertility reviews[100][101] |
Medical Indications and Outcomes
Primary Infertility Treatments
Primary infertility refers to the failure to achieve a pregnancy after 12 months of regular, unprotected sexual intercourse in couples who have never previously conceived.[102][103] In vitro fertilisation (IVF) serves as a primary treatment for primary infertility in cases where less invasive options, such as ovulation induction or intrauterine insemination (IUI), are contraindicated, ineffective, or bypassed due to severe underlying causes.[10][104] IVF is indicated as a frontline intervention for primary infertility stemming from tubal pathology, such as bilateral blockage or hydrosalpinx, where surgical repair offers limited success and IVF bypasses the fallopian tubes entirely, providing an advantage over natural conception by directly overcoming these anatomical barriers.[10][13] It is also primary for severe endometriosis distorting pelvic anatomy or reducing ovarian reserve, diminished ovarian function in younger women, advanced maternal age-related decline, or ovulatory disorders like polycystic ovary syndrome (PCOS) unresponsive to clomiphene citrate or letrozole after 3-6 cycles.[10][104] For male factor infertility involving oligospermia, asthenozoospermia, or teratozoospermia below IUI thresholds, intracytoplasmic sperm injection (ICSI) combined with IVF addresses low fertilization potential directly, compensating for poor sperm quality unavailable in natural processes.[10][105] Unexplained primary infertility after empirical IUI trials warrants IVF to maximize oocyte yield and embryo selection, particularly in women aged 38 or older to shorten time to pregnancy.[106][104] Live birth rates from IVF for primary infertility vary by maternal age, diagnosis, and embryo quality but generally align with overall assisted reproductive technology (ART) benchmarks.[5] For women under 35 years using autologous eggs, national U.S. data report live birth rates of approximately 44-55% per embryo transfer, with cumulative rates reaching 66% after three cycles in select cohorts.[107][108] Primary unexplained infertility exhibits lower per-cycle success compared to secondary cases, with ongoing pregnancy rates around 57% for euploid embryo transfers versus 62% in secondary infertility, though differences narrow after adjustment for confounders like age.[109][110] Factors reducing efficacy include advanced age (live birth rates drop to 10-20% per cycle over 40), obesity, smoking, and suboptimal embryo morphology, while preimplantation genetic testing can enhance outcomes by 10-15% in select primary infertility subgroups through selection of euploid embryos, reducing risks of chromosomal abnormalities, miscarriages, and associated birth defects—advantages not possible in natural conception for high-risk couples.[111][104] Despite these variables, IVF yields higher live birth rates than expectant management or IUI alone for most primary infertility etiologies, with per-cycle rates of 20-40% versus 5-10% for IUI, offering improved chances over unsuccessful natural attempts.[112][113] Children born via IVF for primary infertility show long-term health, IQ, and developmental outcomes comparable to those from natural conception.[114]Applications Beyond Infertility
In vitro fertilization (IVF) facilitates fertility preservation for individuals undergoing treatments that may impair reproductive capacity, such as chemotherapy or radiation for cancer, even among those currently fertile. Egg or embryo cryopreservation via IVF allows postponement of reproduction until after treatment completion and provides control over family planning timing, with success rates for thawing and subsequent pregnancy varying by age and cryopreservation method; for instance, oocyte vitrification yields live birth rates of approximately 30-40% per transfer in women under 35.[115][116] This approach, termed oncofertility, has expanded due to improved cancer survival rates, enabling thousands of patients annually to bank gametes without delaying oncologic care.[117] IVF enables preimplantation genetic testing (PGT) for fertile couples carrying hereditary disorders, allowing biopsy and selection of embryos free from specific monogenic or chromosomal abnormalities before transfer. This reduces the transmission risk of conditions like cystic fibrosis or Huntington's disease, with studies showing cost savings over natural conception followed by prenatal diagnosis and termination; for example, PGT-IVF for single-gene defects can lower long-term healthcare expenses by avoiding affected births.[118][119] Outcomes include implantation rates improved by selecting euploid embryos, though it requires creating multiple embryos via IVF, which introduces procedural risks absent in unassisted conception.[120] Gestational surrogacy relies on IVF to generate embryos from intended parents' or donors' gametes, which are then transferred to a fertile surrogate's uterus, bypassing genetic relation to the carrier. This method supports reproduction for individuals with uterine factors or same-sex male couples, with pregnancy rates per transfer comparable to standard IVF (around 40-50% in optimal cases), though surrogates must undergo hormonal preparation and monitoring.[121][122] Legal and ethical variations exist globally, with higher risks of complications like preeclampsia noted in surrogacy pregnancies compared to autologous IVF.[123] Elective IVF in non-infertile individuals, often for PGT or social deferral, yields clinical pregnancy rates of about 37% per cycle, higher with euploid embryo selection, diverging from infertility-driven cycles due to better baseline ovarian reserve.[124] Such uses, including single embryo transfer to minimize multiples, reflect broadened indications since the 1978 advent of IVF, incorporating social and preventive motives alongside medical ones.[125]Health Risks and Long-Term Effects
Risks to Mothers and Egg Providers
Ovarian hyperstimulation syndrome (OHSS) represents a primary acute risk to women undergoing controlled ovarian stimulation for IVF, characterized by rapid ovarian enlargement, vascular permeability, and fluid shifts leading to abdominal pain, nausea, and in severe cases, thromboembolism, renal failure, or death. Incidence of moderate OHSS ranges from 3% to 6%, while severe cases occur in 0.1% to 2% of IVF cycles, though rates have declined to under 5% with modern protocols like GnRH agonist triggers. High-risk factors include polycystic ovary syndrome, young age, low BMI, high antral follicle count (>24), and prior OHSS episodes, elevating severe OHSS risk to up to 20% in susceptible individuals.[126][127][50][128] Egg retrieval, performed transvaginally under sedation or anesthesia, carries procedural risks including bleeding from ovarian puncture, infection from vaginal flora translocation, and rare organ perforation or vascular injury, with severe hemoperitoneum reported in isolated cases requiring surgical intervention. Anesthesia-related complications, such as respiratory depression or allergic reactions, add further peril, though general anesthesia is increasingly supplanted by lighter sedation to mitigate these. Overall complication rates from retrieval remain low, but symptoms like post-procedure cramping, bloating, or minor bleeding affect most patients transiently.[129][130][131] Long-term risks for IVF mothers include potential ovarian malignancies, with cohort studies indicating no definitive elevation in invasive ovarian cancer but a modest increase in borderline tumors, possibly linked to underlying infertility or stimulation regimens exceeding 12 months' duration. Breast cancer risk shows no sustained association after 21 years' follow-up, though transient elevations in breast, uterine, or thyroid diagnoses have been observed shortly post-treatment. Infertility itself confers higher baseline ovarian cancer risk, confounding attribution to IVF specifically.[132][133][134][135] IVF pregnancies carry additional considerations during delivery. Vaginal delivery is possible and not contraindicated solely due to IVF conception; the mode of delivery is determined by standard obstetric factors such as maternal health, fetal position, and complications. However, cesarean section rates are significantly higher in IVF pregnancies (around 45%) compared to spontaneous conceptions (around 31%), due to factors including advanced maternal age, multiple gestations, gestational complications, and increased monitoring. Cesarean delivery entails surgical risks such as infection, hemorrhage, and extended recovery for mothers.[136] Egg providers, typically young women undergoing similar stimulation and retrieval for donation, face comparable acute risks, including OHSS with 10.3% reporting severe symptoms and 1.6% requiring hospitalization in U.S. surveys. Short-term effects encompass hormone-induced mood swings, bloating, and ovarian cysts, while procedural hazards mirror those in IVF patients. Long-term outcomes remain understudied, with anecdotal reports of premature infertility, breast, or colon cancer emerging years post-donation, but no population-level data confirming elevated risks; donors' awareness of these uncertainties is often incomplete, particularly regarding anesthesia, infection, or bleeding complications. Compensation incentives may encourage repeat cycles, amplifying cumulative exposure without proportional safety data.[137][138][139][140]Risks to Offspring, Including Epigenetic and Developmental Issues
Children conceived through in vitro fertilisation (IVF) and other assisted reproductive technologies (ART) exhibit elevated risks of adverse perinatal outcomes compared to those from natural conception, even among singletons. Singleton IVF births have a preterm delivery rate of approximately 10.7% versus 7.6% in natural conceptions, alongside a 9-10% increased odds of low birth weight.[141] [142] These risks persist after adjusting for confounders such as maternal age and subfertility, though they have declined over time due to practices like elective single embryo transfer, with low birth weight and prematurity rates dropping threefold since the 1990s.[143] In basic terms, IVF babies face a slightly higher risk of birth defects—about 1.2 times that of naturally conceived babies (for example, 2-3 per 100 natural births versus slightly more in IVF)—though the vast majority grow up healthy. This modest increase partly arises from parental factors like age and infertility causes, or multiple pregnancies, rather than solely the IVF method, and can be reduced via genetic testing of embryos. Congenital malformations occur at higher rates in IVF offspring, with meta-analyses indicating a 22% increased odds (OR 1.22, 95% CI 1.17-1.28) of birth defects compared to naturally conceived children.[144] Major anomalies, including cardiac defects, are more prevalent, though risks vary by technique: intracytoplasmic sperm injection (ICSI) shows slightly higher rates than conventional IVF (OR 0.68 for reduced risk with IVF versus ICSI).[145] [146] These elevations are partly attributable to ART procedures beyond underlying parental infertility, as evidenced by systematic reviews separating procedural effects.[147] Epigenetic alterations represent a specific concern, with IVF linked to disrupted genomic imprinting, leading to rare but increased incidences of disorders such as Beckwith-Wiedemann syndrome (BWS), characterized by overgrowth and tumor predisposition due to 11p15 locus methylation errors.[148] Children conceived via ART, particularly fresh embryo transfers, face a several-fold higher risk of imprinting disorders like BWS, Prader-Willi syndrome, and Silver-Russell syndrome, potentially from in vitro culture conditions or superovulation affecting methylation.[149] [150] Observational data report ART conceptions comprising 4-10% of BWS cases despite representing ~1% of births, suggesting a causal procedural role beyond subfertility alone.[151] Long-term developmental outcomes show mixed evidence, but cohort studies indicate that IVF-conceived children have similar overall health, IQ, and development to naturally conceived peers, with comparable cognitive and behavioral profiles up to school age, including no significant differences in internalizing or externalizing behaviors.[152][153] However, risks of cerebral palsy are elevated (up to twofold in singletons), alongside potential increases in neurodevelopmental conditions like autism spectrum disorder and attention deficit hyperactivity disorder, though causality remains debated due to confounding by multiple gestation history; IVF increases multiple births (twins/triplets), leading to higher rates of preterm birth, low birth weight, and cesarean deliveries (around 45% vs. 31% in spontaneous conceptions), which independently raise autism risk, with adjustment for these factors eliminating much of the IVF-autism association.[154][155][156] Cardiovascular and metabolic sequelae, such as altered blood pressure, may persist into adolescence, warranting ongoing surveillance.[157] Overall, while many cohorts demonstrate reassuring general health trajectories, procedural factors like embryo culture media may contribute to subtle epigenetic and physiological vulnerabilities not fully captured in short-term assessments.[158]Technological Expansions
Preimplantation Genetic Testing
Preimplantation genetic testing (PGT) involves the genetic analysis of embryos created via in vitro fertilisation (IVF) to identify chromosomal or genetic abnormalities prior to transfer to the uterus.[159] It encompasses three main categories: PGT for aneuploidy (PGT-A), which screens for abnormal chromosome numbers; PGT for monogenic/single-gene defects (PGT-M), targeting specific inherited disorders; and PGT for structural rearrangements (PGT-SR), detecting chromosomal translocations or inversions.[160] The procedure typically occurs at the blastocyst stage (day 5-6 post-fertilisation), where 5-10 trophectoderm cells are biopsied for analysis using techniques like next-generation sequencing (NGS) or array comparative genomic hybridisation.[161] PGT-M and PGT-SR are established for couples with known genetic risks, such as carriers of cystic fibrosis mutations or balanced translocations, enabling selection of unaffected embryos and thereby avoiding disease transmission or miscarriage due to unbalanced karyotypes.[162] For instance, PGT-M has successfully prevented inheritance of over 600 monogenic conditions since its inception in the early 1990s, with high diagnostic accuracy exceeding 98% when family-specific probes are used.[63] These applications reduce the risk of affected pregnancies from near 50% in at-risk couples to under 2%, though they require prior identification of the causative variant via parental testing.[163] This selective capability addresses genetic risks not mitigable through natural conception alone, supported by empirical data showing sustained reductions in transmission rates across cohorts. PGT-A aims to select euploid (chromosomally normal) embryos to improve IVF outcomes by minimising implantation failures and miscarriages linked to aneuploidy, which affects up to 70% of embryos from women over 40.[164] Retrospective data indicate potential benefits in older cohorts, with improved live birth rates per cycle (e.g., up to 10-15% higher in women aged 35-43) and reduced miscarriage rates (from 20-30% to 10-15%) when transferring tested euploid embryos.[164] [165] However, randomised controlled trials, including a 2021 multicentre study of 1,000+ women aged 20-36, found no overall increase in cumulative live birth rates per IVF cycle with PGT-A (38.5% vs. 42.3% without), attributing this to fewer transferable embryos and potential over-selection against viable mosaic ones.[166] [167] Limitations include embryo biopsy risks, such as potential cell loss or impaired viability, though trophectoderm biopsy yields low damage rates (<1% non-viable post-biopsy).[168] A key challenge is chromosomal mosaicism, where embryos contain mixed cell populations; detected in 10-20% of blastocysts via biopsy, but true self-correcting mosaicism may resolve, leading to viable euploid pregnancies from initially mosaic embryos.[169] Transfers of low-level mosaic embryos (<30% abnormal cells) yield live birth rates of 30-40%, albeit with 1.5-2 times higher miscarriage risk than euploid ones, prompting debates on discarding potentially viable embryos.[170] [171] False positives/negatives occur in 5-10% of cases due to technical artifacts or biopsy sampling error, underscoring PGT's role as probabilistic rather than definitive.[160] Cost-effectiveness analyses favour PGT-M for severe diseases but question PGT-A for broad use, given added expenses ($3,000-6,000 per cycle) without consistent cumulative live birth gains.[172]Cryopreservation and Advanced Storage
Cryopreservation enables the storage of gametes and embryos produced during IVF cycles, allowing deferred transfer and reducing risks such as ovarian hyperstimulation syndrome by separating fertilization from immediate implantation.31871-X/pdf) Techniques involve cooling cells to below -130°C in liquid nitrogen to halt biological activity, with vitrification—the rapid cooling method using cryoprotectants to form a glass-like state—now predominant over traditional slow freezing, which risks ice crystal formation damaging cellular structures.[173] Vitrification yields higher post-thaw survival rates, such as 94.8% for day-3 embryos compared to 88.7% with slow freezing, and 84-99% for oocytes versus 74-90%.[174] [175] For embryos, frozen embryo transfer (FET) outcomes vary by patient factors but often match or exceed fresh transfers in optimized protocols; however, some analyses report live birth rates of 44% for FET versus 56.6% for fresh in certain cohorts, particularly with donor oocytes where fresh yields 55.9% versus 46.2% frozen.[176] [177] In women with low prognosis, fresh transfers may achieve higher live births than freeze-all strategies.[178] Embryo vitrification facilitates multiple cycles from a single retrieval, with survival exceeding 90% in many programs.[179] Oocyte cryopreservation, increasingly used for elective fertility preservation, shows post-thaw survival around 74%, with fertilization rates enabling live births in 30-60% of cycles; cryopreserving at least 20 mature oocytes before age 38 offers a 70% cumulative chance of one live birth.[180] [181] [182] This supports deferred reproduction, extending reproductive options beyond natural timelines, with empirical data confirming comparable ongoing pregnancy rates to fresh oocytes in younger patients. Utilization rates remain low, at 12.3% after 5 years and 25.5% after 10 years, reflecting deferred childbearing intentions.[183] Sperm cryopreservation, routine since the 1950s, requires less stringent conditions due to sperm resilience but benefits from vitrification and pre-freeze microfluidic sorting to enhance post-thaw motility and DNA integrity.[184] [185] Advanced storage employs automated cryogenic systems with continuous nitrogen vapor monitoring to maintain viability, though evidence on duration limits is mixed: some data indicate no impact on outcomes even beyond 6 years, while others show reduced pregnancy rates after 6 months of vitrification due to subtle cryoprotectant effects or thawing inefficiencies, without altering neonatal health.[186] [187] 00381-8/fulltext) Longest reported viable storage exceeds 30 years for embryos, supporting indefinite theoretical preservation under stable conditions.[188]Emerging Innovations (AI, Non-Invasive Methods)
Artificial intelligence (AI) has been integrated into IVF protocols primarily for embryo selection, leveraging machine learning algorithms to analyze time-lapse imaging and morphological features for predicting viability and implantation potential. Systems such as multilayer perceptron artificial neural networks combined with genetic algorithms, as evaluated in a 2025 study, demonstrate capacity to forecast gestational success by processing dynamic embryo data, outperforming traditional morphological assessments in predictive accuracy.[189] Similarly, deep learning models applied to time-lapse sequences identify optimal embryos with precision exceeding embryologist evaluations in multiple retrospective analyses conducted between 2023 and 2025.[190] [191] Commercial platforms like AIVF's EMA further automate this process, reducing evaluation time while standardizing selections across clinics.[192] Despite these advancements, clinical outcomes remain variable; a 2024 randomized trial reported clinical pregnancy rates of 46.5% with AI-driven scoring versus 48.2% via manual morphology, indicating no statistically significant superiority in live birth rates.[193] Time-lapse imaging augmented by AI shows promise in single-embryo transfers, with one 2024 analysis suggesting enhanced ongoing pregnancy rates through refined morphokinetic scoring.[194] However, broader meta-analyses, including a 2024 Lancet study, found time-lapse systems yielded pregnancy rates of 42.2% compared to 43.4% in standard culture, underscoring that while AI improves selection efficiency, it does not consistently elevate overall IVF success rates beyond conventional methods.[195] Non-invasive methods address limitations of invasive biopsies in preimplantation genetic testing by analyzing cell-free DNA (cfDNA) shed into embryo culture media, enabling aneuploidy screening without compromising embryo integrity. Techniques like non-invasive PGT (niPGT), advanced in 2025 workflows, extract cfDNA from spent media to assess chromosomal normality, with studies reporting concordance rates up to 95% against invasive biopsies in select cohorts.[196] [197] The EMBRACE test, introduced by Igenomix in June 2025, exemplifies this by providing accessible chromosomal analysis via media sampling, potentially broadening niPGT adoption in IVF centers.[198] Additional non-invasive assessments, such as metabolomic profiling of blastocoel fluid or media, predict embryo quality and implantation viability, as demonstrated in a 2024 UCSD study correlating media biomarkers with IVF outcomes.[199] These approaches mitigate biopsy-associated risks like reduced viability, though challenges persist in cfDNA yield variability and false positives, necessitating validation against long-term implantation data.[200]Ethical Considerations
Moral Status of Embryos and Destruction Practices
In vitro fertilization routinely involves creating multiple embryos by fertilizing numerous oocytes, with only a subset selected for implantation based on quality assessments; the remainder are cryopreserved, resulting in an estimated 1.2 million frozen embryos stored in the United States as of recent analyses.[201] Globally, between 1.5 million and 1.8 million embryos produced annually through IVF fail to result in live births, indicating widespread non-implantation and subsequent disposal.[202] This surplus arises from the need to maximize success rates, as single-embryo transfers yield lower pregnancy probabilities, prompting ethical scrutiny over the moral equivalence of these embryos to born humans. Biologically, fertilization marks the formation of a distinct human organism with unique DNA, initiating a continuous developmental trajectory toward maturity absent external interference; proponents of full moral status argue this continuity precludes arbitrary thresholds for rights, equating embryo destruction to homicide regardless of size or location.[203] Philosophers like those advancing equality-based arguments contend that denying personhood to embryos discriminates on non-essential traits such as cognitive capacity or viability, mirroring historical injustices against marginalized groups, and that potentiality—coupled with species membership—confers inherent dignity from conception.[204] Empirical continuity is evidenced by the embryo's self-directed growth, challenging claims of mere "potential" as undervaluing its actual ontological status as a human being. Opposing views, prevalent in bioethics literature, posit that moral status accrues gradually, with embryos lacking personhood attributes like consciousness, sentience, or relational interests until later stages such as implantation or the eighth week; ethicists like Peter Singer maintain early embryos are not individuated persons, justifying their use in research if parental consent is obtained, as their moral weight does not rival that of developed humans.[205] Such gradualist frameworks often prioritize aggregate benefits, such as medical advancements from embryo-derived stem cells, over individual protections, though critics note these positions risk inconsistency by permitting destruction for utility while safeguarding later fetuses.[206] Institutional biases in academia, which frequently endorse research-friendly stances, may amplify these arguments despite unresolved philosophical tensions.[207] Destruction practices for surplus embryos typically involve thawing without uterine transfer, often delayed until day 6 of development to assess viability, followed by disposal via cryopreservation tank removal or direct discard; alternatives include donation for research—ethically permissible under guidelines requiring oversight and consent—or anonymous transfer to other couples, though storage fees deter indefinite retention.[208] [209] Thawing entails cellular demise through ice crystal formation and osmotic shock, effectively ending the organism's viability; surveys indicate over 50% of patients opt for destruction when deciding fates, influenced by completion of family-building goals.[210] These methods underscore causal realities: intentional non-implantation equates to electing death for entities biologically equivalent to pre-born humans, raising consent dilemmas as initial agreements for creation may evolve with parental regrets.[211] While single-embryo protocols mitigate surplus, they reduce efficacy, perpetuating the trade-off between efficiency and ethical costs.[212]Eugenics Risks from Selection and Editing
In vitro fertilization (IVF) combined with preimplantation genetic testing (PGT) enables the selection of embryos based on genetic profiles, raising concerns about eugenic practices through the preferential implantation of those deemed genetically superior. PGT, initially developed for detecting single-gene disorders like cystic fibrosis, has expanded to polygenic risk scoring (PRS), which assesses embryos for complex traits influenced by thousands of genetic variants, such as risks for heart disease, diabetes, or even cognitive potential. Companies like Genomic Prediction and Orchid Biosciences offer PRS-based screening, allowing parents to rank embryos by predicted outcomes for health or intelligence, with reported boosts in polygenic scores for IQ up to several points per embryo selected. This process discards non-selected embryos, echoing historical eugenics by prioritizing heritable traits over natural variation, though proponents argue it mitigates disease rather than enhances population quality.[213][214][215] Critics highlight the slippery slope from therapeutic selection to non-medical enhancements, as PRS accuracy diminishes in diverse populations and fails to account for environmental factors, potentially fostering false optimism and unintended eugenic pressures. For instance, a 2021 analysis noted that embryo selection via PRS yields minimal trait shifts—e.g., 2.5 IQ points on average—yet could normalize discarding embryos for traits like height or educational attainment, amplifying social inequalities where affluent families access "optimized" offspring. Ethical reviews express alarm over reduced genetic diversity, as widespread selection against common variants might eliminate beneficial alleles, increasing vulnerability to novel diseases, similar to monoculture crop failures. Moreover, societal normalization could impose indirect coercion, where unselected children face stigma or where insurance incentives favor screened embryos, reviving "liberal eugenics" without state mandates.[216][217][218] Gene editing technologies like CRISPR-Cas9 introduce direct germline modifications in IVF embryos, amplifying eugenics risks by enabling precise alterations beyond selection. In 2018, Chinese researcher He Jiankui announced the birth of twins edited for CCR5 resistance to HIV, using CRISPR to introduce mutations, which sparked international condemnation for unproven safety, off-target effects, and ethical overreach toward designer babies. While editing targets therapeutic fixes, such as eliminating hypertrophic cardiomyopathy mutations, it opens pathways to enhancements like disease resistance or cognitive boosts, with animal studies showing heritable changes but human trials banned in many jurisdictions due to mosaicism risks—where not all cells edit uniformly—and potential oncogenic mutations. Bioethicists warn this constitutes "new eugenics," as parental choices could converge on similar edits, homogenizing the gene pool and devaluing natural human variation, particularly given biases in PRS data from European ancestries that disadvantage non-Europeans.[219][220][221] These risks are compounded by limited empirical safeguards; while PGT-A (aneuploidy screening) reduces miscarriage rates by 10-15% in some cohorts, polygenic extensions lack long-term outcome data, with surveys showing 92% public concern over exaggerated expectations. Regulatory gaps persist, as the U.S. lacks federal bans on germline editing, allowing private clinics to pursue enhancements, unlike stricter EU frameworks. Overall, while selection and editing avert severe disorders—e.g., avoiding Tay-Sachs carriers—they risk commodifying reproduction, where embryo viability hinges on parental preferences, potentially eroding intrinsic human dignity without robust oversight.[222][223][224]Donor Anonymity and Consent Withdrawal
Donor anonymity in in vitro fertilisation (IVF) refers to policies preventing recipient families or offspring from accessing identifying information about gamete or embryo donors, a practice historically justified to encourage donations by protecting donor privacy.[225] Many jurisdictions once permitted full anonymity, but shifts toward identity disclosure have occurred amid ethical debates over offspring rights to genetic origins. In the United States, no federal mandate exists, allowing clinics to offer anonymous donations, though direct-to-consumer genetic testing has increasingly revealed donor identities, complicating assurances of privacy.[226] Internationally, regulations diverge sharply. The United Kingdom ended anonymity for donors registering after April 1, 2005, under the Human Fertilisation and Embryology Authority (HFEA), enabling donor-conceived individuals to access donor identity at age 18; pre-2005 donors may opt to release information voluntarily.[227] This change initially reduced sperm donor numbers by about 50% but saw recovery, with registrations rising 80% by 2007 due to compensation increases and recruitment efforts.[228] Sweden prohibited anonymous donations in 1984, requiring identifiable donors, while Australia became the first nation to fully abolish anonymity in 2004, granting offspring access to donor details.[229] [230] In contrast, Canada maintains donor anonymity, barring contact between donors and offspring, and countries like Bulgaria permit it to attract donors.[231] [232] Consent withdrawal allows gamete donors to revoke permission for use of their material before embryo transfer or insemination, reflecting the revocable nature of initial agreements until clinical application. In the UK, donors retain this right up to the point of gamete or embryo use in treatment, potentially disrupting cycles if invoked.[233] Australian law similarly permits withdrawal at any stage prior to transfer without legal penalty, emphasizing donor autonomy over completed donations.[234] Known donors face heightened scrutiny in withdrawal decisions due to relational complexities, with ethicists arguing for allowance to minimize harm compared to anonymous cases.[235] Intended parents typically secure agreements disclaiming donor parental rights post-use, but pre-use revocation underscores the non-binding status of preliminary consents.[236] Controversies center on balancing donor recruitment incentives against offspring welfare, with anonymity critics citing psychological risks from unknown heritage, such as identity crises documented in donor-conceived surveys where 91% involved anonymous sperm donation.[237] Proponents argue anonymity sustains supply, as non-anonymous mandates correlate with donor shortages in nations like the UK post-2005, though empirical links to long-term offspring outcomes remain debated without large-scale causal studies.[238] Genetic testing's rise has eroded anonymity de facto, prompting calls for identity-release models; the American Society for Reproductive Medicine endorses disclosing conception origins to offspring, viewing non-disclosure as ethically fraught.[239] [240] Proposed UK expansions to remove anonymity from birth for post-2023 donors highlight ongoing tensions, potentially further deterring participation amid unproven benefits for child well-being.[241]Social and Industry Controversies
Family Structure Implications and Non-Traditional Uses
In vitro fertilisation (IVF) has enabled the intentional creation of non-traditional family structures, including single-parent households by choice and families headed by same-sex couples, often involving donor gametes, embryo donation, or gestational surrogacy to bypass biological limitations tied to heterosexual intercourse within marriage. This suitability for single individuals and same-sex couples, using donor eggs or sperm where natural conception is not feasible due to the absence of an opposite-sex partner, expands reproductive options beyond those available naturally.[242] This decoupling of reproduction from sexual union and stable marital bonds has risen in prevalence; in Australia, single women and female same-sex couples initiated 20% of IVF cycles in 2023, up from prior years reflecting broader access to third-party reproduction.[243] [244] Similarly, in the United Kingdom, the number of single women undergoing IVF increased from 2,021 in 2019 to 3,693 in 2023, while female same-sex IVF patients rose from 1,761 to 2,559 over the same period.[80] These trends contribute to a redefinition of kinship, where children may lack genetic ties to their social or gestational parents, potentially disrupting biological continuity and traditional intergenerational lineage.[242] Empirical studies on child outcomes in these families report generally positive short-term psychological adjustment, with children in solo mother families conceived via IVF or intrauterine insemination (IUI) with donor sperm showing no elevated behavioral problems compared to those in two-parent households, attributing resilience to factors like maternal intentionality and socioeconomic stability rather than paternal absence.[245] [246] For children of female same-sex couples using IVF, meta-analyses and cohort data indicate comparable or superior school performance and internalizing behaviors relative to heterosexual-parented peers, though externalizing symptoms show no significant differences.[247] [248] However, these findings derive largely from small, non-representative samples selected for family stability, with limited longitudinal data on adulthood; broader population-level evidence on single-parent or same-sex-led households reveals elevated risks of emotional distress, educational underachievement, and relational instability, suggesting IVF does not fully mitigate disadvantages associated with absent complementary parental figures.[249] Critics, drawing on causal analyses of family stability, contend that IVF exacerbates these risks by commodifying gametes and surrogacy, prioritizing adult reproductive autonomy over children's interests in dual-gender parenting and genetic relatedness.[250] Non-traditional applications extend to posthumous reproduction, where sperm, eggs, or embryos stored or retrieved after death enable offspring creation without the deceased parent's presence, as in cases of terminal illness or accidents.[251] This practice, feasible since semen cryopreservation in the 1950s but expanded via IVF post-1978, has produced documented births, such as the 1999 case of a child conceived from sperm extracted 30 months postmortem, raising questions of consent validity and child welfare absent real-time parental involvement.[252] [253] Surrogacy integrated with IVF further diversifies structures, allowing single men or male same-sex couples to commission gestation via donor oocytes and carriers, yielding children with no gestational or genetic maternal link; a 2022 study of such single-father surrogacy families found children exhibited low anxiety and strong adjustment at ages 3-9, yet highlighted unique complexities like reliance on non-biological caregivers.[254] [255] These uses, while fulfilling individual desires, intensify debates over whether engineered absences—father, mother, or both—align with evidence favoring biparental, biologically anchored rearing for optimal developmental trajectories.[256]Commercialization, Corruption, and Mix-Ups
The in vitro fertilization (IVF) industry has expanded into a multibillion-dollar global market, valued at approximately USD 25.3 billion in 2023 and projected to reach USD 37.4 billion by 2030, driven by rising infertility rates and technological advancements.[257] In the United States, a single IVF cycle typically costs between USD 15,000 and USD 20,000, often requiring multiple cycles for success, which amplifies financial incentives for clinics to prioritize volume over individualized care.[258] Critics argue that this profit orientation exploits vulnerable patients, with aggressive marketing of add-ons like preimplantation genetic testing inflating costs without proportional evidence of improved outcomes, though industry proponents counter that competition fosters innovation.[259] In the UK, over 60% of IVF treatments are privately funded, with cycles exceeding £5,000, raising concerns about unequal access and potential overtreatment in a largely unregulated commercial landscape.[259] Corruption and ethical violations in IVF clinics have surfaced through cases of fertility fraud, where physicians covertly used their own sperm to impregnate patients without consent, leading to at least 50 such accusations against U.S. doctors as of 2023.[260] Notable instances include a Florida fertility doctor ordered to pay USD 5.25 million in damages in 2022 for using his own sperm in treatments 45 years prior, highlighting long-term accountability gaps in the field.[261] Over 30 U.S. physicians have been implicated or confirmed in similar acts, often uncovered decades later via DNA testing, which has prompted calls for stricter donor verification and criminal penalties, though enforcement remains inconsistent across jurisdictions.[262] Internationally, a 2024 Greek clinic scandal involved eight employees arrested for illegal egg and surrogate trafficking from Eastern Europe, exploiting lax oversight to facilitate cross-border procedures for profit.[263] Other ethical breaches include clinics implanting destroyed or compromised embryos, as in a 2024 Ovation Fertility case where a toxic incubator allegedly killed embryos before implantation, resulting in lawsuits over negligence and misrepresentation of viability.[264][265] Embryo mix-ups, involving the wrongful implantation of non-intended embryos, have occurred in multiple high-profile incidents, eroding trust in clinic protocols and exposing vulnerabilities in labeling, storage, and transfer processes. In February 2025, a 38-year-old U.S. woman sued a fertility clinic after giving birth to a boy genetically unrelated to her or her partner due to an implantation error, discovered post-delivery via DNA testing.[266][267] Similar errors struck Australia in 2025: one Brisbane clinic case led to a woman unknowingly carrying and birthing a stranger's child in April, raising unprecedented custody disputes, while a second Monash IVF incident in June involved implanting a patient's own embryo instead of one with her partner's sperm.[268][269][270] In the U.S., a 2021 California lawsuit alleged a Los Angeles clinic implanted wrong embryos into two women, resulting in non-biological births and claims of negligence in embryology labs.[271] These events, often linked to human error or inadequate safeguards rather than malice, underscore the industry's rapid commercialization outpacing regulatory frameworks, with federal tracking in the U.S. limited to success rates rather than error prevention.[272] Malpractice claims frequently cite failures in carrier screening, genetic testing, and informed consent, amplifying emotional and financial harms for affected families.[273]Equity, Access, and Demographic Disparities
Access to in vitro fertilization (IVF) is predominantly constrained by high financial costs, with a single cycle in the United States averaging $15,000 to $30,000, rendering it inaccessible for many without substantial resources or insurance support.[274] Only 15 states mandate insurance coverage for IVF, leaving the majority of Americans to bear out-of-pocket expenses, which exacerbates socioeconomic disparities and limits utilization among lower-income groups.[275] Globally, costs vary significantly, with U.S. cycles priced 271% higher than the mean in 25 other countries, often due to differing public funding models in Europe and elsewhere that subsidize treatments for eligible patients.[276] Racial and ethnic disparities further compound access barriers, as Black and Hispanic women are less likely to receive fertility evaluations or initiate IVF compared to White women, with Black patients reporting race as a barrier at rates of 14.7% versus 0% for White patients.[277] Black and Hispanic individuals cite income constraints twice as frequently (26.5% and 20.3%, respectively) as barriers to care, alongside structural factors like geographic availability of clinics concentrated in affluent areas.[278] While some studies indicate no direct link between race and IVF success rates independent of access, overall lower initiation and completion rates among minorities persist, potentially tied to higher infertility prevalence from conditions like tubal factor in African-American and Hispanic populations.[279] [94] Socioeconomic status strongly predicts IVF utilization, with lower-income and minority groups exhibiting reduced access despite comparable or higher infertility rates; for instance, non-Hispanic Asian women show higher IVF rates (17.2 per 1,000 live births) than non-Hispanic White women in certain datasets, reflecting relative economic advantages within that demographic.[96] Geographic inequities amplify these issues, as rural or underserved areas lack specialized clinics, forcing reliance on costly travel.[280] In low-resource settings globally, such disparities can lead to higher multiple gestation risks from unmonitored practices, underscoring how uneven access influences not only uptake but also safety outcomes.[281]Legal and Regulatory Landscape
National Variations and Key Rulings
Regulations governing in vitro fertilization (IVF) exhibit significant national variations, shaped by cultural, religious, ethical, and legal considerations regarding embryo status, donor practices, and access restrictions. In permissive jurisdictions, IVF is broadly available with minimal limits on embryo creation or genetic testing, while restrictive regimes often cap the number of embryos produced, prohibit preimplantation genetic diagnosis (PGD), or ban certain uses like research or donation. Some nations outright prohibit IVF due to moral objections to embryo manipulation, reflecting debates over whether embryos constitute persons with rights equivalent to born children.[282] In the United States, IVF operates without comprehensive federal oversight on embryo creation or disposal, relying instead on state-level laws and professional guidelines from bodies like the American Society for Reproductive Medicine. The Fertility Clinic Success Rate and Certification Act of 1992 mandates annual reporting of IVF outcomes to track efficacy but imposes no substantive restrictions on procedures. State variations include insurance mandates for coverage in 21 states as of 2024, though embryo personhood claims have prompted legal challenges.[283][282] European policies diverge sharply. The United Kingdom, site of the first IVF birth in 1978, regulates via the Human Fertilisation and Embryology Authority, permitting up to 14 embryos per cycle but requiring licenses for storage (up to 55 years post-2022 amendments) and research, with disposal only after consent protocols. Germany enforces stringent Embryo Protection Act provisions, limiting IVF to fertilization of one egg at a time to minimize surplus embryos, banning their destruction except for transfer and prohibiting anonymous donation or PGD for non-lethal conditions. Italy similarly restricts to three embryos per cycle, mandating all be transferred or cryopreserved without discard. In contrast, Spain and Greece facilitate "fertility tourism" with fewer embryo limits, anonymous donation allowed, and gestational surrogacy regulated in Greece since 2025 updates.[282][284] Australia mandates state-based licensing with embryo creation capped at three per cycle in some jurisdictions like Victoria, prohibiting sex selection and commercial surrogacy while allowing research on excess embryos under strict ethics review. In Asia, China permits IVF under national guidelines limiting embryos to avoid multiples but bans commercial egg donation; India regulates via the 2021 Assisted Reproductive Technology Act, requiring clinics to register and capping donor anonymity. Several Sunni-majority countries, including Saudi Arabia and Pakistan, prohibit IVF due to Islamic rulings against third-party gametes, though Shia interpretations in Iran allow it with restrictions on surrogacy. Latin American nations influenced by Catholic doctrine, such as the Philippines, maintain outright bans, while Costa Rica lifted its prohibition in 2015 following an Inter-American Court ruling.[282][285] Key rulings have centered on embryo legal status. On February 16, 2024, the Alabama Supreme Court in LePage v. Center for Reproductive Medicine held that frozen embryos qualify as "unborn children" under the state's Wrongful Death of a Minor Act, applying regardless of location outside the uterus, which prompted temporary clinic closures amid liability fears before legislative immunity was granted. The Texas Supreme Court in June 2024 declined to expand a divorce custody case to broadly define embryo rights, preserving IVF access by avoiding personhood precedents. Internationally, the European Court of Human Rights in Parpala v. Romania (2023) upheld restrictions on multiple embryo transfers to protect maternal health, reinforcing regulatory balances over unrestricted access. These decisions underscore tensions between embryo protection—grounded in their biological continuity as human organisms—and reproductive autonomy, with personhood recognitions potentially curtailing surplus creation or disposal practices.[286][287][288]| Country/Region | Embryo Creation Limits | Key Restrictions | Legal Status of Embryos |
|---|---|---|---|
| United States | None federally; varies by state | Reporting required; no federal disposal rules | Property in most states; "unborn children" in Alabama per 2024 ruling[282][286] |
| United Kingdom | Up to 14 per cycle | Licensed storage/research; no sex selection | Not persons; regulable for welfare[282] |
| Germany | One egg per cycle | No PGD for non-lethal traits; no discard | Protected from harm; no research[282] |
| Greece | Flexible; donation allowed | Age caps (e.g., 50 for women); surrogacy regulated | Not persons; transfer priority[284] |
| Australia | Up to 3 in some states | No commercial surrogacy; ethics for research | Not persons; consent for use[282] |
Embryo Rights and Disposal Regulations
In most jurisdictions, IVF embryos lack full legal personhood and are treated as the property of the gamete providers or progenitors, allowing parents to decide their disposition, though ethical and regulatory constraints often apply to creation, storage, and destruction.[282] This status contrasts with the biological fact that embryos are distinct human organisms from fertilization, prompting debates over protections against arbitrary disposal.[289] Disposal options for unused embryos typically include destruction (e.g., thawing without transfer), donation for adoption or research, or indefinite cryopreservation, but regulations impose storage limits, consent requirements, and prohibitions in some cases to prevent commodification or waste. In the United States, no federal laws govern embryo rights or disposal, leaving decisions to clinics and parents under state guidelines or contracts, with common practices permitting destruction after parental consent and no mandated storage duration.[282] [209] However, the Alabama Supreme Court ruled on February 16, 2024, that cryopreserved embryos qualify as "unborn children" under the state's Wrongful Death of a Minor Act, enabling civil suits for their negligent destruction, as in a 2020 clinic incident involving misplaced embryos.[286] [290] This first-of-its-kind decision, rooted in 19th-century law defining minors to include "unborn children," led to temporary halts in IVF at major Alabama clinics due to liability fears.[291] The state legislature responded with a March 6, 2024, law granting civil and criminal immunity to IVF providers and patients for embryo handling, though it sidestepped resolving personhood status.[292] In 2024, 13 states considered bills extending rights to embryos, but none passed, highlighting ongoing tensions between fertility access and protections.[293] Abandoned embryos pose challenges, as clinics may dispose of them after failed contact attempts, with no uniform federal rules on storage fees or timelines.[294] Internationally, regulations reflect cultural and ethical variances, often limiting embryo numbers to minimize surplus and disposal. In Germany, the Embryo Protection Act restricts creation to three embryos per cycle for immediate transfer, prohibits cryopreservation of surplus, bans research or destruction of viable embryos, and limits donation, treating embryos with near-personhood protections.[282] Italy similarly forbids disposal, donation, or research on embryos, requiring all created to be available for transfer without preimplantation genetic testing except for severe diseases.[282] Poland mandates donation of viable embryos after 20 years of cryopreservation, disallowing destruction.[282] In contrast, the United Kingdom permits disposal with consent after a 55-year renewable storage limit (extended from 10 years in 2022), alongside donation and research use under the Human Fertilisation and Embryology Authority.[282] France allows disposal after five years but restricts embryo donation and genetic testing.[282]| Country | Max Embryos Created | Cryopreservation Limit | Disposal Allowed? | Key Restrictions |
|---|---|---|---|---|
| United States | None | None | Yes, with consent | State variations; Alabama personhood ruling applies Wrongful Death Act to embryos.[282] [286] |
| Germany | 3 per cycle | Prohibited for surplus | No (viable) | No research/destruction; immediate transfer required.[282] |
| Italy | As needed for transfer | None specified | No | No donation/research; all for potential implantation.[282] |
| United Kingdom | None | 55 years (renewable) | Yes | HFEA oversight; consent for research/donation.[282] |
| Poland | 6 | 20 years | No (viable) | Compulsory donation post-limit.[282] |
| Spain | None | Case-by-case | Yes | Donation limited to 6 children per donor.[282] [295] |
Religious and Philosophical Perspectives
Responses from Major Faiths
The Catholic Church has consistently opposed in vitro fertilization since the 1987 instruction Donum Vitae, deeming it morally unacceptable for separating procreation from the conjugal act, typically involving masturbation for gamete collection and the production of excess embryos often discarded or frozen, which violates the dignity of human life from conception.[296][297] This stance was reaffirmed in subsequent documents, emphasizing that techniques must respect the unity of spouse, child, and act of generation, while permitting only interventions aiding natural conception within marriage.[298] Protestant denominations exhibit diverse views, lacking a unified doctrine; many evangelical and mainline groups accept IVF with the couple's gametes as a means to overcome infertility, provided excess embryos are minimized or implanted to avoid destruction, aligning with beliefs in life's sanctity from conception.[299][300] However, the Southern Baptist Convention, the largest U.S. Protestant body, condemned IVF in a June 2024 resolution for commodifying children and entailing embryo loss, urging ethical alternatives.[300] Eastern Orthodox Christianity discourages IVF, viewing it as unnatural and contrary to divine order in conception, with embryos considered human persons deserving protection; while no formal synodal prohibition exists, clergy advise against it, permitting pursuit only with pastoral blessing, strict limits on embryo creation to prevent surplus, and no third-party involvement.[301][302] In Islam, IVF is permissible under Sunni and Shia fatwas when limited to a married couple's own gametes, performed by licensed physicians, and avoiding embryo freezing or donation to preserve lineage (nasab) and prevent zina-like mixing; third-party donors are prohibited, but gestational surrogacy by the wife's sister may be allowed in some rulings if no alternatives exist.[303][304] Selective reduction is condoned only if the mother's life is endangered.[305] Judaism, particularly Orthodox branches, endorses IVF to fulfill the biblical mandate to procreate (pru u'rvu), allowing it with the couple's gametes and embryo transfer, though donor eggs or sperm raise halakhic concerns over lineage and incest prohibitions; preimplantation genetic diagnosis is accepted for avoiding severe defects, and rabbinic authorities adapt procedures under supervision to comply with ritual purity laws.[306][307] The embryo lacks full personhood status until 40 days post-conception in some views, easing disposal of non-viable ones.[308] Hinduism lacks centralized opposition to IVF, viewing it as a medical intervention aiding dharma's emphasis on progeny—especially sons for ancestral rites (pitru karma)—with no doctrinal bar on gamete collection or embryo creation, though excess embryos pose ethical dilemmas tied to reincarnation and karma, often resolved by donation or disposal without ritual.[309][310] Buddhism takes a non-dogmatic stance, permitting IVF if motivated by compassion and minimizing harm, such as avoiding surplus embryos to prevent suffering or disrupted rebirth; no objection exists to sperm procurement methods, with focus on intention (cetana) over ritual, though creating life artificially raises questions of karmic continuity for the consciousness entering the embryo.[311][312]Secular Critiques and First-Principles Analysis
Secular critics of in vitro fertilisation (IVF) highlight elevated health risks to offspring, attributing them to procedural interventions rather than solely parental infertility. Longitudinal studies indicate that children conceived via IVF face a 1.5- to 2-fold increased risk of congenital malformations, including cardiac defects and neural tube anomalies, compared to naturally conceived peers, with rates persisting into adolescence.[152] [313] Epigenetic alterations from embryo culture and cryopreservation contribute to higher incidences of imprinting disorders like Beckwith-Wiedemann syndrome, occurring in approximately 1 in 1,000-4,000 IVF cases versus rarer natural occurrences.[314] Cardiovascular risks, such as elevated blood pressure and metabolic syndrome, emerge in young adults, with cohort data showing a 20-30% higher prevalence linked to ART manipulations disrupting normal fetal programming.[315] These outcomes stem causally from supraphysiological hormone exposures and in vitro conditions that deviate from mammalian reproductive physiology, amplifying perinatal complications like preterm birth (12-15% rate in IVF versus 8-10% naturally).[152] From a first-principles standpoint, IVF's laboratory-based fertilization fragments the integrated biological process of reproduction, where gamete fusion occurs in a controlled environment absent natural selection mechanisms, leading to suboptimal embryo viability. Human procreation fundamentally entails coitus-driven gamete delivery in vivo, fostering synchronized developmental cues absent in Petri dishes, which empirical data correlates with reduced implantation rates (25-35% per cycle) and excess embryo production—often 5-10 per cycle, with 70-90% discarded or frozen indefinitely.[7] This excess generation treats nascent human organisms as selectable commodities, raising secular concerns over instrumentalization: embryos, possessing unique genomes from fertilization, are evaluated for utility via preimplantation genetic testing (PGT), discarding those with aneuploidies or undesired traits at rates exceeding 50% in screened cycles.[316] Such practices echo eugenic selection, prioritizing parental preferences over impartial regard for potential persons, as PGT enables avoidance of conditions like Down syndrome (trisomy 21) in 95% of detected cases, skewing toward "optimized" offspring without addressing root infertility causes.[7] Critics argue IVF commodifies reproduction by marketizing gametes and embryos, with egg donor compensation averaging $5,000-$10,000 per cycle in the U.S., incentivizing high-risk ovarian hyperstimulation that yields ovarian hyperstimulation syndrome in 1-5% of procedures. This economic model, generating a $20 billion global industry by 2023, conflates parental autonomy with child-centered welfare, as surplus embryos—estimated at over 1 million frozen in the U.S. alone—face indefinite storage or destruction, bypassing natural attrition.[317] Causal analysis reveals IVF's reliance on multiple embryo transfers (2-3 average) heightens twin pregnancies (15-20% of IVF births versus 1-2% natural), imposing iatrogenic burdens like cerebral palsy risks doubled due to prematurity.[313] Secular ethicists contend this over-medicalizes fertility, diverting from lifestyle or diagnostic alternatives while entrenching disparities, as success rates plummet below 10% for women over 40, yet procedures persist amid low live birth yields (1 in 5 cycles overall).[7] Ultimately, these dynamics prioritize technological intervention over biological realism, where reproduction's purpose—sustaining species via viable offspring—clashes with lab-engineered variability introducing unquantified long-term genotypic instabilities.[314]Global Utilization and Economics
Availability, Costs, and Usage Trends
In vitro fertilization (IVF) is legally available in approximately 100 countries worldwide as of 2025, though restrictions on aspects such as embryo research, donor gametes, surrogacy, and sex selection vary significantly by jurisdiction.[282] In the United States, IVF is unregulated at the federal level and accessible through over 450 clinics, with recent executive actions in 2025 aimed at expanding insurance coverage and affordability.[318] European nations like Spain and Greece offer broad availability with permissive laws on egg donation, while countries such as Italy prohibit donor eggs and impose strict embryo disposal rules.[319] Availability is limited or banned in some regions, including parts of the Middle East and certain U.S. states with embryo protection laws, such as Louisiana, where unused embryos cannot be discarded.[320] Costs for a single IVF cycle, excluding medications and add-ons like preimplantation genetic testing, average $20,000–$25,000 in the United States, with costs typically higher in California ($20,000–$40,000, often $17,000–$30,000 in Los Angeles) and varying widely in New York (from $5,769 to over $30,000 per cycle, with urban averages comparable to or higher than the national figure) due to location, clinic, and add-ons; insurance mandates, stronger in New York, can reduce out-of-pocket expenses, though affordable options exist. Often requiring multiple cycles due to success rates below 50% for most patients.[9] In contrast, costs are substantially lower in countries attracting fertility tourism, such as India, where the average cost of a single IVF cycle in 2025-2026 typically ranges from ₹1,00,000 to ₹2,50,000 (approximately $1,200-$3,000 USD), varying by location, clinic, and additional procedures (e.g., ICSI, donor eggs, medications), with private hospitals often averaging ₹2,00,000-₹2,30,000 out-of-pocket and public hospitals around ₹1,10,000—costs remained similar between 2025 and 2026 with no major reported changes—and Turkey at $4,000 to $4,500 per cycle, or Iran at $1,200 to $2,500.[321][322] European options like Spain average €4,000 to €7,000, frequently including basic monitoring and transfers.[323] In the United States (2025-2026 estimates), costs vary significantly between traditional autologous IVF (using the patient's own eggs) and donor egg IVF cycles.- A standard autologous IVF cycle ranges from $15,000–$25,000 per cycle (including medications and add-ons), though some clinics offer packages as low as $7,000–$12,000.
- Donor egg cycles are typically 1.5–3 times more expensive due to donor compensation ($5,000–$20,000+), extensive screening, and coordination: fresh donor cycles range from $35,000–$65,000 (average $38,000–$45,000), while frozen donor cycles cost $12,000–$35,000.
| Country/Region | Average Cost per IVF Cycle (USD, 2025) | Notes |
|---|---|---|
| United States | $20,000–$25,000 | Excludes medications (~$3,000–$5,000 extra); higher in CA ($20,000–$40,000) and NY ($5,769–$30,000+); limited insurance coverage in most states.[9] |
| Spain | $4,400–$7,700 | Often includes ICSI and basic tests; donor eggs extra.[323] |
| India | $1,200–$3,000 | Varies by public/private clinics (₹1,00,000–₹2,50,000); popular for international patients.[321] |
| Turkey | $4,000–$4,500 | Packages may cover medications; popular for international patients.[322] |
| Mexico | $7,500–$10,000 | Comprehensive packages; fewer regulatory hurdles.[285] |
| North America trails in per capita terms, with the US at 922 cycles per million, yielding about 2.6% of 2023 births from IVF despite over 300,000 cycles performed that year; high costs averaging $20,000–$25,000 per cycle and insurance coverage in approximately 15 states limit broader access.[43] [3] [9] | ||
| Global IVF usage has risen steadily, with an estimated 2.5 million cycles performed annually as of recent data, contributing to over 13 million cumulative IVF births by 2025.[324] [325] In the U.S., cycles increased 11% from 389,993 in 2022 to 432,641 in 2023, yielding over 95,000 babies and reflecting greater adoption among women delaying childbearing.[3] The UK reported 77,500 cycles in 2023, up from prior years, with about 20,700 resulting births.[80] Success rates, defined as live births per cycle, have improved due to advances like single embryo transfer, reaching nearly 55% for women under 35 in the U.S., but declining sharply with age—to 5% or less for those 43 and older.[326] [80] Demographic trends show increasing utilization among older patients and same-sex couples, though empirical data indicate lower efficacy for advanced maternal age, underscoring biological limits over technological mitigation.[327] The global market, valued at $25.3 billion in 2023, projects growth to $37.4 billion by 2030, driven by infertility prevalence and delayed parenthood.[257] |
Regional Differences in Adoption
Adoption of in vitro fertilisation (IVF) varies widely across regions, reflecting differences in regulatory support, economic accessibility, cultural attitudes, and healthcare infrastructure. Per capita IVF cycle initiation rates in 2018 ranged from a high of 5,711 per million inhabitants in Israel to 922 in the United States, with many European and Asian nations clustering above 3,000 per million due to subsidized access.[43] These disparities persist, as high-income regions account for the majority of global cycles—approximately half in Europe, followed by North America and parts of Asia—while low- and middle-income countries (LMICs) conduct far fewer, limited by costs exceeding annual incomes and sparse clinic availability.[328] [329] In Europe, adoption is elevated in nations with robust public funding, such as Denmark (3,575 cycles per million in 2018) and Spain (3,003), where assisted reproductive technologies (ART) contribute to nearly 9% and over 7% of births, respectively, in recent years.[43] [330] Nordic countries and others with universal coverage achieve higher utilization through policies reimbursing multiple cycles, contrasting with lower rates in Ireland and Lithuania, where less than 2% of births involve ART amid stricter regulations or funding gaps.[330] Cultural acceptance and lower stigma in these high-adoption areas further bolster uptake, though intra-regional variation underscores the role of national policies over broader continental trends.[331] Asia shows heterogeneous patterns, with Japan leading at 3,603 cycles per million in 2018—supported by national subsidies amid a fertility rate below 1.3—while China performs over 1 million cycles annually in absolute terms due to sheer population size and expanding private clinics.[43] [332] Government incentives in response to demographic pressures drive adoption here, yet religious and familial norms in parts of South and Southeast Asia constrain it compared to East Asian peers.[331] North America trails in per capita terms, with the US at 922 cycles per million, yielding about 2.6% of 2023 births from IVF despite over 300,000 cycles performed that year; high costs averaging $20,000–$25,000 per cycle and insurance coverage in only 13 states limit broader access.[43] [3] [9] In contrast, Israel's near-universal funding elevates it as an outlier in the Middle East, where religious endorsements and policy prioritize IVF.[43] [331] LMICs, including much of Africa and Latin America, exhibit minimal adoption, with infertility affecting 1 in 6 globally but IVF cycles rare due to infrastructure deficits and out-of-pocket expenses prohibitive for most; for instance, sub-Saharan Africa relies more on basic treatments than advanced ART.[333] [329] Cultural stigma, religious prohibitions on embryo manipulation, and political underprioritization exacerbate these gaps, though emerging low-cost models in India and select African nations signal potential growth.[331] [334]| Country/Region | IVF Cycles per Million Inhabitants (2018) | Key Driver of Adoption |
|---|---|---|
| Israel | 5,711 | Universal government funding[43] |
| Japan | 3,603 | Subsidies amid low fertility[43] |
| Denmark | 3,575 | Public healthcare coverage[43] |
| United States | 922 | Limited insurance mandates[43] |
